

## **EUROGUIDERM *GUIDELINE ON ATOPIC ECZEMA***

Version 4.1, April 2026

**EUROPEAN  
CENTRE FOR  
GUIDELINES  
DEVELOPMENT**



**European  
Dermatology  
Forum**

**CHARITÉ  
dEBM**

A Wollenberg<sup>1,2,3</sup>, M Kinberger<sup>4</sup>, B Arents<sup>5</sup>, N Aszodi<sup>2</sup>, S Barbarot<sup>6</sup>, T Bieber<sup>7</sup>, HA Brough<sup>8</sup>, P Calzavara-Pinton<sup>9</sup>, S Christen-Zaech<sup>10</sup>, M Deleuran<sup>11</sup>, M Dittmann<sup>4</sup>, N Fosse<sup>12</sup>, K Gáspár<sup>13</sup>, LAA Gerbens<sup>14</sup>, U Gieler<sup>15</sup>, G Girolomoni<sup>16</sup>, S Gregoriou<sup>17</sup>, S Holland<sup>18</sup>, CG Mortz<sup>19</sup>, A Nast<sup>4</sup>, U Nygaard<sup>20</sup>, EM Rehbinder<sup>21,22</sup>, J Ring<sup>23</sup>, M Rossi<sup>9</sup>, E Serra-Baldrich<sup>24</sup>, D Simon<sup>25</sup>, ZZ Szalai<sup>26</sup>, JC Szepietowski<sup>27,28</sup>, A Torreló<sup>29</sup>, T Werfel<sup>30</sup>, RN Werner<sup>4</sup>, C Flohr<sup>31,32</sup>

### **Affiliations:**

<sup>1</sup> Department of Dermatology and Allergology, University Hospital Augsburg, Augsburg, Germany

<sup>2</sup> Department of Dermatology and Allergy, Ludwig Maximilian University Munich, Munich, Germany

<sup>3</sup> Comprehensive Center for Inflammatory Medicine, University of Luebeck, Luebeck, Germany

<sup>4</sup> Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Dermatology, Venereology and Allergology, Division of Evidence-Based Medicine (dEBM), Charitéplatz 1, 10117 Berlin, Germany

<sup>5</sup> European Federation of Allergy and Airways Diseases Patients' Associations (EFA), Brussels, Belgium

<sup>6</sup> Nantes Université, Department of Dermatology, CHU Nantes, UMR 1280 PhAN, INRAE, F-44000 Nantes, France

<sup>7</sup> Christine Kühne-Center for Allergy Research and Education, Medicine Campus, Davos, Switzerland

<sup>8</sup> Children's Allergy Service, Evelina London Children's Hospital, Guy's and St. Thomas' NHS Foundation Trust, London, and Paediatric Allergy Group, Department of Women and Children's Health, School of Life Course Sciences, King's College London, United Kingdom

<sup>9</sup> Dermatology Department, University of Brescia, Brescia, Italy

<sup>10</sup> University Hospital Lausanne, Lausanne, Switzerland

- <sup>11</sup> Dept. of Dermatology, Aarhus University Hospital and Aarhus University, Aarhus, Denmark  
<sup>12</sup> Department of Dermatology, University Hospital Basel, Basel, Switzerland  
<sup>13</sup> Dept. of Dermatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary  
<sup>14</sup> Department of Dermatology, Amsterdam UMC, Academic Medical Center, Amsterdam Public Health & Infection and Immunity, University of Amsterdam, Amsterdam, The Netherlands  
<sup>15</sup> Dept. Dermatology, Univ. Giessen, Giessen, Germany  
<sup>16</sup> Dermatology and Venereology Section, Department of Medicine, University of Verona, Verona, Italy  
<sup>17</sup> Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece

#### Holand

- <sup>18</sup> Eczema Outreach Support (UK), Linlithgow, The United Kingdom  
<sup>19</sup> Dept. of Dermatology and Allergy Centre, Odense University Hospital, University of Southern Denmark, Odense, Denmark  
<sup>20</sup> Dept. of Dermato-Venerology, Aarhus University Hospital, Aarhus, Denmark  
<sup>21</sup> Dermatology Department, Oslo University Hospital, Oslo, Norway  
<sup>22</sup> Clinical Medicine, University of Oslo, Norway  
<sup>23</sup> Dept Dermatology Allergology Biederstein, Technical University Munich, Munich, Germany  
<sup>24</sup> Dermatology, Hospital of Sant Pau, Barcelona, Spain  
<sup>25</sup> Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland  
<sup>26</sup> Pediatric dermatology unit, Heim Pál National Children's Institute Budapest, Budapest, Hungary  
<sup>27</sup> Department of Dermato-Venereology, 4th Military Hospital, Wroclaw, Poland  
<sup>28</sup> Faculty of Medicine, Wroclaw University of Science and Technology, Wroclaw, Poland  
<sup>29</sup> Hospital Infantil Niño Jesús, Madrid, Spain  
<sup>30</sup> Dept. Dermatology and Allergy, Hannover Medical School, Hannover, Germany  
<sup>31</sup> St John's Institute of Dermatology, King's College London, London, The United Kingdom  
<sup>32</sup> Guy's & St Thomas' NHS Foundation Trust, London, The United Kingdom

## Table of contents

I.	Notes on use/Disclaimer .....	5
II.	Accompanying documents .....	5
III.	Funding (standard) Statement.....	5
IV.	Scoping and defining the purpose of the guideline.....	5
V.	Population and health questions covered by the guideline.....	5
VI.	Targeted users of this guideline .....	6
VII.	Treatment and treatment goals .....	6
VIII.	Methods Section.....	8
IX.	Recommendations.....	15
X.	Guideline text and recommendations.....	24
1.	Patient’s perspective .....	25
2.	Basic emollients and moisturizers .....	28
2.1	Emollient therapy .....	29
2.2	Cleansing and bathing .....	31
3.	Antiinflammatory treatment .....	33
3.1	Topical corticosteroids .....	34
3.2	Topical calcineurin inhibitors .....	36
3.3	Topical phosphodiesterase 4 inhibitors .....	39
3.4	Upcoming topical treatment .....	39
4.	Antimicrobial treatment.....	40
4.1	Anti-bacterial treatment .....	40
4.2	Anti-viral treatment.....	42
4.3	Anti-fungal treatment .....	43
5.	Antipruritic treatment .....	44
5.1	Anti-pruritic effect of anti-inflammatory treatment.....	44
5.2	Anti-pruritic treatment .....	45
6.	Phototherapy and Photochemotherapy.....	49
6.1	Efficacy of different photo(chemo)therapy modalities in clinical trials.....	50
6.2	Safety of different photo(chemo)therapy modalities in clinical trials.....	51
7.	Introduction to systemic treatment .....	53
8.	Conventional immunomodulatory drugs .....	59
8.1.	Introduction conventional immunomodulatory drugs .....	59

8.2.	Azathioprine .....	59
8.3.	Ciclosporin .....	62
8.4.	Methotrexate .....	65
8.5.	Systemic glucocorticosteroids .....	68
9.	Interleukin-13-Inhibitors.....	70
9.1.	Interleukin-13-Inhibitors Introduction .....	70
9.2.	Dupilumab .....	70
9.3.	Lebrikizumab .....	72
9.4.	Tralokinumab.....	74
10.	Interleukin-31-Inhibitors.....	76
10.1	Interleukin-31-Inhibitors Introduction .....	76
10.2	Nemolizumab .....	76
11.	JAK-Inhibitors.....	78
11.1	JAK-Inhibitors introduction.....	78
11.2	Abrocitinib .....	80
11.3	Baricitinib.....	82
11.4	Upadacitinib .....	85
12.	Other systemic treatment .....	88
12.1	Alitretinoin.....	88
12.2	Treatments under investigation .....	89
12.3	Therapies that were used in past .....	89
13.	Avoidance techniques in atopic eczema .....	91
14.	Dietary interventions in atopic eczema.....	94
15.	Allergen-specific immunotherapy .....	99
16.	Complementary medicine .....	101
17.	Psychological and educational interventions .....	105
18.	Pregnancy, breastfeeding, and family planning .....	107
18.1	Pregnant Women .....	107
18.2	Breastfeeding women .....	112
18.3	Family planning .....	113
19.	Considerations for paediatric and adolescent patients.....	114
20.	Occupational aspects.....	116
XI.	Strengths and limitations.....	120
XII.	References .....	121

## I. Notes on use/Disclaimer

The EuroGuiDerm Guideline on Atopic Eczema was developed in accordance with the EuroGuiDerm Methods Manual [v1.3](#), which can be found on the website of the European Dermatology Forum (EDF), subsection EuroGuiDerm/EDF Guidelines <https://www.edf.one/de/home/Guidelines/EDF-EuroGuiDerm.html>.

This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 (CC BY NC).

## II. Accompanying documents

- [Methods Report](#)
- [Evidence Report](#)
- [Implementation Slides](#)
- [Publications](#)

## III. Funding (standard) Statement

The development of this EuroGuiDerm guideline was funded through the EuroGuiDerm Centre for Guideline Development. The European Dermatology Forum is responsible for fundraising and holds all raised funds in one account. The EuroGuiDerm Team is not involved in fundraising or in the decision making on which guideline (GL) or consensus statement (CS) development is funded. The decisions on which GL/CS is funded are made by the EuroGuiDerm Board of Directors independently. The EDF or any other body supporting the EuroGuiDerm is never involved in the guideline development and had no say on the content or focus of the guideline.

## IV. Scoping and defining the purpose of the guideline

The aim of this guideline is to provide guidance on the management and treatment of patient with atopic eczema (AE) of all severities and age groups. According to the scoping document, the objectives of the guideline are:

- To generate recommendations and treatment algorithms on topical therapy, phototherapy as well as novel and established systemic treatments for AE, based on the latest evidence.
- Provide guidance in the management of AE patients during pregnancy and AE patients with allergic and other comorbidities.

## V. Population and health questions covered by the guideline

The target population are patients with AE of all ages. Major health questions (regardless of sex, ethnicity or gender) regarding AE are:

- What is the optimal treatment with regard to patients' needs, taking efficacy, safety/tolerability of different treatment options and comorbidities into consideration?
- How should the selected treatment option best be managed and monitored?

Whenever possible and feasible, the recommendations are evidence-based, taking into account the results of systematic evidence synthesis based on rigorous methods as well as on the practical experience obtained by the expert group.

## VI. Targeted users of this guideline

This guideline has been prepared for physicians, especially dermatologists, paediatricians, allergists, general practitioners and other specialists taking care of patients suffering from AE. Patients and caregivers may also be able to get reliable information and advice with regard to evidence-based therapeutic modalities.

## VII. Treatment and treatment goals

Terminology	Definition
<b>Acute flare</b>	Clinically significant worsening of signs and symptoms of AE requiring therapeutic intervention.
<b>Acute intervention</b>	Treatments that address acute flares and typically lead to treatment response within days (in contrast to 'maintenance treatment').
<b>Short term</b>	When used in the context of clinical trials this refers to treatment up to 16 weeks.
<b>Reactive</b>	Treatment initiations or adaptations in response to a visible change in disease severity, in particular disease flares (in contrast to 'proactive' treatment).
<b>Long term</b>	When used in the context of clinical trials this refers to treatment longer than 16 weeks.
<b>Proactive</b>	Intermittent (typically twice a week) application of anti-inflammatory therapy to previously affected skin, in addition to an ongoing emollient treatment of unaffected and affected skin (in contrast to 'reactive' treatment)
<b>Maintenance treatment</b>	Regular, usually daily application of topical or systemic therapy for several months (in contrast to 'acute intervention').

*Treatment goals*

<b>Treatment goal</b>	<b>Definition</b>
<b>Remission/Control</b>	Satisfactory reduction of the signs and symptoms of AE whilst being on a safe long-term anti-inflammatory treatment.
<b>Complete remission</b>	Disappearance of the signs and symptoms of AE without use of anti-inflammatory treatment.

## VIII. Methods Section

The EuroGuiDerm guideline on AE was developed in accordance with the EuroGuiDerm Methods Manual v1.3. For the detailed description of the guideline development process as well as an overview of the evidence referred to, please see the EuroGuiDerm guideline on AE Methods Report and the Evidence Report.

Both are available alongside the guideline document on the EDF website: <https://www.edf.one/de/home/Guidelines/EDF-EuroGuiDerm.html>

### Nomination of experts, management of conflicts of interest

The guideline development group comprised 26 experts from twelve countries nominated by EuroGuiDerm national partner societies or the two guideline co-coordinators (AW and CF). All nominations were reviewed and confirmed by the EuroGuiDerm Board of Directors. In addition, three patient representatives participated in the guideline development.

38% of the experts declared personal-financial interests (for details on classification see EuroGuiDerm Methods Manual v1.3.). *These members were neither eligible to take the lead in a respective working group nor for voting on recommendations pertaining to systemic treatment and on the stepped-care plan.*

### Development of the guideline and the consensus process

The chapters of the guideline and the recommendations had been developed by the group members, who formed a number of working groups. Each chapter and all recommendations were reviewed, discussed and amended where appropriate by the entire group. All texts and recommendations were voted on with a necessary minimal agreement of >50% during the consensus conferences. AN facilitated all four consensus conferences using a structured consensus technique. Both internal and external review were conducted. Dissemination and implementation plans were developed. For more details, see Methods Report.


The wording of the recommendations was standardized (as suggested by the GRADE Working Group <sup>1</sup>).

#### Wording of recommendations

Strength	Wording	Symbols	Implications
<b>Strong</b> recommendation <b>for</b> the use of an intervention	'We recommend . . .'	↑↑	We believe that all or almost all informed people would make that choice.
<b>Weak</b> recommendation <b>for</b> the use of an intervention	'We suggest . . .'	↑	We believe that most informed people would make that choice, but a substantial number would not.
<b>No recommendation</b> with respect to an intervention	'We cannot make a recommendation with respect to . . .'	0	At the moment, a recommendation in favour or against an intervention cannot be made due to certain reasons (e.g. no reliable evidence data available, conflicting outcomes, etc.)
<b>Weak</b> recommendation	'We suggest against . . .'	↓	We believe that most informed people would make a choice against that intervention, but a substantial number would not.

<b>against</b> the use of an intervention			
<b>Strong</b> recommendation <b>against</b> the use of an intervention	'We recommend against ...'	↓↓	We believe that all or almost all informed people would make a choice against that intervention.

The recommendation are presented throughout this guideline as displayed below: alongside the wording of the recommendations the arrow(s) and colors indicate the direction and the strength of each recommendation. The rate of agreement (consensus strength) is also displayed as the actual percentage and in form of a category-type pie chart. For all systemic drugs, we added the dosages (according to the European Medical Agency). Additionally, the certainty of evidence was added where applicable (bold – significant difference; Associations are reported in line with Drucker et. al<sup>2</sup>).

<p>We <b>recommend</b> dupilumab in AE patients who are candidates for systemic treatment.</p>	<p>↑↑</p>	<p><b>100%</b></p>  <p><b>100 % Agreement</b></p> <p>Evidence and consensus based, see Evidence Report</p>
--	-----------	---

dupilumab: in licence for ≥ 6 months of age;  
 age 6 months-6 years: from 5kg <15 kg 200 mg Q4W, 15kg <30 kg 300 mg Q4W  
 age 6-11: from 15kg <60kg, initially 300 mg s.c. day 1 and 15 followed by 300 mg Q4W, when ≥60 kg, initially 600 mg s.c. day 1 followed by 300 mg Q2W  
 age 12-17: <60 kg: initially 400 mg s.c. day 1 followed by 200 mg Q2W, when ≥60 kg: initially 600 mg s.c. day 1 followed by 300 mg Q2W  
 adults: initially 600 mg s.c. day 1 followed by 300 mg Q2W

Certainty of evidence: Network meta-analysis from 2024<sup>3, 4</sup>;

Short term (up to 16 weeks) vs placebo (NMA medications used in clinical practice)

⊕⊕⊕⊕ HIGH for mean difference **EASI** -10.5 (-11.9, -9.2); **POEM** -7.3 (-8, -6.7); **peak pruritus NRS** -2.1 (-2.3, -1.8); **DLQI** (-4.9 (-5.4, -4.3)

*For dupilumab versus other drugs, see Evidence Report*

### Update 2025

The third update of the guideline was initiated to incorporate nemolizumab. As nemolizumab received EMA approval after the previous guideline update, it had not yet been addressed in earlier versions. In addition, the guideline group decided to include guidance on vaccination prior to initiating systemic therapy and during ongoing systemic treatment, as well as guidance on switching systemic therapies and adjusting treatment frequency and intervals.

Furthermore, an update of the network meta-analysis by Drucker et al. was published in May 2025.<sup>5</sup> The updated data from the network meta-analysis from May 2025 were summarised in an updated evidence report.

The new evidence from the updated network meta-analysis, and the updated chapters on systemic treatment and on pregnancy, breastfeeding, and family planning and new versions of the stepped-care plans and drug tables were presented to the GDG and put to the vote in an online survey.

All experts were asked to vote (agree, abstain, reject). Alternative suggestions could be entered as a reply option. Experts could not see how others had voted. Only the EuroGuiDerm team had access to the results. All authors could participate but the votes of those with personal financial conflicts of interest did not count.

All recommendations that did not achieve full approval in the online vote, as well as background-text changes requiring further discussion, were reconsidered during an online consensus conference on 30 September 2025. The process was moderated by Ricardo N. Werner, a certified guideline facilitator, using the nominal group technique. He first presented the anonymised results, comments, and suggested modifications from the pre-voting survey, then opened the floor for discussion. Benefits, harms, processes, and procedures were discussed in detail. Final voting followed, with experts choosing to agree, disagree, or abstain for each recommendation. All GDG members were asked to participate. As before, the definitive evaluation included only the votes of members without COIs.

For the second update in 2025, the group comprised experts from twelve countries. Thirteen experts (46.4%) declared personal financial conflicts of interest, see below.

Title	First name	Last name	Relevant personal- financial conflicts of interest
	Bernd	Arents	None
Dr.	Nora	Aszodi	None
Prof. Dr.	Sebastien	Barbarot	Abbvie, Almirall, Galderma, Lilly, Leo, Pfizer, Sanofi
Prof. Dr.	Thomas	Bieber	Abbvie, Almirall, Galderma, Lilly, Leo, Pfizer, Sanofi
Dr.	Helen A.	Brough	Leo
Prof. Dr.	Piergiacomo	Calzavara Pinton	None
Dr.	Stéphanie	Christen-Zäch	None
Dr.	Mette	Deleuran	Abbvie, Almirall, Lilly, Leo, Pfizer, Sanofi
Prof. Dr.	Carsten	Flohr	Almirall, Leo, Pfizer, Sanofi
Dr.	Nicole	Fosse	None
Dr.	Krisztián	Gáspár	Abbvie, Sanofi
Dr.	Louise	Gerbens	None
Prof. Dr.	Uwe	Gieler	None
Prof. Dr.	Giampiero	Girolomoni	Abbvie, Almirall, Lilly, Leo, Pfizer, Sanofi

Prof. Dr.	Stamatis	Gregoriou	None
	Holland	Suzi	None
Prof. Dr.	Charlotte	Mortz	None
MD PhD	Uffe	Nygaard	None
MD PhD	Eva Maria	Rehbinder	None
Prof. Dr. Dr.	Johannes	Ring	Abbvie, Sanofi
Dr.	Mariateresa	Rossi	None
Dr.	Esther	Serra-Baldrich	Abbvie, Almirall, Galderma, Lilly, Leo, Pfizer, Sanofi
Prof. Dr.	Dagmar	Simon	None
Prof. Dr.	Zsuzsanna	Szalai	None
Prof. Dr.	Jacek C.	Szepietowski	Almirall, Leo, Pfizer, Sanofi
Dr.	Antonio	Torrelo	Abbvie, Lilly, Pfizer, Sanofi
Prof. Dr.	Thomas	Werfel	Abbvie, Almirall, Galderma, Sanofi
Prof. Dr. med. Dr. h.c.	Andreas	Wollenberg	Abbvie, Almirall, Galderma, Lilly, Leo, Pfizer, Sanofi

The updated guideline document (chapters on systemic treatment, chapter on pregnancy, breastfeeding, and family planning, the stepped-care plans and the drug tables) were sent to all members of the guideline development group for internal review. After the review phase all comments were combined in a word documents by the EuroGuiDerm Team. Editorial comments were directly resolved by the EuroGuiDerm Team. All other comments were sent to the coordinators AW and CF to be resolved. All changes to the guideline were made using the `track changes`function. All reviewers received feedback to their comments. Changes resulting from the commenting phase were clearly visible. An anonymised version of all comments, feedback and action taken are available from [euroguiderm@debm.de](mailto:euroguiderm@debm.de).

After the internal review the updated guideline chapters, the Evidence Report and the Methods Report were sent to: EDF Board, all supporting societies and pharmaceutical companies for external review. After the review phase all comments from the reviewer were combined in an word documents. Editorial comments were resolved by the EuroGuiDerm Team. All other comments were sent to the clinical coordinators AW and CF to be resolved. All changes to the guideline were made using the “track changes” function. All reviewers received feedback to their comments and all changes resulting from the commenting phase are clearly visible. An anonymised version of all comments, feedback and action taken are available from [euroguiderm@debm.de](mailto:euroguiderm@debm.de)

**Evidence**

The living systematic review by Drucker and colleagues<sup>3-5</sup> was used as the evidence base based on which we created an evidence-to-decision framework (see Evidence Report). Furthermore, challenges exist with comparing clinical trials in AE due to their differences in trial design, including study comparators, rules for rescue treatment, washout periods for topical and systemic treatments, inclusion criteria, and the duration of the screening period.<sup>6</sup> Finally, this analysis does not take into consideration the overall management plan that targets long-term stabilization, flare prevention and avoidance of side-effects beyond 16 weeks<sup>7</sup>. We only summarize the results here. For limitations please refer to the website.

For each recommendations that is evidence-based, we added the certainty of the evidence when compared to placebo<sup>2</sup>. The assessment of the certainty of evidence leads to four grades, see Figure 1 (Table 5.1. GRADE Handbook<sup>8</sup>).

**High ⊕⊕⊕⊕:** we are **very confident** that the true effect lies close to that of the estimate of the effect.  
**Medium ⊕⊕⊕○:** we are **moderately confident** in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.  
**Low ⊕⊕○○:** our **confidence in the effect estimate is limited: The true effect may be substantially different** from the estimate of the effect.  
**Very low ⊕○○○:** we have **very little confidence** in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

Figure 1 Definitions of “certainty of evidence”<sup>8</sup>

**Excerpt from the publication of the network meta-analysis ‘Living network meta-analysis to compare nemolizumab against other available targeted systemic treatments for atopic dermatitis ‘ by Aaron M. Drucker and colleagues, May 2025.<sup>5</sup>**

„[...] Our analysis shows that nemolizumab improves the signs of AD measured by the Eczema Area and Severity Index (EASI) by 6 fewer points [95% credible interval (CrI) 3.7–8.5 fewer] than dupilumab, indicating that dupilumab is probably associated with a small important reduction in EASI scores compared with nemolizumab (moderate certainty; see <https://doi.org/10.6084/m9.figshare.29066576>). According to GRADE, certainty was downgraded from high to moderate because the credible intervals include 6.6, the MID for EASI,<sup>8</sup> indicating that it is possible that dupilumab may be associated with a large (rather than small) important reduction in EASI scores compared with nemolizumab.

We also found that dupilumab is probably associated with a large important reduction in Patient-Oriented Eczema Measure (POEM) scores (moderate certainty), a measure of symptoms, and is probably associated with a small but important reduction in Dermatology Life Quality Index (DLQI, moderate certainty), a measure of skin-specific health-related quality of life vs. nemolizumab.

One outcome for which dupilumab was not more efficacious compared with nemolizumab is the Peak Pruritus Numeric Rating Scale (PP-NRS). We found no difference between dupilumab and nemolizumab [–0.1 points (95% CrI –0.6 to 0.4), Figure 1d], leading us to conclude that dupilumab is probably associated with no important difference in reduction in PP-NRS scores compared with nemolizumab (moderate certainty). Nemolizumab has the best pathophysiological rationale for this symptom given that IL-31 is considered an ‘itch cytokine’. [...] page 549-550, Drucker et al. 2025<sup>5</sup>

**Linking evidence to recommendations**

In the table below, we link the evidence from the NMA directly to the recommendations made. For additional information and justifications, please see the corresponding chapters.

<b>Recommendation</b>	<b>Short term (8-16 weeks) vs placebo</b> Bold = statistically significant difference
We recommend ciclosporin to achieve disease control in AE patients who are candidates for systemic treatment.	Network meta-analysis from 2022 <sup>2,9</sup> : Higher dose ⊕⊕⊕○ MODERATE for standardized mean difference <b>change in signs</b> -1 (-1.6, -0.4) ⊕⊕⊕○ MODERATE for standardized mean difference <b>QoL</b> -0.7 (-1.3, -0.1) ⊕⊕○ ○ LOW for standardized mean difference <b>itch</b> -0.7 (-1.5, 0.2) Lower dose ⊕⊕⊕○ MODERATE for standardized mean difference <b>change in signs</b> -0.7 (-1.4, -0.1) ⊕⊕○ ○ LOW for standardized mean difference <b>QoL</b> -0.5 (-1.1, 0.2) ⊕⊕○ ○ LOW for standardized mean difference <b>itch</b> -0.7 (-1.6, 0.3)
We suggest methotrexate in AE patients who are candidates for systemic treatment.	Network meta-analysis from 2022 <sup>2,9</sup> : ⊕⊕○ ○ LOW for standardized mean difference <b>change in signs</b> -0.6 (-1, -0.2), <b>QoL</b> -0.4 (-0.9, 0.1), <b>itch</b> -0.6 (-1.2, 0)
We recommend dupilumab in AE patients who are candidates for systemic treatment.	Network meta-analysis from 2024 <sup>9,10</sup> : ⊕⊕⊕⊕ HIGH for mean difference <b>EASI</b> -10.5 (-11.9, -9.2); <b>POEM</b> -7.3 (-8, -6.7); <b>peak pruritus NRS</b> -2.1 (-2.3, -1.8); <b>DLQI</b> (-4.9 (-5.4, -4.3)
We recommend lebrikizumab in AE patients, who are candidates for systemic treatment.	Network meta-analysis from 2024 <sup>9,10</sup> : ⊕⊕⊕⊕ HIGH for mean difference <b>POEM</b> -6.2 (-7.4, -5.1) ⊕⊕⊕○ MODERATE for mean difference <b>EASI</b> -8.5 (-10.4, -6.5); <b>DLQI</b> -4.7 (-6.4, -2.8) ⊕⊕○ ○ LOW for mean difference <b>peak pruritus NRS</b> -2.1 (-2.6, -1.7)
We recommend nemolizumab in AE patients, who are candidates for systemic treatment.	Network meta-analysis from 2025 <sup>5</sup> : ⊕⊕⊕○ MODERATE for mean difference <b>EASI</b> -4.4 (-6.5, -2.4); <b>POEM</b> -3.9 (-5.1, -2.8); <b>DLQI</b> -2.4 (-3.4, -1.3); <b>peak pruritus NRS</b> -2 (-2.4, -1.6)
We recommend tralokinumab in AE patients, who are candidates for systemic treatment.	Network meta-analysis from 2024 <sup>9,10</sup> : ⊕⊕⊕⊕ HIGH for mean difference <b>POEM</b> -4.2 (-5, -3.4) ⊕⊕⊕○ MODERATE for mean difference <b>peak pruritus NRS</b> -1 (-1.2, -0.7); <b>DLQI</b> -2.4 (-3.1, -1.6) ⊕⊕○ ○ LOW for mean difference <b>EASI</b> -6.2 (-7.8, -4.7)
We recommend abrocitinib in AE patients who are candidates for systemic treatment.	Network meta-analysis from 2024 <sup>9,10</sup> : 100 mg ⊕⊕⊕⊕ HIGH for mean difference <b>EASI</b> -8.5 (-10.3, -6.7); <b>POEM</b> -5.1 (-6.1, -4.1) ⊕⊕⊕○ MODERATE for mean difference <b>peak pruritus NRS</b> -1.6 (-2.1, -1.1); <b>DLQI</b> -3.4 (-4.3, -2.6) 200 mg ⊕⊕⊕⊕ HIGH for mean difference <b>EASI</b> -12.8 (-14.6, -11.1); <b>POEM</b> -8.4 (-9.3, -7.5); <b>DLQI</b> -5.6 (-6.3, -4.8) ⊕⊕⊕○ MODERATE for mean difference <b>peak pruritus NRS</b> -2.4 (-3, -1.8)
We recommend baricitinib in AE patients who are candidates for systemic treatment.	Network meta-analysis from 2024 <sup>9,10</sup> : 2 mg ⊕⊕⊕○ MODERATE for mean difference <b>EASI</b> -5.1 (-6.9, -3.4); <b>POEM</b> -3.8 (-4.9, -2.7); <b>peak pruritus NRS</b> -1.2 (-1.6, -0.9); <b>DLQI</b> -2.3 (-3.1, -1.4) 4 mg ⊕⊕⊕⊕ HIGH for mean difference <b>POEM</b> -5.4 (-6.6, -4.2); <b>peak pruritus NRS</b> -1.6 (-2, -1.3) ⊕⊕⊕○ MODERATE for mean difference <b>EASI</b> -7.5 (-9.4, -5.6); <b>DLQI</b> -3.5 (-4.4, -2.6)
We recommend upadacitinib in AE patients who are candidates for systemic treatment	Network meta-analysis from 2024 <sup>9,10</sup> : 15 mg ⊕⊕⊕⊕ HIGH for mean difference <b>EASI</b> -11 (-12.6, -9.4) ⊕⊕⊕○ MODERATE for mean difference <b>POEM</b> -7 (-11.2, -2.9); <b>peak pruritus NRS</b> -2.4 (-2.8, -2) 30 mg


⊕⊕⊕⊕ HIGH for mean difference **EASI** -13.5 (-15.2, -11.9); **POEM** -10.7 (-14.8, -6.5); **peak pruritus NRS** -3.3 (-3.6, -3.1)

AE = atopic eczema; DLQI = Dermatology Life Quality Index; EASI = Eczema Area and Severity Index; NMA = network meta analysis; OR = Odds ratio; POEM = Patient-Oriented Eczema Measure; PPNRS = Peak Pruritus Numerical Rating Scale; RoB = Risk of Bias; VAS = visual analog scale

## IX. Recommendations

### EuroGuiDerm Guideline on Atopic Eczema Stepped-care plan for adults with atopic eczema

- Add antiseptic/antibiotic/antiviral/antifungal treatment in cases of infections
- Consider compliance and diagnosis, if therapy has insufficient effect
- Refer to table 3 for TCS classes recommended



<sup>1</sup> refer to guideline text for restrictions, <sup>2</sup> licensed indication, <sup>3</sup> off-label treatment

↑↑ (dark green) strong recommendation for the use of an intervention / ↑ (light green) weak recommendation for the use of an intervention


For definitions of disease severity, acute, reactive, proactive see section 'VII' and section 'Introduction to systemic treatment' of the EuroGuiDerm Atopic Eczema Guideline

Abro= abrocitinib; Bari=baricitinib; CyA=ciclosporin; Dupi=dupilumab; Lebri=lebrikizumab; MTX=methotrexate; Nemo=nemolizumab; TCI=topical calcineurin inhibitors; TCS= topical corticosteroids; Tralo=tralokinumab; Upa=upadacitinib; UVA1=ultraviolet A1; NB-UVB=narrow-band ultraviolet B

# EuroGuiDerm Guideline on Atopic Eczema

## Stepped-care plan for children and adolescents with atopic eczema

- Add antiseptic/antibiotic/antiviral/antifungal treatment in cases of infections
- Consider compliance and diagnosis, if therapy has insufficient effect
- Refer to table 3 for TCS classes recommended



<sup>1</sup> refer to guideline text for restrictions, <sup>2</sup> licensed indication, <sup>3</sup> off-label treatment

↑↑ (dark green) strong recommendation for the use of an intervention / ↑ (light green) weak recommendation for the use of an intervention

For definitions of disease severity, acute, reactive, proactive see section 'VII' and section 'Introduction to systemic treatment' of the EuroGuiDerm Atopic Eczema Guideline

Abro= abrocitinib; Bari=baricitinib; CyA=ciclosporin; Dupi=dupilumab; Lebri=lebrikizumab; MTX=methotrexate; Nemo=nemolizumab; TCI=topical calcineurin inhibitors; TCS= topical corticosteroids; Tralo=tralokinumab; Upa=upadacitinib; UVA1=ultraviolet A1; NB-UVB=narrow-band ultraviolet B

<b>Symbols</b>	<b>Implications (adapted from GRADE 1)</b>
↑↑	We believe that all or almost all informed people would make that choice.
↑	We believe that most informed people would make that choice, but a substantial number would not.
0	We cannot make a recommendation.
↓	We believe that most informed people would make a choice against that intervention, but a substantial number would not.
↓↓	We believe that all or almost all informed people would make a choice against that choice.
	No recommendation

**Table 1: General recommendations for systemic drugs for AE adult patients, who are candidates for systemic treatment (for details see corresponding chapter)**

	Conventional immunomodulatory drugs		Interleukin-13-Inhibitors			Interleukin-13-Inhibitors	JAK-Inhibitors			Rescue therapy
	Ciclosporin	Methotrexate	Dupilumab	Lebrikizumab	Tralokinumab	Nemolizumab	Abrocitinib	Baricitinib	Upadacitinib	Systemic corticosteroids
Recommendation	↑↑	↑	↑↑	↑↑	↑↑	↑↑	↑↑	↑↑	↑↑	↑
Dose for adults <sup>1</sup>	licensed ≥ 16 years of age; standard dosage adults: 2.5-5 mg/kg per day in two single doses	off-label; commonly used dosage adults: initial dose: 5*-15 mg / per week; maximum dose: 25 mg/ week	licensed ≥ 6 months of age; dosage adults: initially 600 mg s.c. day 1 followed by 300 mg s.c. Q2W	licensed for ≥ 12 years of age; dosage adults: initially 500 mg s.c. day 1 and 15 followed by 250 mg s.c. Q2W up to week 16. Some patients with initial partial response may further improve with continued treatment Q2W up to week 24. Once clinical response is achieved, the recommended maintenance dose is 250 mg Q4W. <b>From week 24 onwards, generally Q4W</b>	licensed for ≥ 12 years of age; dosage adults: initially 600 mg s.c. day 1 followed by 300 mg s.c. Q2W; consider Q4W after week 16 in those achieving clear or almost clear skin	licensed for ≥ 12 years of age; dosage adults: initially 60 mg s.c. day 1 followed by 30 mg s.c. Q4W; after week 16 recommended maintenance dose of is 30 mg Q8W for patients who achieve clinical response	licensed for ≥ 12 years of age; dosage adults: 100 mg or 200 mg once daily based on individual patient characteristic:  starting dose of 100 mg: patients at higher risk of VTE, MACE and malignancy. If the patient does not respond adequately to 100 mg once daily, the dose can be increased to 200 mg once daily.  starting dose of 200 mg: patients who are not at higher risk of VTE, MACE and malignancy with high disease burden or for patients with an inadequate response to 100 mg once daily. Upon disease control, dose should be decreased to 100 mg once daily. If disease control is not maintained after dose reduction, re-treatment with 200 mg once daily can be considered.	licensed for ≥ 2 years of age; dosage adults: 4 mg once daily.  A dose of 2 mg once daily should be considered for patients who have achieved sustained control of disease activity with 4 mg once daily and are eligible for dose tapering  2 mg once daily is recommended for patients at higher risk of VTE, MACE and malignancy, for patients aged ≥ 65 years and for patients with a history of chronic or recurrent infections. A dose of 4 mg once daily may be considered for patients who do not achieve adequate control of disease activity with 2 mg once daily dose. A	licensed ≥ 12 years of age; dosage adults:  15 mg or 30 mg once daily based on individual patient characteristic:  starting dose of 15 mg once daily is recommended for patients at higher risk of VTE, MACE and malignancy  starting dose of 30 mg once daily may be appropriate for patients with high disease burden who are not at higher risk of VTE, MACE and malignancy or patients with an inadequate response to 15 mg once daily.  The lowest effective dose to maintain response should be used.  For patients 65 years of age and older, the recommended dose is 15 mg once daily	general unspecific licence for adults and children for steroid responsive skin disease; dosage maximum: 1 mg/kg per day

<b>Time to response (weeks)<sup>2</sup></b>	1-2	8-12	4-6	4-6	4-8	4-8	1-2	1-2	1-2	1-2
<b>Time to relapse (weeks)<sup>2</sup></b>	<2	>12	>8	>8	>8	>8	<2	<2	<2	<2
<b>Monitoring</b>	complete blood count, renal and liver profile, blood pressure,	complete blood count, renal and liver profile, PIIINP if available,	not required	not required	not required	not required	complete blood count, lipid profile, liver profile	complete blood count, lipid profile, liver profile	complete blood count, lipid profile, liver profile	not required for short-term treatment, consider blood glucose and testing for adrenal gland suppression with high doses/longer-term treatment
<b>Selection of most relevant adverse events</b>	serum creatinine↑, blood pressure ↑	nausea, fatigue, liver enzymes ↑, myelotoxicity	Conjunctivitis, upper respiratory tract infections, arthralgia	Conjunctivitis, nasopharyngitis, headache, dry eyes, allergic rhinitis	Conjunctivitis, upper respiratory tract infections;	Injection site reactions, nasopharyngitis, upper respiratory tract infections, headache	upper respiratory tract infections, increase in LDL cholesterol; thrombocytopenia, increased creatine phosphokinase, nausea and abdominal pain herpes virus infections, acne  From a medical point of view, the risk of MACE, VTE and malignancy are relevant but low and applies to all JAK-Inhibitors in the same way	upper respiratory tract infections, increase in LDL cholesterol; thrombocytosis, nausea and abdominal pain herpes virus infections, acne  From a medical point of view, the risk of MACE, VTE and malignancy are relevant but low and applies to all JAK-Inhibitors in the same way	upper respiratory tract infections, increase in LDL cholesterol, anaemia and neutropenia, increased creatine phosphokinase, nausea and abdominal pain, headache, herpes virus infections, acne  From a medical point of view, the risk of MACE, VTE and malignancy are relevant but low and applies to all JAK-Inhibitors in the same way	skin atrophy, weight gain, sleep disturbance, mood changes, hyperglycaemia or new onset diabetes, peptic ulcers/gastritis, osteoporosis

<b>Symbols</b>	<b>Implications (adapted from GRADE <sup>1)</sup></b>
↑↑	We believe that all or almost all informed people would make that choice.
↑	We believe that most informed people would make that choice, but a substantial number would not.
0	We cannot make a recommendation.
↓	We believe that most informed people would make a choice against that intervention, but a substantial number would not.
↓↓	We believe that all or almost all informed people would make a choice against that choice.
	No recommendation.

**Table 2: General recommendations for systemic drugs for special AE patient populations (for details see corresponding chapter)**

	Conventional immunomodulatory drugs		Interleukin-13-Inhibitors			Interleukin-31-Inhibitors	JAK-Inhibitors			Rescue therapy
	Ciclosporin	Methotrexate	Dupilumab	Lebrikizumab	Tralokinumab	Nemolizumab	Abrocitinib	Baricitinib	Upadacitinib	Systemic corticosteroids
Children and adolescents with AE who are candidates for systemic treatment	↑↑	↑	↑↑	↑↑	↑↑	↑↑	↑↑	↑↑	↑↑	
Dose for children	licensed for ≥ 16 years of age; commonly used dosage children: 2.5-5 mg/kg per day in two single doses	off-label; commonly used dosage children: 0.2–0.4 mg/kg per week	licensed for ≥ 6 months of age; dosage: age 6m-5y: from 5kg <15kg: 200 mg s.c. Q4W; 15kg<30kg: 300 mg s.c. Q4W age 6y-11y: from 15kg <60kg, initially 300 mg s.c. day 1 and 15 followed by 300 mg s.c. Q4W, when ≥60 kg, initially 600 mg s.c. day 1 followed by 300 mg s.c. Q2W age 12-17: <60 kg: initially 400 mg s.c. day 1 followed by 200 mg s.c. Q2W, when ≥60 kg: initially 600 mg s.c. day 1 followed by 300 mg s.c. Q2W adults: initially 600 mg s.c. day 1 followed by 300 mg s.c. Q2W	licensed for ≥ 12 years of age (with bodyweight ≥40kg); dosage: initially 500 mg s.c. day 1 and 15 followed by 250 mg s.c. Q2W up to week 16. Some patients with initial partial response may further improve with continued treatment Q2W up to week 24. Once clinical response is achieved, the recommended maintenance dose is 250 mg Q4W. From week 24 onwards, generally Q4W	licensed for ≥ 12 years of age; dosage: initially 600 mg s.c. day 1 followed by 300 mg s.c. Q2W; consider Q4W after week 16 in those achieving clear or almost clear skin	licensed for ≥ 12 years of age; dosage adults: initially 60 mg s.c. day 1 followed by 30 mg s.c. Q4W; after week 16 recommended maintenance dose of is 30 mg Q8W for patients who achieve clinical response	licensed for ≥ 12 years of age; dosage: 100 mg per day. If the patient does not respond adequately and there are no risk factors the dose can be increased to 200 mg per daily	licensed for ≥ 2 years of age; dosage: from 10kg<30kg: 2 mg per day; from 30kg: 4 mg per day dosage. A reduction to half the dose should be considered for patients who have achieved sustained control of disease activity with the recommended dose and are eligible for dose tapering.	licensed for ≥ 12 years of age; dosage: age 12-17 with bw ≥ 30 kg: 15 mg per day	general unspecific licence for children for steroid responsive skin disease; dosage maximum: 1 mg/kg per day
Pregnancy	↑	↓↓↓	↑	0	0	0	↓↓↓	↓↓↓	↓↓↓	↑ prednisolone (0.5mg/kg/d) only as rescue therapy for acute flares
Breast-feeding	↓	↓	0	0	0	0	↓	↓	↓	↑ prednisolone (0.5mg/kg/d) only as rescue therapy for acute flares

Symbols	Implications (adapted from GRADE <sup>1</sup> )
↑↑	We believe that all or almost all informed people would make that choice.
↑	We believe that most informed people would make that choice, but a substantial number would not.
0	We cannot make a recommendation.
↓	We believe that most informed people would make a choice against that intervention, but a substantial number would not.
↓↓	We believe that all or almost all informed people would make a choice against that choice.
	No recommendation.

**Table 3: General recommendations for topical drugs for treatment of atopic eczema (for details see corresponding chapter)**


Overall recommendation	TCS ↑↑		TCI ↑↑	
	TCS class I and II	TCS class III and IV	Tacrolimus 0.1% Tacrolimus 0.03%	Pimecrolimus 1%
<b>For further information see background text</b>	class I not suitable for long-term proactive treatment; long-term proactive treatment only class II	acute flare; proactive treatment with TCS class III class IV <i>not</i> for long term daily treatment or head and neck; class IV not recommended for proactive treatment either	acute flare; long-term proactive treatment; especially in face, intertriginous sites, anogenital area	acute flare; especially in face, intertriginous sites, anogenital area
<b>Most important side effects</b>	skin atrophy telangiectasia striae distensae ecchymosis hypertrichosis perioral dermatitis	skin atrophy telangiectasia striae distensae ecchymosis hypertrichosis perioral dermatitis corticosteroid addiction syndrome suppression of adrenal function	initial warmth, tingling or burning	initial warmth, tingling or burning
	TCI class II and III are off label for proactive treatment		in label for proactive treatment	not suitable for proactive treatment
<b>Special considerations</b>				
Suitable for <b>children &gt; 2 to &lt; 16</b> years of age	yes	yes	yes (0.03%) <sup>2</sup>	yes <sup>2</sup>
Suitable for <b>babies</b> < 2 years of age	yes	under specialist supervision	yes (0.03%) <sup>1</sup>	yes <sup>2</sup> (from the age of three months)
Suitable during <b>pregnancy</b>	yes	yes	yes (0.03% & 0.1%) <sup>1</sup>	yes <sup>1</sup>
Suitable during <b>breastfeeding</b>	yes	yes	yes (0.03% & 0.1%) <sup>1</sup>	yes <sup>1</sup>
Suitable for pruritus	yes	yes	yes (0.03% & 0.1%)	yes


<sup>1</sup> off label use    <sup>2</sup> licensed use


Symbols	Implications (adapted from GRADE 1)
↑↑	We believe that all or almost all informed people would make that choice.
↑	We believe that most informed people would make that choice, but a substantial number would not.
0	We cannot make a recommendation.
↓	We believe that most informed people would make a choice against that intervention, but a substantial number would not.
↓↓	We believe that all or almost all informed people would make a choice against that choice.
	No recommendation.


## **X. Guideline text and recommendations**


## 1. Patient's perspective


<p>We <b>recommend</b> that health care providers treat each patient as a whole person, not just the skin, while considering the burden of skin disease on life.</p>	↑↑	100%  Patient/caregiver consensus
--	----	--

<p>We <b>recommend</b> that health care providers use the principle of shared decision-making, i.e. discuss the patients' beliefs, lifestyle and preferences when deciding on a treatment plan.</p>	↑↑	100%  Patient/caregiver consensus
---	----	--

<p>We <b>recommend</b> that patients with co-morbidities are treated by multi-disciplinary teams.</p>	↑↑	100%  Patient/caregiver consensus
---	----	---

<p>We <b>recommend</b> that health care providers are given time, training and resources to educate patients/caregivers in lay language about treating and managing their own condition.</p>	↑↑	100%  Patient/caregiver consensus
--	----	--

<p>We <b>recommend</b> that patients/caregivers receive adequate knowledge, skills, resources and support to treat their AE at home and cope with its impact on life.</p>	↑↑	100%  Patient/caregiver consensus
---	----	--

<p>We <b>recommend</b> that patients have access to all available treatments and that these treatments are affordable and practical.</p>	↑↑	100%  Patient/caregiver consensus
--	----	--

## **Burden of disease**

The burden of disease in atopic eczema does not consist of symptoms only, but it affects life in general, for patients/caregivers, partner, family, etc. As well as being a painful and frustrating condition, atopic eczema affects all aspects of life, from sleep to relationships, work/school and social activities. The condition can also negatively impact on self-esteem and psychological well-being, which may lead to anxiety and depression. Therefore the whole burden of the disease needs to be taken into account when treating patients with mild to severe atopic eczema, without any judgement on their personal experiences of the disease.<sup>11</sup>

## **Shared decision-making**

Shared decisions about treatment choices between patient and clinician increase adherence to treatment and thus the patient's long term health outcomes. When the relationship is based on trust and understanding of the patient's deep beliefs in regards to their condition and their treatment options, compliance is further increased. This complies with the definition of Evidence Based Medicine as per Sackett *et al.*<sup>12</sup>

## **Multidisciplinary approach**

Atopic and non-atopic co-morbidities are common. These include food allergies, allergic rhino-conjunctivitis and asthma, but also psychological and psychiatric diseases, such as anxiety and depression, which can profoundly affect the patient's physical, emotional and social life. In addition, the impact of atopic eczema on the patient's psychological well-being can be profound and require specialist intervention. Whilst in most cases atopic eczema can be treated by a general/family physician, dermatologist or paediatrician, in some cases a pulmonologist, allergist, ENT-specialist, ophthalmologist, specialised nurse, psychologist or social worker may be needed. The advantages of a multidisciplinary approach are a combined agreed treatment plan with no contradictory advice and better control of all aspects of atopic eczema and its co-morbidities. The severity of the skin condition, treatment adherence, sleep and overall quality of life will likely improve as a result.<sup>13</sup>

## **Adequate resources to educate patients**

Basic treatment of atopic eczema includes the regular use of a range of topical treatments, as well as using strategies such as managing triggers. Due to the individual and complex nature of the condition, health care providers need adequate resources to teach patients/caregivers in lay language indispensable self-management skills. They also often need to address common concerns about topical corticosteroids, to avoid adherence problems.<sup>14</sup> In practice, however, many health care providers lack those resources, mostly due to lack of time, materials and standardised programmes.

## **Self-management of atopic eczema**






As already pointed out, the treatment of atopic eczema can be laborious, complex and confusing; to self-manage their atopic eczema successfully, patients/caregivers require personalised education, guidance and on-going support by health care providers and patient networks. As atopic eczema can be a life-long disease, with serious exacerbations from time-to-time, it is important that patients/caregivers have timely access to these educational and support resources. Indeed, in many cases, escalation to more aggressive therapies or referrals to specialist care could be prevented by better self-management skills and adherence to treatment at home.<sup>15</sup>

## **Access to affordable and practical treatment**


Many long-standing atopic eczema treatments such as emollients, topical corticosteroids, bandages and systemic therapy are generally accessible to patients; however, other treatments such as phototherapy, whilst also an option, may not be practical due to their burden on life (many hospital visits). New emerging systemic therapies offer much hope to patients with severe atopic eczema however they are not always available. Cost effective treatments should be made available and practical to all patients who would benefit from them.

For patients/caregivers, the cost of treating and managing atopic eczema includes purchasing treatments when these are not reimbursed (e.g. emollients in some countries), extra expenses to avoid triggers (special cosmetics, clothing, bedding, diets, etc.) and indirect costs for loss of education/income.<sup>16</sup> National healthcare provisions and insurance regulations vary widely country by country and for individuals, leading to significant health inequalities, which must be addressed urgently.

## 2. Basic emollients and moisturizers

<p>We <b>recommend</b> gentle cleansing and bathing procedures especially in acutely inflamed or superinfected skin in patients with AE.</p>	<p>↑↑</p>	<p>100%</p> <div style="text-align: center;">  <p><b>100 % Agreement</b></p> </div> <p>(18/18) Expert Consensus</p>
<p>We <b>suggest</b> bathing in moderately warm water over a short duration of time in patients with AE.</p>	<p>↑</p>	<p>&gt;75%</p> <div style="text-align: center;">  </div> <p>(17/19) Expert Consensus</p>
<p>We <b>suggest against</b> the use of alkaline soaps in patients with AE.</p>	<p>↓</p>	<p>100%</p> <div style="text-align: center;">  <p><b>100 % Agreement</b></p> </div>
<p>We <b>suggest</b> that patients with AE use body care products, for example gentle cleansers that do not contain potent irritants or relevant allergens.</p>	<p>↑</p>	<p>(19/19) Expert Consensus</p>
<p>We <b>recommend</b> daily use of emollients, liberally and frequently for patients with AE, as basic treatment of the disturbed skin barrier function.</p>	<p>↑↑</p>	<p>&gt;75%</p> <div style="text-align: center;">  </div> <p>(20/23) Expert Consensus</p>
<p>We <b>suggest</b> using moisturizers with a hydrophilic formula in the summer and moisturizers with a higher lipid content in the winter in patients with AE.</p>	<p>↑</p>	<p>&gt;75%</p> <div style="text-align: center;">  </div> <p>(15/18)<sup>1</sup> Expert Consensus</p>
<p><sup>1</sup> Abstention</p>		
<p>We <b>recommend</b> to apply emollients immediately after bathing or showering and soft pat drying (“soak and seal technique”).</p>	<p>↑↑</p>	<p>100%</p>

		 <p><b>100 % Agreement</b></p> <p>(19/19) Expert Consensus</p>
--	--	---

<p>We <b>recommend</b> the use of emollients as background treatment to prevent flares and to reduce the symptoms of AE.</p>	<p>↑↑</p>	 <p>&gt;75%</p> <p>(18/19)<sup>1</sup> Expert Consensus</p>
--	-----------	--

<sup>1</sup> Abstention

A disturbance of epidermal skin barrier function, clinically manifesting as dry skin, is one of the characteristic features of AE; there is evidence from animal experimental and human studies that the skin barrier anomaly is genetically driven and facilitates the penetration of allergens and other possible noxious substances into the upper skin at the same time leading to increased transepidermal water loss (TEWL).<sup>17, 18</sup>

Filaggrin mutation is the best known anomaly,<sup>19</sup> but alterations in proteases and protease inhibitors as well as altered composition of intraepidermal epidermal lipids (cholesterol, ceramides, free fatty acids) are supposed to also play a role in the pathophysiology of this condition.<sup>20-23</sup> All procedures to improve disturbed skin barrier function or maintain normal function are often called ‘skin care’; they also include measures to avoid irritant influences. It would be better to talk about ‘basic therapy of disturbed skin barrier function’ instead of ‘skin care’. For emollient treatment often the term ‘drug free vehicles’ is used in order to distinguish this from pharmacotherapeutic modalities;<sup>18, 24, 25</sup> indeed only few emollients are registered as drugs but more often as cosmetics or medicinal products.<sup>26-29</sup>

The major principle of this basic therapy of disturbed skin barrier function is the introduction of lipids into the upper epidermis in order to restore the skin barrier.

## 2.1 Emollient therapy

### Basic emollient therapy

Basic emollient therapy is the essence of every treatment of AE.<sup>30, 31</sup> Emollients usually contain a humectant or moisturizer (promoting stratum corneum hydration such as urea or glycerol) and an occludent (reducing evaporation such as lipids or petrolatum). Recently, marketing of non-medicated ‘emollients’ containing active ingredients has softened the delineation of pure emollients working through their physical properties from topical drugs.

Throughout this guideline, ‘emollients’ are defined as ‘*topical formulations with vehicle-type substances without active ingredients*’, whereas ‘emollients plus’ refers to ‘*topical formulations with vehicle-type substances plus additional active, non-medicated substances*’.<sup>32</sup>

A Cochrane review compared moisturizer containing emollients versus no moisturizer and found a better effect in reducing investigator reported severity as well as leading to fewer flares and reduced

use of corticosteroids.<sup>33</sup> There were studies using glycerol-containing moisturizers versus vehicle or placebo.<sup>27, 30</sup> More participants in the glycerol group noticed skin improvement but the MID (minimal important difference) was not met.<sup>34</sup>

Some studies investigated oil-containing moisturizer versus no treatment or vehicle and found no significant differences between the groups. In one study there were fewer flares in the oil group and reduced use of topical corticosteroids. Overall topical active treatment combined with moisturizers was more effective than emollient treatment alone with various outcomes measured.<sup>33, 35</sup>

It is recommended to apply emollients immediately after bathing or showering and soft pat drying. A small study suggests that an emollient applied alone without bathing may have a longer duration as measured by capacitance.<sup>36</sup>

Only emollient preparation devoid of proteinaceous allergens or haptens known to cause contact allergy (such as lanolin/wool wax alcohol or preservatives such as methylisothiazolinone)<sup>37</sup> should be used, especially in children under the age of 2.

The long-term use of maintenance (e.g. twice weekly) emollient therapy after remission may prolong the duration of flare free intervals.<sup>35, 38, 39</sup>

The direct, sole use of emollients on inflamed skin is often poorly tolerated, and it is better to treat the acute flare first with anti-inflammatory procedures including wet wraps (see chapter anti-inflammatory treatment). Emollients are the mainstay of management. Hydration of the skin is usually maintained by at least twice daily application of emollients with a hydrophilic basecontaining for instance 5 % urea or glycerol.<sup>25</sup>

Galenic aspects of the formula should be considered with regard to seasonal differences (more hydrophilic in summer, more lipid content preferably in winter time). Also regional aspects of body sites involved play a role (pastes for intertriginous areas, not too greasy for the face).

According to the acuity of the skin condition, also lipophilic bases may be helpful, especially in more chronic conditions. The use of barrier ointments, bath oils, shower gels, emulsions or micellar solutions enhancing the barrier effect is also recommended.

The applied amount of the topical is crucial, about 250g/week are recommended.<sup>40, 41</sup> It may follow the finger-tip unit rule: a finger-tip unit (FTU) is the amount of ointment expressed from a tube with a 5 mm diameter nozzle and measured from the distal skin crease to the tip of the index finger (ca. 0.5 g); this is an adequate amount for application to two adult palm areas, which is approximately 2 % of an adult body surface area.<sup>24</sup>

The cost of quality emollient (low in contact allergens or hazardous substances) therapies often restricts their use because such therapies are considered to be non-prescription drugs (except for paediatric patients in some European countries).<sup>42</sup>

The use of pure oil products such as coconut or olive oil instead of emulsions will dry out the skin and increase the transepidermal water loss and thus is not recommended.<sup>43</sup>

### **Emollients with non-medicated, active ingredients (emollients plus)**

Several non-medicated products for topical treatment of AE contain putative active ingredients, but are neither fulfilling the definition of nor needing a licence as a topical drug. These products, referred to as 'emollients plus' by the European guideline since 2018, may contain, for example, flavonoids such as licochalcone A, saponins and riboflavins from protein-free oat plantlet extracts<sup>38</sup>, bacterial lysates

from *Aquaphilus dolomiae* or *Vitreoscilla filiformis* species<sup>44-46</sup>, or a synthetic derivative of menthol such as menthoxypropanediol.<sup>32</sup>

The oral supplementation with unsaturated fatty acids like gammalinolenic acid from evening primrose oil or eicosapentaenoic acid from fish oils have been studied as ingredients both improving barrier function as well as enhancing patient acceptance, showing conflicting results.<sup>47, 48</sup> The efficacy of topical evening primerose oil-containing emollients is dependent on the choice of vehicle.

To improve the moisturizing effect of the emollient, several ingredients are used such as urea or glycerol or propylene glycol. Emollients can also be enriched by other ingredients like moisturizers or tannin, ammonium bituminosulfonate, flavonoids or unsaturated fatty acids like omega-3 or omega-6 compounds.

### **Prevention aspect**

Use of emollients has a definite place in secondary and tertiary prevention in patients with AE. There is controversial evidence on primary preventive effects of emollients: Newborns with high risk for atopy/AE, who were treated daily with emollients developed less atopic dermatitis and/or allergic sensitisations in the first year of life.<sup>49, 50</sup> Two larger and longer randomized controlled trials with a less stringent intervention did not confirm these effects.<sup>51, 52</sup> Some experienced clinicians still feel comfortable using emollients in individuals at risk for AE early in life.

### **Safety**

The use of emollients is safe, except for occasional cases of contact allergy. Using emollients may be associated with irritative and allergic side effects. In patients for whom topical anti-inflammatory treatment is indicated, the use of emollients alone involves a considerable risk of disseminating bacterial or viral infections typical for AE.<sup>53</sup>

Emollients may contain ingredients eliciting contact sensitisation such as emulsifiers, preservatives or fragrances.<sup>37, 54, 55</sup> Depending upon the body site also local irritation such stinging or burning sensations may occur in individuals with "sensitive skin".<sup>56</sup> There is a high inter-individual variability in skin tolerability of topical preparations, which has to be considered in the management of AE patients.

Urea may cause irritation in infants and should be avoided in this age group, while toddlers should be treated with lower concentrations than adults. Glycerol seems to be better tolerated than urea plus sodium chloride.<sup>30</sup>

Propylene glycol is easily irritating in young children under two years of age.

Bath oils should not contain strong protein allergens. Peanut or coconut oil preparations may increase the risk of developing skin sensitisation. However, in refined products no protein allergens are present.<sup>57</sup>

## **2.2 Cleansing and bathing**

Skin hygiene procedures play an important role in the management of AE, especially in infants and small children. Some authors consider alkaline soaps as disadvantageous compared to liquid cleansers with adequate skin surface pH and lipid content.<sup>58</sup> Bathing is regarded generally superior to washing or showering – especially in young children – also with regard to emotional and psychological interactions between infants and parents.<sup>59, 60</sup> The water temperature should also not be too high.<sup>61</sup> A

recent systematic review has shown that daily bathing or showering is not associated with changes in disease severity, but 3 studies with qualitative analysis found an improvement of itch and IGA by bathing. Showering may be permitted.<sup>62</sup>






The skin must be cleansed thoroughly, but gently and carefully, in order to get rid of crusts and mechanically eliminate bacterial contaminants in case of superinfection. Cleansers with or without antiseptics can be used. The duration of action of antiseptics is rather short, mechanical cleansing is probably more important. Cleansing agents are available in various galenic forms (syndets, aqueous solutions) and should not be too irritant and should not contain strong allergens.<sup>37, 63</sup> The pH values should be between 5 – 6. A small randomized study regarding the frequency of bathing procedures did not show any difference between twice weekly versus every day.<sup>64</sup>


In infants, it is easier to perform the first stage of gentle cleansing on the nappy mattress rather than directly in the bathtub. The mechanical component of cleaning helps removing bacteria from the stratum corneum. A further cleansing is followed by a rapid rinse performed in the bath (27 – 30 °C). The short duration of the bath (ca. 5 minutes) and the use of bath oils (added for the last 2 minutes of bathing) are aimed at avoiding epidermal dehydration. Topical emollients are preferentially applied directly after a bath or a shower following gentle drying when the skin is still slightly moist.<sup>36</sup> It should be emphasized that most bath oils commercially available in Europe are practically free of proteinaceous allergens.<sup>57</sup> A recent study has found no evidence for a benefit of adding bath additives in addition to standard treatment regimens.<sup>65</sup>, while another study found that some bathing additives such as dead sea salt, oatmeal or natural oils may augment the benefit and reduce the need for or side-effects of pharmacological treatments.<sup>66</sup>

The addition of antiseptics such as sodium hypochlorite (bleach bath) has been proven helpful and is discussed in the chapter antimicrobial therapy.

Adding sodium chloride to bathing water containing oil has been recommended, because of its keratolytic and skin moisturizing effect in concentrations up to 5%.<sup>67</sup> In adults higher salt concentrations with the addition of magnesium have been used to mimic the effect of balneotherapy in the dead sea, also together with UV therapy<sup>68</sup> (see chapter phototherapy).

### 3. Antiinflammatory treatment

<p>We <b>recommend</b> the use of topical corticosteroids (TCS) as anti-inflammatory agents.</p>	<p>↑↑</p>	<p>&gt;75%</p> 
<p>We <b>recommend</b> the use of topical calcineurin inhibitors (TCI) as anti-inflammatory agents.</p>		<p>(24/26) Expert Consensus</p>
<p>We <b>suggest</b> using anti-inflammatory topical agents according to the fingertip unit rule.</p>	<p>↑</p>	<p>&gt;75%</p>  <p>(23/26) Expert Consensus</p>
<p>We <b>suggest</b> the use of wet wraps with diluted (see background text) or low potency topical corticosteroid in acute AE.</p>	<p>↑</p>	<p>&gt;50%</p>  <p>(14/22) Expert Consensus</p>
<p>We <b>recommend</b> TCS in AE especially for treatment of acute flares.</p>	<p>↑↑</p>	<p>100%</p>
<p>We <b>recommend</b> to note and adequately address patients concerns or fears about corticosteroid side effects.</p>		<p>100 % Agreement</p> 
<p>We <b>recommend</b> using TCI particularly in skin areas with a risk of skin atrophy due to TCS application (face, intertriginous sites, anogenital area).</p>		<p>(23/23) Expert Consensus</p>
<p>We <b>suggest</b> initial treatment with topical corticosteroids before switching to a TCI to reduce the risk of skin stinging and burning.</p>	<p>↑</p>	<p>100%</p> <p>100 % Agreement</p>  <p>(23/23) Expert Consensus</p>

<p>We <b>recommend</b> proactive therapy (e.g. twice weekly application) with a suitable TCS or a suitable TCI (see background text) to reduce the risk of relapse and for better disease control.</p>	<p>↑↑</p>	<p>100%</p>  <p>100 % Agreement</p> <p>(22/22) Expert Consensus</p>
--	-----------	--

Effective topical therapy depends on three fundamental principles: sufficient potency, sufficient dosage and correct application.<sup>69</sup> Current approved topical anti-inflammatory therapies are corticosteroids (TCS), calcineurin inhibitors (TCI) and a phosphodiesterase 4 (PDE-4) inhibitor, which is approved in the European Union but not yet available.

Aim of this chapter was to give an overview of the efficacy and safety profile of the current topical therapies and provide a summary of emerging topical treatments for AE.

Based on a systematic search in common databases we conducted a revision of the existing consensus papers.

The applied amount of anti-inflammatory topicals should follow the fingertip unit rule (see chapter emollient therapy). Topical treatment should ideally be applied on hydrated skin, especially when using ointments ('soak and seal' approach).

Topical anti-inflammatory therapy can be done by two approaches: reactive and proactive management. In the reactive treatment regimen, anti-inflammatory topical therapy is applied to lesional skin only and is stopped or rapidly tapered, once visible lesions are cleared or almost cleared. The proactive therapy is defined as a combination of predefined, long-term, anti-inflammatory treatment applied usually twice a week to previously affected areas of skin in combination with liberal daily use of emollients on the entire body. Additionally, it is marked by a predefined appointment schedule for clinical examinations.<sup>70</sup> The proactive regimen is started after the therapy of the acute flare, when lesions have been successfully treated with regular anti-inflammatory therapy. The duration of the proactive management is usually adapted to the severity and persistence of the disease.<sup>71</sup>

Patients with acute, erosive and oozing lesions as well as paediatric patients sometimes do not tolerate standard topical application and may first be treated with 'wet wraps' until the oozing stops. Where clinically superinfected skin is suspected, adding oral antibiotic cover should be considered. Wet wrap medications are highly effective in acute AE and improve tolerance. The use of wet-wrap dressings with diluted or lower potency corticosteroids (group II, III, typical dilutions used are 1:3-1:10, usually just for a few days is sufficient) are a safe crisis intervention treatment of severe and/or refractory flares of AE with temporary systemic bioactivity of the corticosteroids as the only reported serious side effects.<sup>72-75</sup> Wet wraps can be conducted with topical corticosteroid creams and ointments.<sup>76</sup> However, this treatment approach is not standardized yet, and the evidence that it is more effective than conventional treatment with topical corticosteroids in AE is not of high quality. Simple or occlusive medications in less sensitive skin areas and for brief time periods may also increase efficacy and speed up lesion resolution.

### 3.1 Topical corticosteroids

#### Mechanisms of action and efficacy

Topical corticosteroids (TCS) are a first-line anti-inflammatory treatment, typically applied on acutely inflamed skin according to the needs (pruritus, sleeplessness, new flare).<sup>77, 78</sup> The lipophilicity and the low molecular weight of TCS allows good penetration into the skin and binding to a steroid receptor in the cytoplasm. The CS-receptor complex acts as a transcription factor with dual activity decreasing the synthesis of proinflammatory cytokines and increasing the synthesis of anti-inflammatory mediators. The potency of topical corticosteroids is grouped according to Niedner from mild (class I) to super-potent (class IV).<sup>79</sup> This classification is used across Europe, except for France, where this classification is similar but in an inversed ranking. This classification is used throughout this guideline. In contrast, the US-American classification differs and recognises 7 groups: from VII (weakest) to I (most potent).

Latest generation TCS with a better risk-benefit ratio are favoured over earlier generation TCS.

### **Dosage: acute flare, short term, long term**

When choosing a TCS beside potency the galenic formulation, patient age and body area to which the medication will be applied should be considered. In children, low to moderate potency TCS should routinely be used. Adolescent and adult patients can use potent to very potent TCS under specialist supervision in an acute flare of AE for a short period of time. Potent and very potent TCS are sometimes also used in younger age groups under specialist supervision.

Treatment of the face and especially the peri-orbital region or other sensitive areas (folds, neck) should be restricted to mild-to-moderate TCS (class I and II).<sup>80</sup>

With mild disease activity a small amount of TCS twice to thrice weekly (monthly amounts in the mean range of 15 g in infants, 30 g in children and up to 60–90 g in adolescents and adults, roughly adapted to affected body surface area), associated with a liberal use of daily emollients allows for a good weekly maintenance treatment routine.

Also, patients with moderate or severe AE can benefit from long-term proactive treatment with a moderate to potent TCS. Twice weekly application of fluticasone propionate or methylprednisolone aceponate (TCS class III) has shown a significantly reduction of AE-flare recurrence. Outside of the context of clinical trials, similar experience also exists for other class III and even class II TCS.<sup>77, 78, 81</sup>

### **Safety**

Potent and very potent TCS of group III and IV may be absorbed systemically and can more likely cause depression of adrenal function than group I and II treatments, but their systemic effects will decrease more quickly due to more rapid restitution of the skin barrier, and cases of significant adrenal suppression from long-term TCS use are very rare.<sup>82</sup> Ghajar et al. reviewed 9 studies (n=371) measuring serum cortisol levels after two weeks of TCS application. Low to moderate potency TCS showed no risk for adrenal suppression after short-term use.<sup>83</sup> Fishbein et al. reviewed 12 studies with 2224 children using TCS. In 4 of 157 measured participants (3%) mild adrenal suppression was reported.<sup>84</sup>

Side-effects of TCS comprise a variety of skin changes mostly in the sense of skin atrophy – except from contact allergy to corticosteroid substances. The skin changes manifest as thinning of the skin, development of teleangiectasia (rubeosis steroïdica), spontaneous scars (pseudo-cicatrices stellaires), ecchymosis, striae distensae (stretch marks) and hypertrichosis.<sup>85</sup>

A review of 11 trials showed a prevalence rate of burning, pruritus, irritation or warmth after TCS application ranging from <1% to 6%.<sup>86</sup>

In infants, inappropriate use of high potency TCS in the diaper area can lead to granuloma gluteale infantum or even iatrogenic Cushing's disease.<sup>87</sup>

The risk of ocular complications by TCS seems to be low. The application of TCS to the eyelids and periorbital region in adults with AE, even over longer periods of time, was not associated to the development of glaucoma or cataracts.<sup>88</sup> However, there are single case reports of increased

intraocular pressure after topical application of TCS, therefore physicians should be aware of this potential risk.<sup>89, 90</sup>

In the face, rosacea-like perioral dermatitis can be induced by inappropriate, long term use of potent or super-potent TCS (group III, IV) and the skin can become dependent on TCS use (“red face syndrome” or “corticosteroid addiction syndrome”). It is characterized by persistent erythema, burning and stinging sensation and it has been reported mostly on the face and genital area of women.<sup>91</sup>

## **Monitoring**

Monitoring by physical examination for cutaneous side effects during long term use of potent TCS is very important.

Itch, which can be assessed by itch Numeric Rating Scale (NRS), is the key symptom for evaluation of response to treatment, and tapering should not be initiated before the itch has largely resolved. In addition to continuous background emollient skin care, one to two applications of TCS per day may be necessary with low and mid-potency TCS to reduce the itch at the beginning, but one correctly dosed treatment per day is typically sufficient.<sup>92, 93</sup> Dose tapering is usually performed to avoid rebound flares, although no controlled studies have demonstrated its usefulness. Tapering strategies consist of switching to a less potent corticosteroid or keeping a more potent one while reducing the frequency of application (intermittent regimen). The most constructive way to spare corticosteroids and avoid corticosteroid-related side-effects is to start the anti-inflammatory treatment early and use them intensively during the acute flares.<sup>69</sup>

## **Combination with other treatments**

The combination of TCS with topical calcineurin inhibitors (TCI) at the same site does not seem to be useful. At least in pediatric patients with severe AE, the efficacy and safety profile of pimecrolimus cream 1% combined with fluticasone were similar to that of fluticasone alone.<sup>94</sup> Treating sensitive body areas such as the face (with predilection to skin thinning) with TCI while treating other affected body areas with a TCS is a common practice but class I and II TCS can be used equally effectively in the face and neck for acute flares. Initial treatment with TCS may be considered in patients with acute flare to minimize TCI site reactions (stinging and burning).<sup>71</sup>

## **Special considerations**

Patient fear of side effects of corticosteroids (corticophobia) is quite common and should be recognized (e.g., by TOPICOP score<sup>95</sup>) and adequately addressed to improve adherence and avoid undertreatment.<sup>96-98</sup>

In pregnancy and lactation lower potency TCS should be used where possible (see chapter Pregnancy, breastfeeding, and family planning).

## **3.2 Topical calcineurin inhibitors**

### **Mechanisms of action and efficacy**

Two topical calcineurin inhibitors (TCI) (tacrolimus ointment and pimecrolimus cream) are licensed for AE treatment. Pimecrolimus 1% cream and tacrolimus 0.03% ointment are approved in the EU from 2 years of age and above. Elidel® cream has additionally been approved in Europe down to 3 months of age. Tacrolimus 0.1% ointment is only licensed in patients age 16 years and above. TCIs have an immunosuppressive effect by inhibiting the activity of the phosphorylase enzyme calcineurin and thus inhibiting the activation of T lymphocytes. The transepidermal penetration of TCI is lower than TCS.<sup>99</sup>

<sup>100</sup> TCI are a first line therapy for sensitive areas where TCS use is likely associated with side effects or in areas where TCS had already caused side effects. The efficacy of both formulations has been demonstrated against vehicle in clinical trials for short-term (three weeks)<sup>101, 102</sup> and long-term use up to one year.<sup>103, 104</sup>

The efficacy of long-term monotherapy with tacrolimus ointment has been shown in children and adults.<sup>105-107</sup> In adults, long-term proactive treatment with 0.1% tacrolimus ointment has shown good effectiveness for flare prevention, similar to class III TCS.<sup>106</sup> Proactive tacrolimus ointment, but not Pimecrolimus 1% cream, has been shown to be safe and effective for up to 1 year in reducing the number of flares and improving the quality of life (QoL) in both adults and children.<sup>108, 109</sup> Pimecrolimus 1% cream has been studied in infants and children in a combination regimen with TCS<sup>110, 111</sup>, the latter being given if a flare occurred. Less data are available for children under 2 years of age.<sup>112, 113</sup> In children, twice-weekly treatment with tacrolimus 0.03% ointment has been reported to reduce the number of flares and to prolong flare free intervals.

### **Dosage: acute flare, short term, long term**

The anti-inflammatory potency of 0.1% tacrolimus ointment is similar to a potent corticosteroid (class III)<sup>105, 106, 114</sup>, and 0.1% tacrolimus ointment is clearly more effective than 1% pimecrolimus cream.<sup>107</sup>

TCS and TCI can be used in a daily regimen during an acute AE-flare. The efficacy of intermittent treatment twice or three times weekly has been investigated in different trials.<sup>108, 109</sup>

### **Safety**

Safety data of both TCI have been reported in many clinical trials and registries and high-quality long-term safety data have been published on 10-year tacrolimus and 5-year pimecrolimus studies, demonstrating the safety of this anti-inflammatory treatment in daily practice.<sup>115, 116</sup>

None of the TCI induces skin atrophy.<sup>117, 118</sup> This favors their use over TCS in sensitive body areas such as the eyelid region, the perioral skin, the genital area, the axilla region or the inguinal fold, and makes them suitable for long-term management. In addition, the use of TCI may potentially reverse some of the side effects of TCS when applied on sensitive areas.<sup>119</sup>

The most frequently observed side effect is transient warmth, tingling or burning sensation at the application site, which may last up to 1 h.<sup>94, 106</sup> However, this side effect typically vanishes within a few days.<sup>120</sup> Some patients also experience a transient worsening of their AE. These side effects are more common with tacrolimus ointment than with pimecrolimus cream, in particular when they are applied on acutely inflamed skin. In some patients they are severe enough to induce prompt treatment discontinuation. Initial treatment with TCS should thus be considered in patients with an acute flare to minimize these site reactions.<sup>71</sup> In some patients intake of alcohol can trigger transient but marked facial flushing, this innocent but annoying side effect is very inconsistent even in the same patient.

Generalized viral infections such as eczema herpeticum or eczema molluscatum have been observed during TCI treatment in some studies<sup>121, 122</sup>, but a high number of clinical trials failed to demonstrate an increased frequency or showed only a transient increase in viral infection.<sup>121, 123-125</sup>

After initial concerns from animal studies, resulting in a black box warning from the US Food and Drug Administration (FDA), no convincing evidence for an increased risk of lymphoma has been found in humans.<sup>126</sup> A long-term safety study over 10 years using tacrolimus ointment 0.03% or 0.1% in children did not show an increased risk of cancer or lymphoma.<sup>127</sup> The application of TCI is not associated with an increased risk for non-melanoma skin cancer, other malignancies or photocarcinogenicity.<sup>116, 128-132</sup> In a retrospective cohort study with more than 90,000 participants and over ten years, no increased risk of basal cell carcinoma or squamous cell carcinoma was observed.<sup>133</sup> The JOELLE study investigated

the risk of lymphoma and skin cancers with the use of TCI and TCS in a very large cohort of paediatric and adult patients and found a positive association. However, given the study design, confounding factors, such as disease severity, have not been ruled out.<sup>134</sup> A recent paediatric prospective observational cohort study (APPLES, n=7,954) found no significant association between regular tacrolimus use and lymphoma risk over a 10 year follow up period. Nevertheless, given that the long-term oral use of cyclosporine (calcineurin inhibitor) is associated with an increased photocarcinogenicity risk in solid organ transplant patients, exposure of the skin to sunlight should be minimized and effective UV protection through the use of sunscreens and appropriate clothing should be recommended in all patients using TCI. Furthermore, the combined use of TCI and phototherapy should be avoided.<sup>135</sup>

Clinicians should be aware of the black-boxed warning on the use of TCI inhibitors and may discuss this with patients to improve adherence, even if the observational study evidence has not found a convincing association between long-term TCI use and cancer development.<sup>127</sup>

### **Monitoring**

Monitoring by physical examination for cutaneous side effects during long term treatment with TCS and TCI is important (also see above).

### **Special considerations**

Though TCIs are not approved in pregnancy and lactation (see chapter Pregnancy, breastfeeding, and family planning), off-label use in pregnancy and lactation is possible as there is no teratogenic potential reported for the entire substance class.<sup>136</sup>

### 3.3 Topical phosphodiesterase 4 inhibitors

#### Mechanisms of action and efficacy

The topical phosphodiesterase 4 (PDE-4) inhibitor, crisaborole, is approved for treatment of mild to moderate AE in patients 2 years of age and older in the United States of America, Canada, Australia, Israel and Hong Kong. Crisaborole has been approved in the European Union in 2020 but is not commercialized in the European market.

The inhibition of PDE-4 leads to increased levels of intracellular cAMP, which results in a reduction of inflammatory cytokines.<sup>137, 138</sup> Several studies have reported anti-inflammatory and anti-pruritic effects of crisaborole in AE.<sup>139, 140</sup> A systematic review by Fahrback et al. with nine randomized controlled trials confirmed the efficacy of crisaborole.<sup>141</sup> However, only three studies provided baseline EASI and none provided SCORAD measurement. In the pivotal studies, efficacy was only assessed by Investigator Static Global Assessment (ISGA).<sup>142</sup> Therefore, a direct comparison of the efficacy of crisaborole against TCI or TCS is currently not possible. Based on available data the efficacy of PDE-4-inhibitors seems to be similar to mild TCS or pimecrolimus, however further studies are needed.

#### Safety

Reported side-effects of crisaborole were short-term application-site pain, burning or stinging.<sup>142</sup> Also the long-term safety profile over 48 weeks appears to be favorable.<sup>143</sup>

#### Special considerations

Other topical phosphodiesterase 4 inhibitors under investigation include Lotamilast (RVT-501) and Difamilast (OPA-15406).<sup>144-146</sup>


### 3.4 Upcoming topical treatment

Upcoming topical therapies include several topical janus-kinase (JAK) inhibitors. First promising phase II clinical trial data with the topical JAK-inhibitor tofacitinib have been published.<sup>147</sup> Despite these promising results, the clinical development programme of tofacitinib has been stopped. Delgocitinib has been approved for the use in AE in Japan.<sup>147, 148</sup> In a 4-week study the selective JAK-1 and JAK-2 inhibitor ruxolitinib showed a similar or even higher efficacy in mild to moderate AE compared to triamcinolone cream (group III TCS), and has recently been approved in the US.<sup>149</sup> Other JAK inhibitors with similar or different selectivity (brepocitinib) are in the pipeline for topical therapy, but none is currently licensed in Europe.


Further upcoming therapies include tapinarof, an aryl hydrocarbon receptor agonist, which showed greater efficacy in AE treatment than vehicle twice daily after 12 weeks.<sup>150</sup>

The transient receptor potential vanilloid 1 (TRPV1) antagonist, PAC-14028, was investigated in a phase IIb study in patients with mild-to-moderate AE and showed a significantly higher reduction in IGA than vehicle cream. Although there was an improvement in AE according to SCORAD and EASI, the effects of PAC-14028 were not statistically significant compared to the vehicle.<sup>151</sup>

## 4. Antimicrobial treatment

<p>We <b>suggest</b> treatment with topical antiseptic drugs – including sodium hypochlorite 0.005% baths -in patients with a history of recurrent skin infections.</p>	<p>↑</p>	<p>100%</p>  <p>100 % Agreement</p> <p>(24/24) Expert Consensus</p>
---	----------	--

### 4.1 Anti-bacterial treatment

<p>We <b>recommend</b> a short course of systemic antibiotics only in AE patients with extensive clinically superinfected lesions.</p>	<p>↑↑</p>	<p>100%</p>  <p>100 % Agreement</p> <p>(25/25) Expert Consensus</p>
<p>We <b>suggest</b> against the long-term application of topical antibiotics, due to the risk of resistance development .</p>	<p>↓</p>	
<p>We <b>suggest</b> that topical anti-inflammatory treatments are continued during the treatment of <i>Staphylococcus aureus</i> superinfection episodes.</p>	<p>↑</p>	

The prevalence of *Staphylococcus aureus* (SA) colonization among patients with AE is typically above 80% for lesional skin and 40% for nonlesional skin versus 10% in healthy individuals, but this depends largely on the culture methods used. The density of the colonization correlates with the disease severity.<sup>152</sup> Topical corticosteroids and calcineurin inhibitors reduce the colonization rate of SA in AE. Although AE patients are prone to SA skin infections, most AE patients colonized by SA do not show overt signs of infection (i.e. weeping, honey-coloured crusts, and pustules). Clinical signs of skin inflammation during AE flares may overlap with signs of skin infection, making the diagnosis of skin infection *per se* challenging.<sup>153</sup> Bacterial swabs are commonly unhelpful, as they do not alter the treatment approach, unless the patient is infected with a resistant bacterial species. SA is a major trigger of AE flares, but its role in the development of AE is still debated. There are a number of mechanisms through which SA can drive eczematous inflammation, including the release of superantigen toxins, which enhance T cell activation of superantigen-specific and allergen-specific T cells, the expression of IgE anti-staphylococcal antibodies and increased expression of IL-31 which leads to pruritus and subsequent scratching.<sup>153, 154</sup> Scratching favors binding of SA to the skin, and the increased amount of SA derived ceramidase aggravates the skin barrier defect. Moreover, superantigen production increases expression of alternative glucocorticoid receptors that do not bind to topical corticosteroids, which leads to treatment resistance.<sup>155</sup> Biofilm formation by AE-associated staphylococci most certainly also plays a major role in the occlusion of sweat ducts and leads to inflammation and pruritus.<sup>155</sup>


A Cochrane review by George et al.<sup>156</sup> with 41 studies and 1,753 participants assessed the effect of different interventions to reduce SA on the skin in people with AE. Four studies evaluated oral

antibiotics versus placebo. No difference was found in the global severity assessment (RR 0.80; 95% CI 0.18 to 3.50; 2 RCTs; GRADE: low-quality) and little to no effect was reported for QoL (MD 0.11, 95% CI -0.10 to 0.32; 1 RCT; GRADE moderate-quality). Fourteen studies compared topical corticosteroids plus antibiotic with topical corticosteroids alone. Steroids/antibiotics combination participant may have a slightly greater improvement in the global signs and symptoms (RR 1.10, 95% CI 1.00 to 1.21; 3 RCTs; GRADE: low-quality). For QoL, little to no effect was found (MD -0.18, 95% CI -0.40 to 0.04; 1 RCT GRADE: moderate-quality). For bleach baths versus placebo or bath emollients, no difference was reported in the global improvement at one month follow-up (RR 0.78; 95% CI 0.37 to 1.63; 1 RCT; GRADE: low-quality) and little to no effect was documented for QoL (MD 0.90; 95% CI -1.32 to 3.12; 1 RCT; GRADE: moderate quality). This corresponds to recent data showing no antimicrobial effect in vitro of diluted bleach baths.<sup>157</sup>

For all three interventions adverse events leading to withdrawal of treatment were rare and evidence was very low quality. For antibiotic resistance, no significant difference was demonstrated between intervention groups and placebo but results remain uncertain because quality of evidence was very low.

Eight randomized controlled trials evaluated treated textiles (as silver) versus placebo, studies were not pooled due to heterogeneous design but no clear advantage was reported. Juenger et al.<sup>158</sup> found no effect in the overall disease control of AE in the silver textile group compared with non-silver textile (RR 2.40; 95% CI 0.91 to 6.36; RoB: high) and Gauger et al.<sup>159</sup> reported no significant difference between groups in the quality of life questionnaire (RoB: high). For summary of findings tables (modified), see appendix III.

## 4.2 Anti-viral treatment

<p>We <b>recommend</b> to treat eczema herpeticum without delay using systemic antiviral therapy, such as aciclovir.</p>	<p>↑↑</p>	<p>100%</p>  <p>100 % Agreement</p>
<p>We <b>recommend</b> to perform vaccinations in line with national guidelines.</p>	<p>↑↑</p>	

Viral infections including herpes simplex, varicella zoster, molluscum contagiosum, smallpox and coxsackie viruses occur more frequently in AE patients than in healthy individuals, with a tendency to disseminated, widespread disease.<sup>160</sup>

**Eczema herpeticum (EH)**, a disseminated herpes simplex virus (HSV) infection, is a potentially serious complication of AE that requires immediate medical action. Patients, mostly children, present with disseminated vesicles, fever and lymphadenopathy and can develop complications such as keratoconjunctivitis, meningitis and encephalitis. Predisposing factors of first episode of EH or recurrent EH are early onset and severe or untreated forms of AE with high IgE levels and atopic comorbidities (extrinsic AE). Pre-treatment with topical corticosteroids or calcineurin inhibitors is not associated with an increased risk of developing EH. There is no evidence to recommend discontinuation of topical anti-inflammatory treatments during an EH outbreak.<sup>161</sup> Mainstay of EH therapy is systemic treatment with aciclovir or valaciclovir.<sup>162</sup> Treatment should be started immediately, once the clinical diagnosis is made.<sup>40</sup>

**Varicella-zoster virus (VZV)** infection in an immunocompetent child is usually a mild, self-limiting disease. This infection is, however, known to facilitate secondary local or systemic bacterial infection and a particular concern in children with AE. Earlier studies demonstrated the safety and efficacy of VZV vaccination in these children who appear to benefit from this vaccination.<sup>163</sup> Moreover, in children with AE, immune response to VZV vaccine is comparable to healthy children.<sup>164</sup> Therefore, parents of atopic children should be encouraged to fully immunize their children depending on specific local guidelines.


**Molluscum contagiosum virus (MCV)** infection is in general benign and self-limiting but frequent in patients with severe AE. A large variety of topical treatments have been reported such as cantharidin, potassium hydroxide, tretinoin cream, and topical cidofovir.<sup>165</sup> Physical therapies including cryotherapy and curettage are also effective, but not always well tolerated in paediatric patients and usually unnecessary given the self-limiting nature of MCV infections.<sup>53</sup> Topical treatment of AE with TCS should be continued during MCV infection.

**Eczema vaccinatum (EV)** is a complication of smallpox vaccination known to occur in AE patients. The vaccinia virus disseminates and causes an extensive rash and severe systemic illness with a mortality rate estimate at 5-40%.<sup>166</sup> Therefore, smallpox vaccination is contraindicated in patients with a history of or currently active AE.<sup>167</sup> The existence of an attenuated vaccine (Modified Vaccinia Ankara virus) and three antiviral drugs, in addition to vaccinia immunoglobulin, provides means of preventing or treating EV.<sup>168, 169</sup> Should a smallpox outbreak necessitate an emergency mass vaccination, the choice of vaccination strategies, such as ring or mass vaccination, has to be determined by policymakers.

**Eczema coxsackium (EC)** is a disseminated form of coxsackie virus infection mostly occurring in children with active AE lesions.<sup>170</sup> The coxsackie virus A6 strain leads to atypical disease manifestations, which are classified as i) a diffuse form (lesions extended to the trunk), ii) an acral form (lesions with a mainly acral distribution), or iii) eczema coxsackium (disseminated lesions on preexisting eczematous areas).<sup>171</sup> This rash may be confused with bullous impetigo or eczema herpeticum. Symptomatic treatment includes use of topical corticosteroids and wet wrap therapy.<sup>172, 173</sup>

Regional vaccination programmes should be followed by all AE patients as recommended. The denial of vaccination because of diagnosed AE is a misconception possibly leading to fatal consequences.

### 4.3 Anti-fungal treatment

<p>We <b>suggest</b> topical or systemic antifungal therapy in some patients with AE, mainly in those suffering from the “head and neck” variant of AE. and with demonstrated IgE-sensitization to <i>Malassezia spp.</i></p>	<p>↑</p>	<p style="text-align: center;">&gt;95%</p>  <p style="text-align: center;">(23/24) Expert Consensus</p>
---	----------	--

Despite its role as a commensal on healthy human skin, *Malassezia spp.* is attributed a pathogenic role in AE, as it may interact with the local skin immune response and barrier function. Through a deficient skin barrier, *Malassezia spp.* may activate keratinocytes and dendritic cells causing secretion of a range of pro-inflammatory cytokines including IL-4, IL-13 and IL-17.<sup>174-176</sup> Several randomized, placebo controlled trials investigated the benefit of topical or systemic antifungal treatment for AE patients.<sup>177-179</sup> The ambiguous results of these clinical trials might be attributed to selection bias. It can be speculated that antifungal therapies are more effective in certain subgroup of AE. It seems for example that antifungal therapy shows beneficial effects in patients with a head-neck-type distributed AE and detectable IgE-mediated sensitization against *Malassezia*.<sup>180</sup> It has also been shown that sensitization against this skin-colonizing yeast can correlate with disease activity.<sup>181</sup> The most common class of antifungal drugs prescribed for AE patients are azoles such as ketoconazole and itraconazole which have also some anti-inflammatory properties.<sup>178</sup> Due to a better benefit:side effect ratio imidazole derivatives (fluconazole or itraconazole) should be prescribed instead of ketoconazole for systemic treatment. In summary, antifungal treatment with either topical ketoconazole or ciclopiroxolamine or systemic itraconazole or fluconazole can be considered for those patients who suffer from head–neck dermatitis, particularly for those who are characterized by clear IgE-sensitization to *Malassezia spp.*

## 5. Antipruritic treatment

Itch is the most important clinical symptom in AE with particular impact on emotional dimensions of perception as compared to other pruritic dermatoses. Most drugs successfully used in AE patients, because they are targeting the inflammation, will also have a measurable effect on the itch. There is only a limited number of studies that specifically assessed the antipruritic effect of treatment modalities in AE. The treatment of itch in AE requires a multi-dimensional approach treating itch itself, but also the contributing factors, such as the dry skin and skin inflammation.

### 5.1 Anti-pruritic effect of anti-inflammatory treatment

The anti-inflammatory agents, both topical and systemic ones, reduce skin lesions and significantly relieve itch. Although topical corticosteroids do not act as direct antipruritic agents,<sup>182</sup> several studies described the anti-inflammatory effect of topical corticosteroids in AE, in which pruritus was one parameter among others studied.<sup>183</sup>

Topical calcineurin inhibitors relieve pruritus significantly in AE. Itch is completely relieved after the first days of treatment in both adults and children. Topical calcineurin inhibitors appeared to significantly reduce AE itch by 36% compared to vehicle application.<sup>183</sup>


Crisaborole was shown to be effective in reducing itch in mild-to-moderate AE patients. Reszke et al. in their review consider that patients receiving crisaborole 2% ointment experienced pruritus relief at day 29 more commonly than patients receiving vehicle.<sup>184</sup> Furthermore, crisaborole was more likely to provide antipruritic response at the earliest assessment on day 2 and early improvement of pruritus at day 6 than vehicle.<sup>184</sup> However, crisaborole is not available on the European market.

Dupilumab as systemic anti-inflammatory agent showed high effectiveness in reducing itch in AE patients. All the studies confirmed the efficacy of dupilumab in terms of improvement of skin lesions and alleviation of pruritus.<sup>185-188</sup> Similar data exists for other systemic drugs recently licensed for AE treatment, such as tralokinumab, abrocitinib, baricitinib and upadacitinib (see chapters Biologics and JAK-Inhibitors).<sup>189-192</sup>

A meta-analysis of 1505 patients with moderate-to-severe AE revealed that dupilumab started to unveil its antipruritic properties by days 2 and 5 in adults and adolescents, respectively. The response increased over time and was sustained until the end of the studies (up to 1 year).<sup>186</sup>

## 5.2 Anti-pruritic treatment

### Polidocanol


We <b>cannot make a recommendation</b> on the use of polidocanol in itch treatment in AE.	0	<p>&gt;75%</p>  <p>(16/17) Expert Consensus</p>
---	---	--

Case series described the efficacy of a combination of the anaesthetic polidocanol and 5% urea.<sup>193</sup> In children with AE, the combination showed a pruritus improvement of 30% in comparison with an emollient.<sup>194</sup> Polidocanol is not licensed for AE in Europe, but OTC products are available.

### Capsaicin

Capsaicin is a naturally occurring alkaloid and the principal pungent of hot chilli peppers. Capsaicin binds to the TRPV1 ion channel, which is present on many itch-mediating C-fibres. Capsaicin has been advocated to be antipruritic in various dermatoses. Concerning AE, experimental studies<sup>195</sup> and case series<sup>196</sup> report on clear itch reduction. However, the practical treatment and up dosing are challenging, and no controlled study has been published.


### Topical antihistamines

We <b>recommend against</b> topical antihistamines in itch treatment in AE.	↓↓	<p>&gt;75%</p>  <p>(17/18)<sup>1</sup> Expert Consensus</p>
---	----	--

<sup>1</sup> 1 Abstention

5% doxepin cream exhibited antipruritic effects in three controlled studies in AE; one RCT assessed the efficacy of cromoglycate 4% lotion.<sup>183</sup> The meta-analysis of those studies documented that the use of topical antihistamines markedly reduced itch of AE by 27% in patients in comparison with the vehicle. However, topical doxepin therapy is not licensed and not used in any European country due to an increased risk of contact allergy, especially when the treatment exceeds eight days.



## UV therapy



<p>We <b>suggest</b> UV therapy (both narrowband UVB and UVA1) for the treatment of itch in AE.</p> <p>Also see phototherapy chapter</p>	↑	<p>&gt;75%</p>  <p>(17/19)<sup>1</sup> Expert Consensus</p>
--	---	--

<sup>12</sup> Abstention

UV phototherapy relieves pruritus in AE, which has been demonstrated in several studies. A systematic review of 19 available RCTs suggests the usage of narrowband UVB and UVA1 as the most effective in the treatment of AE, including reduction in itch intensity.<sup>197</sup> A recent study by Jaworek et al.<sup>198</sup> documented that narrowband UVB reduces itch in AE patients significantly better than ciclosporine.<sup>198</sup> There is no 'anti-itch-specific' data for UV phototherapy available, which would differ from the general recommendations for UV phototherapy treatment of AE.

## Systemic antihistamines

<p>We <b>suggest against</b> using first generation systemic antihistamines as a longterm treatment for itch in AE.</p>		<p>100%</p>  <p>100 % Agreement</p> <p>(22/22) Expert Consensus</p>
---	---	--

<p>We <b>suggest against</b> using second generation systemic antihistamines as a treatment for itch in AE.</p>		<p>&gt;75%</p>  <p>(13/15)<sup>1</sup> Expert Consensus</p>
---	---	--


<sup>1</sup> 1 Abstention

Antihistamines (AH) have been used for decades in an attempt to relieve pruritus in patients with AE. However, only a few randomized controlled trials have been conducted and the majority of them showed only a weak or no effect in decreasing pruritus.<sup>199-207</sup> A recent Cochrane review did not find consistent evidence that H1 AH treatments are effective as 'add-on' therapy for AE when compared to placebo.<sup>208</sup> The certainty of evidence for this comparison was of low and moderate quality.<sup>208</sup> It seems that only fexofenadine may lead to small improvement in patient-assessed pruritus (mean difference (MD) -0.25, 95% CI -0.43 to -0.07; n = 400) and a greater reduction in the ratio of physician-assessed pruritus area to whole body surface area.<sup>208, 209</sup> However, these reductions may not be clinically meaningful<sup>208</sup>. In general, AH are safe to use, also for a long period of time.<sup>210</sup> There is limited data for the antipruritic effect of AH (H1 antagonists) in AE in general, and the effect of both first and second generation AH on pruritus in patients suffering from AE is very limited. The clinical value of systemic antihistamines for the anti-pruritic treatment of AE is not supported. Especially the first generation of systemic AH may affect sleep quality and reduce rapid eye movement (REM)-sleep. Therefore, regular long-term use of sedating antihistamines is not recommended.<sup>7, 211, 212</sup>

## Opioid receptor antagonists

The  $\mu$ -opioid receptor antagonist nalmefene was applied in smaller randomized, controlled studies in AE. A dosage of 10 and 20 mg each once per day showed significant relief of pruritus in three studies.<sup>213-215</sup> In open-label trials and one double-blind, placebo-controlled study trial, the only orally active  $\mu$ -opioid antagonist naltrexone 25–150 mg per day showed considerable antipruritic effects.<sup>216, 217</sup> Common adverse events include anxiety, arthralgia, dizziness, drowsiness, fatigue, vomiting and headache. None of these substances is currently licensed for the treatment of AE itch. The benefit-risk ratio is unfavourable.







## Selective serotonin reuptake inhibitors

We <b>suggest against</b> the use of selective serotonin reuptake inhibitors as itch treatment in AE patients.	↓	100%  100 % Agreement (20/20) Expert Consensus
--	---	---

The antipruritic effect of the selective serotonin reuptake inhibitors paroxetine and fluvoxamine was investigated in an open-label trial in dermatological patients. A few patients with pruritus due to AE were included, who responded with considerable reduction in pruritus. In these patients, the pruritus was reduced about half in intensity (maximal antipruritic effect score,  $45.0 \pm 7.1\%$ ).<sup>218</sup> Although the evidence of antipruritic activity of selective serotonin reuptake inhibitors in AE is very low, these agents might be used as second or third line therapy in other types of chronic itch.

Adverse events include constipation, diarrhoea, dizziness, drowsiness, ejaculatory and erectile dysfunction, decreased libido, insomnia, nausea and headache. The risk–benefit ratio of SSRI is highly unfavourable.

## 6. Phototherapy and Photochemotherapy

<p>We <b>recommend</b> narrowband UVB and medium-dose UVA1 for AE patients with moderate-to-severe AE.</p>	<p>↑↑</p>	<p style="text-align: center;">&gt;95%</p>  <p style="text-align: center;">(24/25) Expert Consensus</p>
<p>We <b>suggest</b> the use of narrowband UVB or UVA1 in <i>children and adolescents</i> after the assessment of skin type (see background text), but frequent and/or protracted treatment cycles should be avoided.</p>	<p>↑</p>	<p style="text-align: center;">&gt;95%</p>  <p style="text-align: center;">(24/25)<sup>1</sup> Expert Consensus</p>
<p><sup>1</sup> 1 abstention</p>		
<p>We <b>suggest</b> that other phototherapy modalities (balneophototherapy, UVAB, BB-UVB, UVA) are to be considered as a second choice.</p>	<p>↑</p>	<p style="text-align: center;">100%</p>  <p style="text-align: center;">(25/25) Expert Consensus</p>
<p>We <b>suggest</b> that PUVA therapy is only used, when previous treatment cycles with other phototherapies were ineffective or when approved drug treatments are contraindicated, ineffective or have caused side effects.</p>	<p>↑</p>	<p style="text-align: center;">100%</p>  <p style="text-align: center;">(25/25) Expert Consensus</p>
<p>We <b>suggest</b> co-treatment with topical emollients during phototherapy.</p>	<p>↑</p>	<p style="text-align: center;">100%</p>  <p style="text-align: center;">(25/25) Expert Consensus</p>
<p>We <b>recommend against</b> the use of prolonged or repeated treatment cycles and maintenance regimens with all phototherapy modalities.</p>	<p>↓↓</p>	<p style="text-align: center;">100%</p>  <p style="text-align: center;">(24/24) Expert Consensus</p>

We **recommend against** the use of all phototherapy modalities in patients with a history of skin cancer and with an increased risk of skin cancer (including photodamaged skin and those on systemic immunosuppressants (see background text)).



100%  
100 % Agreement  
(25/25)  
Expert Consensus

## 6.1 Efficacy of different photo(chemo)therapy modalities in clinical trials

Photo(chemo)therapy can be used in patients with moderate-to-severe AE recalcitrant to topical therapy. Background information on photobiology, UV modalities and practical aspects can be found in Appendix I.

The systematic review of Garritsen et al. investigated the efficacy and safety of treatment with photo(chemo)therapy in AE patients up to 26 October 2012.<sup>197</sup> Only RCTs were included. No meta-analysis could be performed due to methodological heterogeneity. Nineteen studies were included with a total of 905 adult participants (sample size range 9 to 180), treatment duration varying between 10 days and 40 weeks, and with a follow-up up to 1 year (mean 15.3 weeks).

Studies on BB-UVB (4 studies, n=120),<sup>219-222</sup> NB-UVB (6, n=188),<sup>223-228</sup> UVA (3, n=84),<sup>221, 222, 227</sup> UVA1 (9, n=259),<sup>223, 225, 226, 229-234</sup> cold-light UVA1 (1, n=50),<sup>234</sup> UVAB (7, n=200),<sup>219, 222, 231, 232, 234-236</sup> full-spectrum light (1, n=20),<sup>237</sup> PUVA (2, n=29),<sup>224, 233</sup> visible light (1, n=20),<sup>220, 227</sup> and balneophototherapy (1, n=90) were included.<sup>228</sup> Concomitant emollient use was permitted in all the RCTs. Detailed tables including patient and treatment characteristics, study outcomes and GRADE assessment can be found in the paper of Garritsen et al.<sup>197</sup> Below is a summary of the results.

Three studies of low<sup>226</sup> to moderate quality<sup>223, 225</sup> compared medium dose (MD) **UVA1 with NB-UVB**; no significant difference was found in clinical signs (apart from 1 clinical sign instrument (Leicester Sign Score) in favour of NB-UVB in 1 RCT of low-quality<sup>226</sup>).

Three studies of low<sup>232</sup>, moderate<sup>231</sup> and high<sup>234</sup> quality found **UVA1** [one medium dose (MD) and two high dose (HD) protocols] to be significantly more effective than **UVAB** regarding clinical signs and symptoms.<sup>231, 232, 234</sup> No significant difference was found between **MD-UVA1** and **HD-UVA1** after stop of treatment and after 6 months of follow-up in two studies of very low<sup>230</sup> (pilot study) and moderate quality (inpatient, side to side comparison study).<sup>229</sup>

One low-quality study showed more improvement in clinical signs and symptoms of **NB-UVB** versus **UVA and visible light** up to 3 months of follow-up (no statistical significance mentioned).<sup>227</sup>

One low-quality study showed **UVB** to be significantly more effective compared to placebo **visible light** for clinical signs and symptoms.<sup>220</sup>

One study of very low quality<sup>222</sup> and one of low quality<sup>219</sup> showed **UVAB** to be significantly more effective compared to **UVA** (clinical signs) and **BB-UVB** (clinical signs and symptoms) respectively. Another study of low quality showed **UVA** to significantly reduce clinical signs compared to **BB-UVB**.<sup>221</sup> **UVAB** combined with **topical corticosteroids** led to significantly greater reduction in clinical signs and symptoms than UVAB alone in a moderate-quality study.<sup>236</sup> **UVAB** compared to **ciclosporin** was significantly less effective on the short-term for clinical signs and QoL.<sup>235</sup>

**PUVA** turned out to be significantly more effective than **MD-UVA1** in clinical signs and duration of remission in one low-quality study.<sup>233</sup> Between **PUVA** and **NB-UVB** no significant difference was

demonstrated in clinical signs after treatment nor after follow-up up to 1 year in one very low-quality study.<sup>224</sup>

**Full-spectrum light** (320-5000nm) versus controls with emollients significantly reduced clinical signs up to a follow-up of 4 weeks in one very low-quality study.<sup>237</sup>

**Balneophototherapy** (saltwater bath plus NB-UVB) was significantly more effective than **NB-UVB** for clinical signs up to 6 months of follow-up in a low-quality study.<sup>228</sup>

Based on this systematic review conclusions must be drawn carefully, because of small and heterogeneous studies, high degrees of bias and varying levels of evidence. In terms of efficacy most evidence is available for MD-UVA-1 and NB-UVB. No difference was found between HD-UVA1 and MD-UVA1; more evidence was available for MD-UVA1. UVAB was more effective than UVA and BB-UVB, but not compared to UVA1. Other options are PUVA, full-spectrum light and balneophototherapy, but studies were small and of low quality. No suitable RCTs on heliothalassotherapy or Goeckerman therapy (coal tar plus UVB) were found.

Of the two RCTs retrieved from the additional search, the first compared **UVA** (n=30) with **UVB** (n=30) thrice weekly for a maximum of 12 weeks, with a follow up of 3 months, in moderate-to-severe AE patients.<sup>238</sup> Both modalities had a similar effect on reduction in clinical signs. The second evaluated **HD-UVA1** (130 J/cm<sup>2</sup>) versus **MD-UVA1** (60 J/cm<sup>2</sup>) five times weekly for 3 weeks in 27 severe adult AE patients.<sup>239</sup> Patients with skin type III-IV responded significantly more to HD-UVA1 than MD-UVA1 concerning clinical signs; patients with skin type II showed no difference between these two.

No evidence on efficacy of phototherapy in acute versus chronic AE was found, and no RCTs for children were found. Apart from some (mostly retrospective) case series,<sup>240-246</sup> two non-randomized studies have been published. In a comparative non-randomized study, 29 AE children and adolescents, aged 3-16 years, were treated with NB-UVB phototherapy for 12 weeks and compared with 26 patients who chose not to undertake treatment.<sup>247</sup> There was a 61% reduction in mean Six Area, Six Sign Atopic Dermatitis (SASSAD) severity score at week 12 in the NB-UVB cohort compared with an increase of 6% in the unexposed cohort. An open-label trial without control group assessed the effectiveness and safety of NB-UVB phototherapy in 30 AE children, aged 4-14 years. There was a significant reduction in severity at the end of treatment compared to baseline; this effect maintained during 2 years of follow-up.<sup>248</sup>

Concluding this section, we must emphasise that the use of phototherapy for AE is largely empiric and based on relatively few evidence-based data. There is a clear need for further research on the effectiveness and safety of phototherapy in AE, given that it is frequently used in AE patients.<sup>249</sup>

## 6.2 Safety of different photo(chemo)therapy modalities in clinical trials

In the RCTs included in the systematic review of Garritsen<sup>197</sup> and in the additional two RCTs<sup>238, 239</sup> no serious side-effects during the treatment and up to 1 year of follow-up were reported. Short-term side-effects (up to 1 year of follow-up) include xerosis cutis, erythema and burning, pruritus (UVA1 and full-spectrum light), gastrointestinal diseases (balneophototherapy), exacerbations of AE (UVA, NVB-UVB, visible light, full-spectrum light), folliculitis (UVA1, PUVA), and photo-onycholysis (PUVA). The open-label trial performed in children reported grade II erythema, reactivation of herpes labialis and chickenpox as side-effects. Follow-up up to 2 years did not show any significant side-effects.

However, it is evident that our current knowledge on the safety of phototherapy in patients with AE is poor because there are no data from RCTs or registries enrolling large patients' cohorts and with prolonged follow-up.

These studies are available for patients treated with UVA1,<sup>250</sup> BB-UVB and NB-UVB for other indications, mainly psoriasis, and they did not show increased risks of basal cell carcinoma, squamous cell carcinoma and melanoma.<sup>251, 252</sup> However, due to the lack of adequate prospective studies a follow up of patients who underwent repeated and protracted treatment cycles is recommended, particularly in lighter skin types.<sup>253</sup> The cancerogenic risk of PUVA is well demonstrated in psoriatic patients, and therefore caution is recommended also in AE patients.<sup>253, 254, 255</sup> However, extrapolating the magnitude of the risk observed with PUVA in patients with psoriasis to the risk in patients with AE is not always correct because psoriatic patients (historically) may have been treated more often with immunosuppressants and / or mutagenic drug therapies.

In patients who use systemic immunosuppressants, especially cyclosporine and azathioprine, phototherapy is not recommended based on their risk of co-carcinogenicity (see chapter Conventional immunomodulatory drugs). There are few papers available on combination therapy and the long-term safety in psoriatic patients;<sup>256, 257</sup> no papers were found specifically for AE. (see separate appendix)

## 7. Introduction to systemic treatment

The area of systemic therapy of AE has flourished during the last few years, as many new substances are marketed, licensed, or in the last step of clinical development. The licensing programs of the various new biologics and small molecules are providing much better levels of evidence than what is available for the longer existing drugs due to more robust RCT evidence.

Systemic therapy of AE is deemed necessary if the signs and symptoms of AE cannot be controlled sufficiently with appropriate topical treatments and UV-light therapy. Systemic therapy can also be useful to reduce the total amount of topical corticosteroids (TCS) in patients who need large amounts of potent TCS over prolonged periods to control their AE.

Candidates for systemic treatment may be either patients with a high composite score such as a SCORAD above 50 (scale definition), or patients clinically failing to respond to an appropriately conducted topical therapy (functional definition), or patients unable to participate in normal daily life activities whilst following an adequate treatment regimen (social definition).

Local regulations may necessitate the use of scores such as physician-reported scores (e.g. EASI) in combination with patient reported outcomes (e.g. DLQI). Many other scores exist summarized and assessed by the HOME initiative that may also serve as a basis to classify disease severity.<sup>258</sup>

It must be highlighted that the indication to systemic treatment is a patient individual decision, and that a signs-only score, such as EASI, is not a sufficient tool to make a final decision on commencing systemic therapy to an individual patient.

**100 % agreement**

Before starting systemic treatment, it is important to rule out relevant differential diagnoses such as cutaneous T-cell lymphoma and in selected cases primary immunodeficiency syndromes<sup>259</sup>, and to ascertain that potential trigger factors such as allergic contact dermatitis and concomitant skin infections have been excluded, and behavioural as well as educational reasons for poor responses have been adequately addressed.

### **Systemic medications for AE:**

Conventional immunomodulatory drugs, such as systemic corticosteroids (SCS), ciclosporin (CyA), azathioprine (AZA), mycophenolate mofetil (MMF), enteric-coated mycophenolate sodium (EC-MPS) and methotrexate (MTX) were used traditionally for difficult-to-treat AE. Most were not licensed for this indication. The newer medications, whose efficacy has been demonstrated in high-quality studies and are approved by the European Medicines Agency (EMA), include the Janus kinase (JAK) inhibitors abrocitinib (Abro), baricitinib (Bari), and upadacitinib (Upa), as well as the biologics targeting IL-13 tralokinumab (Tralo), lebrikizumab (Lebri), the IL-13/4 receptor dupilumab (Dupi), and the IL-31 receptor nemolizumab (NEMO).

The following recommendations for systemic drugs are based on the living systematic review by Drucker et al.<sup>5,9</sup>, other published literature and medical considerations as well as expert opinion, and may differ from the legal licensing status and access routes, which are not uniform in European countries.

	Drug	Recommendation	Strength	Label †	Dose †	Appli- cation	Certainty of evidence (GRADE RATING) ‡
Conventional immunomodulatory drugs	Ciclosporin	We <b>recommend</b> ciclosporin to achieve disease control in AE patients who are candidates for systemic treatment.	↑↑	≥ 16 years severe AE	adults: 2.5-5 mg/kg per day children: 2.5-5 mg/kg per day	oral	Network meta-analysis from 2022 <sup>2,9</sup> : Higher dose ⊕⊕⊕○ MODERATE change in signs*, OoL* ⊕⊕○○ LOW itch Lower dose ⊕⊕⊕○ MODERATE change in signs* ⊕⊕○○ LOW QoL, itch
	Methotrexate	We <b>suggest</b> methotrexate in AE patients who are candidates for systemic treatment.	↑	off-label	adults: 5-25 mg per week children: 0.3–0.4 mg/kg per week (see guideline text)	oral or s.c.	Network meta-analysis from 2022 <sup>2,9</sup> : ⊕⊕○○ LOW change in signs, QoL, itch
Interleukin-13-Inhibitors	Dupilumab	We <b>recommend</b> dupilumab in AE patients who are candidates for systemic treatment.	↑↑	≥ 6 months severe AE; ≥ 12 years moderate-severe AE	age- and weight-adjusted 200–600 mg Q2W-Q4Q (see guideline text)	s.c.	Network meta-analysis from 2024 <sup>9,10</sup> : ⊕⊕⊕⊕ HIGH EASI*, POEM*, PPNRS*, DLQI*
	Lebrikizumab	We <b>recommend</b> lebrikizumab in AE patients, who are candidates for systemic treatment.	↑↑	≥ 12 years moderate-severe AE	500 mg day 1 and 15 followed by 250 mg Q2W-Q4W, from week 24 onwards, generally Q4W (see guideline text)	s.c.	Network meta-analysis from 2024 <sup>9,10</sup> : ⊕⊕⊕⊕ HIGH POEM* ⊕⊕⊕○ MODERATE EASI*, DLQI* ⊕⊕○○ LOW PPNRS*
	Tralokinumab	We <b>recommend</b> tralokinumab in AE patients, who are candidates for systemic treatment.	↑↑	≥ 12 years moderate-severe AE	600 mg day 1 followed by 300 mg Q2W-Q4W (see guideline text)	s.c.	Network meta-analysis from 2024 <sup>9,10</sup> : ⊕⊕⊕⊕ HIGH POEM* ⊕⊕⊕○ MODERATE PPNRS*, DLQI* ⊕⊕○○ LOW EASI*
Interleukin-31-Inhibitors	Nemolizumab	We <b>recommend</b> nemolizumab in AE patients, who are candidates for systemic treatment.	↑↑	≥ 12 years moderate-severe AE	60 mg day 1 followed by 30 mg Q4W-Q8W (see guideline text)	s.c.	Network meta-analysis from 2025 <sup>5,9</sup> : ⊕⊕⊕○ MODERATE EASI*, POEM*, DLQI*, PPNRS*
JAK-Inhibitors	Abrocitinib	We <b>recommend</b> abrocitinib in AE patients who are candidates for systemic treatment.	↑↑	≥ 12years moderate-severe AE	100-200 mg per day based on disease burden and risk factors adults age ≥ 65: 100 mg per day (see guideline text)	oral	Network meta-analysis from 2024 <sup>9,10</sup> : 100 mg ⊕⊕⊕⊕ HIGH EASI*, POEM* ⊕⊕⊕○ MODERATE PPNRS*, DLQI* 200 mg ⊕⊕⊕⊕ HIGH EASI*, POEM*, DLQI* ⊕⊕⊕○ MODERATE PPNRS*
	Baricitinib	We <b>recommend</b> baricitinib in AE patients who are candidates for systemic treatment.	↑↑	≥ 2 years moderate-severe AE	adults: 2 or 4 mg per day adults age ≥ 65: 2 mg per day children: 2-4 mg per day weight-adjusted (see guideline text)	oral	Network meta-analysis from 2024 <sup>9,10</sup> : 2 mg ⊕⊕⊕○ MODERATE EASI*, POEM*, PPNRS*, DLQI* 4 mg

							⊕⊕⊕⊕ HIGH POEM*, PPNRS* ⊕⊕⊕○ MODERATE EASI*, DLQI*
	Upadacitinib	We <b>recommend</b> upadacitinib in AE patients who are candidates for systemic treatment	↑↑	≥ 12 years moderate-severe AE	adults: 15 or 30 mg per day adults age ≥ 65: 15 mg per day children (≥ 30 kg bw): 15 mg per day (see guideline text)	oral	Network meta-analysis from 2024 <sup>9, 10</sup> : 15 mg ⊕⊕⊕⊕ HIGH EASI* ⊕⊕⊕○ MODERATE POEM*, PPNRS* 30 mg ⊕⊕⊕⊕ HIGH EASI*, POEM*, PPNRS*
† In accordance with SmPC and EMA approval. Cost coverage and approval may vary between countries ‡ Short term (8-16 weeks) vs placebo; * = statistically significant superiority over placebo AE = atopic eczema; DLQI = Dermatology Life Quality Index; EASI = Eczema Area and Severity Index; POEM = Patient-Oriented Eczema Measure; PPNRS = Peak Pruritus Numerical Rating Scale							

1

2

**Vaccination prior to the initiation of systemic treatment and during systemic treatment:**

Vaccination before starting systemic therapy for AE is an important part of patient management, especially because many systemic treatments can suppress the immune system and potentially affect vaccine efficacy and safety. Systemic therapies, especially immunosuppressants, can increase susceptibility to infections, reduce vaccine effectiveness, and make live vaccines potentially dangerous. Updating necessary vaccinations should be considered before commencing therapy whenever possible. However, each systemic therapy class affects vaccination strategies differently.<sup>260-262</sup>

**1. Administer vaccines ideally before starting treatment**

- Live vaccines (e.g., measles, mumps, and rubella (MMR), varicella, yellow fever) should be administered at least 4 weeks before starting systemic therapy.
- Inactivated vaccines (e.g., influenza, COVID-19, pneumococcal, or inactivated zoster vaccination) can usually be given up to the start of therapy, though ideally  $\geq 2$  weeks before, to optimize the vaccine effect.

**2. Assess vaccination history and immunity**

- Serologic testing for measles, varicella, hepatitis B, etc. should be considered, if status is unclear and live vaccines are being considered.
- Ensure up-to-date status with:
  - Influenza (annually)
  - Pneumococcal (PCV20 or PCV15 + PPSV23)
  - Diphtheria, Tetanus, Pertussis (DTP) (every 10 years)
  - Hepatitis A & B (as indicated)
  - Human Papillomavirus (HPV) (as per age)

**3. Vaccination during systemic therapy**

- Avoid giving live vaccines during systemic immunosuppressive treatment.
- For JAK-Inhibitors or immunosuppressants, treatment may need to be interrupted for weeks before administering live vaccines (per product-specific recommendation).
- In specific situations a shorter interval may be discussed together with an infectious disease specialist.
- As all biologics, which are currently (November 2025) approved for the treatment of AE, are not considered immunosuppressive, inactivated vaccines can be given during treatment.
- Inactivated vaccines (non-live attenuated vaccines) can be safely used in patients receiving conventional immunomodulatory drugs or JAK-Inhibitors, but the immunogenicity of the vaccine may be reduced.
- As for live vaccinations and systemic therapy with biologics, we acknowledge that SmPCs generally recommend against their administration on treatment, and these should therefore only be used with careful consideration of the risks and benefits.

**Switching systemic treatment:**

Switching between systemic therapies in AE is a nuanced clinical decision that depends on treatment response, side effects, patient preferences, comorbidities, and pharmacologic factors (e.g., immunosuppression, drug half-life, vaccine timing). This guideline can only provide a general overview, as the exact decision-making process is complex.

Common reasons for switching to another therapy include:

- Insufficient response (partial or no improvement)
- Loss of efficacy over time
- Adverse effects or toxicity
- Patient burden or nonadherence (e.g., lab monitoring, injections)
- Change in clinical needs (e.g., comorbidities, pregnancy)
- Access/cost issues

1. From immunosuppressant to biologic

- Often direct switching is possible.
- Some clinicians let medication regimes overlap briefly to prevent flares of AE (especially from ciclosporin to dupilumab).
- For instance, continue ciclosporin for 2–4 weeks after starting dupilumab, then taper off. Similar overlap can be considered for other immunosuppressants.
- Watch for rebound of AE if immunosuppressant is stopped abruptly.

2. From biologic to JAK-Inhibitor

- Usually no washout needed; direct switching is common.
- Biologics have a long half-life (~21 days), but no significant immunosuppression, so overlapping medications are generally safe.

3. Between JAK-Inhibitors or from JAK- Inhibitors to biologic

- JAK-Inhibitors have short half-lives (hours to days).
- No need for overlapping medications in case of switching between JAK-Inhibitors.
- When switching from a JAK-Inhibitor to a biologic, an overlap of medications is usually helpful, especially in patients with high risk of flares.

4. Switching between biologics

- This is sometimes done, for example changing between IL-13 inhibitors (e.g. dupilumab → tralokinumab) or from IL-13 inhibitor to IL-31 inhibitors or vice versa.
- Direct switching is often performed with minimal issues.

**Adaptation of frequency and interval in systemic therapy:**

Adapting the treatment frequency and interval of systemic therapies (often off-label) for AE can help balance disease control with safety, tolerability, and patient convenience. This is often referred to as treatment optimization, maintenance adjustment, or step-down therapy once control is achieved.

Conventional immunomodulatory drugs:

- Tapering dose or frequency is common once control is achieved (often after 3–6 months)
- Long-term use may be limited due to safety issues (organ toxicity, lab monitoring)

Biologics:

- Interval extension in patients with sustained remission
- Can reduce cost, injection burden, and adverse events (e.g., conjunctivitis, facial erythema)
- Rebound risk is generally low, especially if AE is well-controlled
- Complete discontinuation is typically not pursued unless sustained remission has been achieved for several months.

- For tralokinumab, lebrikizumab and nemolizumab dose reduction is built into the label
  - Tralokinumab: After 16 weeks of treatment, patients who achieve good disease control may reduce intervals to q4w.
  - Lebrikizumab: After 16 weeks of treatment, patients achieving good disease control may reduce intervals to q4w. After 24 weeks, a mandatory interval reduction to q4w applies.
  - Nemolizumab: After 16 weeks, patients achieving good disease control may reduce intervals to q8w.
- Other adjustments to the intervals are off-label but common also for dupilumab

JAK-Inhibitors:

- More flexibility in dose adjustment vs biologics
- A typical approach is to start on the higher dose and then reduce to the lower licensed dose upon achieving good disease control.
- Note: JAK-Inhibitors have short half-lives ( $\approx 8-14$  hours), so dose frequency (daily) cannot be changed safely, but dose size can

## 8. Conventional immunomodulatory drugs

### 8.1. Introduction conventional immunomodulatory drugs

In many settings, conventional immunomodulatory drugs must be prescribed or contraindicated before advanced therapeutics can be used. These agents suppress or modulate immune activity and are often effective in controlling AE inflammation. In addition to medication-specific adverse effects, conventional immunomodulatory drugs carry infection risks (e.g., activation or exacerbation of pre-existing or latent infections), requiring pre-treatment screening and ongoing monitoring.

The following baseline laboratory investigations to assess safety are indicated depending on an individual patient risk assessment:

- Hepatitis B & C serology
- HIV testing
- Tuberculosis (TB): tuberculin skin test (TST) or interferon-gamma release assay (IGRA) (ELISA-based or ELISpot-based) (especially if risk factors present) +/- chest radiograph
- Full blood count, liver status, renal function

### 8.2. Azathioprine

Azathioprine is a conventional immunomodulatory drug that is rarely used to treat AE nowadays due to the availability of more advanced therapeutic options. However, in cases where there are contraindications or limitations to other recommended systemic treatments, azathioprine may still be considered as a treatment option on an individual basis.

#### **Mechanisms of action and efficacy**

AZA is a pro-drug which is rapidly converted in vivo to the anti-metabolite 6-mercaptopurine (6-MP), following cleavage of its imidazole side chain. It is believed to exert its primary immunosuppressant effect via metabolites of 6-MP, thioguanine nucleotides (TGNs), which are subsequently incorporated into DNA, inhibiting its synthesis.<sup>263</sup>

The efficacy of AZA is comparable to that of MTX but lower compared to dupilumab or cyclosporine A in clearing clinical signs of AE.<sup>264</sup>

Randomized clinical trials report a significant superiority of AZA vs placebo, with a decrease in clinical scores such as Six Area, Six Sign Atopic Dermatitis and Scoring Atopic Dermatitis (SASSAD) by 26% to 39% after 12 weeks.<sup>265</sup> However, results from retrospective studies are less favorable with a percentage of AZA treatment failure varying from 30 to 57% due to adverse effects or lack of effectiveness.<sup>266-268</sup> An observational follow-up study of 36 adult patients with severe AE treated with MTX or AZA over a 24-week period demonstrated less improvement in subjects with filaggrin mutations (36%, 13/36) compared to those without filaggrin mutations.<sup>265</sup>

Long-term studies on adult patients treated with either AZA or MTX showed a relative reduction in SCORAD of 53% ( $P < .01$ ) and 63% ( $P < .01$ ) after 2 years, and 54% and 53% after 5 years, respectively.<sup>265</sup>

<sup>269</sup> Patients with a Filaggrin mutation seemed to have slower but prolonged effects of therapy compared with patients without a mutation.<sup>265, 269</sup>

### **Dosage: acute flare, short term, long term**

- off licence
- commonly used dosage
  - adults and children: 1-3 mg/kg bodyweight per day
  - If no improvement of AE occurs within 3 months, withdrawing azathioprine should be considered.
- We recommend combining AZA, as any systemic treatment, with emollients and, whenever needed, topical anti-inflammatory treatment in AE patients.
- If timely thiopurine S-methyltransferase (TPMT) activity measurement is available, the following dosing of AZA has been suggested:
  - very low activity (< 2.5 per mL red blood cells [RBC]), treatment should not be started
  - intermediate activity (2.5-7.5 nmol/h/mL RBC): 0.5 mg/kg bodyweight per day for the first 4 weeks and then increase to 1.0 mg/kg bodyweight per day
  - normal activity (>7.5 nmol/h/mL RBC): 2.0 mg/kg bodyweight per day for the first 4 weeks and then increase to 2.5-3.0 mg/kg bodyweight per day

Low azathioprine doses (0.5-1.0 mg/kg bodyweight per day) for the first 4 weeks were shown to reduce gastrointestinal side-effects.<sup>270</sup>

If TPMT results are not available prior to starting AZA therapy, then half of the standard treatment dose should be given for about 4-6 weeks under close monitoring of full blood count and liver profile, prior to going up the full treatment dose.

### **Safety**

In the short and medium term, the most commonly reported serious dose-dependent effects are hepatotoxicity and myelotoxicity, together with gastrointestinal disturbances. Further, idiosyncratic hypersensitivity reactions (e.g. fever, rigors, myalgia, arthralgia and occasionally pancreatitis) may occur.<sup>271</sup>

Concerns have been raised about the potential carcinogenicity induced by long-term treatment with azathioprine (predominantly squamous cell skin cancer and non-Hodgkin's lymphoma), especially if AZA is combined with other immunosuppressant regimens.<sup>272</sup>

### **Screening and monitoring**

- Baseline screening:
  - Complete blood count, renal and liver profile
  - TPMT activity if available
  - Screening for chronic infections (e.g. hepatitis B-/C, HIV) before therapy should be considered (see also section 8.1 Introduction conventional immunomodulatory drugs)

- Follow up monitoring: Complete blood count, renal and liver profile twice monthly for 2 months, monthly for 4 months, then every 2-3 months and with dose increases. Please note that local hospital may have other guidance in place, and the frequency of such and other investigations needs to be adjusted to individual patient needs.
- Pregnancy testing before and during AZA therapy where indicated

### **Combination with other treatments**

We recommend combining azathioprine, as any systemic treatment, with emollients and, whenever needed, topical anti-inflammatory treatment in AE patients. Because of a potentially increased risk to develop skin cancer, AZA should not be combined with UV light therapy (UVA, UVB, PUVA).

### **Special considerations**


There is a theoretical risk of teratogenesis with AZA. This is based on studies in animals in which very high doses of AZA were used. However, in practice AZA has been used for over 30 years in sexually active men and women and no definite association between the drug and the incidence of fetal abnormalities has been observed. There also seems to be no effect on fertility.

According to a position paper by ETFAD<sup>136</sup>, AZA use during pregnancy should be avoided as there are better options, but AZA may be used off-label in the absence of other alternatives as continuation of treatment in women already receiving this treatment at the time of conception. According to experts' opinion of the ETFAD, the dosage of azathioprine should be reduced by 50% if it is continued during pregnancy. Initiation of azathioprine after conception should be avoided.

The use of AZA during lactation is debated. The WHO has recommended that the potential side-effects of AZA outweigh the effects and benefits of the treatment<sup>273</sup>, and studies suggest that AZA intake during breastfeeding could increase the long-term risk of immunosuppression and carcinogenesis in the child.<sup>274</sup>

AZA is not licensed for the treatment of AE in children but it has proven beneficial in several retrospective pediatric case series. The main disadvantage of AZA is that it reaches its maximum treatment effect only after 3-4 months.<sup>275</sup>

### 8.3. Ciclosporin

<p>We <b>recommend</b> using ciclosporin to achieve disease control in AE patients who are candidates for systemic treatment.</p>	<p>↑↑</p>	<p style="text-align: center;">&gt;75%</p>  <p style="text-align: center;">Evidence and consensus based, see Evidence Report</p>
---	-----------	---

ciclosporin: in licence for ≥ 16 years of age  
 standard dosage adults: 2.5-5 mg/kg per day in two single doses  
 commonly used dosage children: 2.5-5 mg/kg per day in two single doses

Certainty of evidence: Network meta-analysis from 2022<sup>2,3</sup>:

Short term (up to 16 weeks) vs placebo (NMA medications used in clinical practice or likely to be approved soon)

Higher dose

⊕⊕⊕○ MODERATE for standardized mean difference **change in signs** -1 (-1.6, -0.4)

⊕⊕⊕○ MODERATE for standardized mean difference **QoL** -0.7 (-1.3, -0.1)

⊕⊕○○ LOW for standardized mean difference itch -0.7 (-1.5, 0.2)


Lower dose


⊕⊕⊕○ MODERATE for standardized mean difference **change in signs** -0.7 (-1.4, -0.1)

⊕⊕○○ LOW for standardized mean difference QoL -0.5 (-1.1, 0.2)

⊕⊕○○ LOW for standardized mean difference itch -0.7 (-1.6, 0.3)

*For ciclosporin versus other drugs, see Evidence Report*

<p>We <b>recommend</b> to start with higher ciclosporin dosages in order to achieve a more rapid response in AE patients who are candidates for systemic treatment.</p>	<p>↑↑</p>	<p style="text-align: center;">100%</p>  <p style="text-align: center;">Expert Consensus</p>
---	-----------	---

<p>We <b>recommend</b> close follow-up for potential blood pressure elevation and signs of renal impairment in AE patients on ciclosporin.</p>	<p>↑↑</p>	<p style="text-align: center;">100%</p>  <p style="text-align: center;">Expert Consensus</p>
--	-----------	---

#### Mechanisms of action and efficacy

Ciclosporin inhibits T cell activation and proliferation by blocking nuclear factor of activated T cells (NFAT)-dependent cytokine production.

Ciclosporin has been approved for treatment of AE in adults in many European countries and is considered as first line option for patients with severe disease if other, novel therapies are not available or indicated. Ciclosporin is very effective for AE in both children and adults with a better tolerability in children.<sup>276-278</sup> Although similarly effective in the above NMA meta-analysis evaluating adult trials up to 16 weeks and in a real world analysis from the UK-Irish Atopic Eczema Systemic TherApy Register (A-STAR) among both adults and children<sup>279</sup>, real life data reveal a longer drug survival of dupilumab compared to ciclosporin after 16 months, but similar effectiveness.<sup>264, 280</sup> In head-to-head adult trials ciclosporin was superior to MTX, prednisolone, IVIG, UVA and UVB, and similarly efficacious as enteric-coated mycophenolate sodium (EC-MPS).<sup>265, 281</sup>

In an investigator-blinded randomised controlled trial comparing ciclosporin (4 mg/kg/day) with MTX (0.4 mg/kg/week) in children aged 2 to 16 years (n=103), participants receiving ciclosporin showed a faster response to treatment by 12 weeks (TREAT trial). However, MTX was superior after this time point, with more sustained disease control seen up to week 60, even after treatment was stopped at 36 weeks (lower disease severity measured by EASI and o-SCORAD as well as less patient-reported flares and reduced need for the use of topical anti-inflammatory treatment), suggesting potential disease modification through MTX.<sup>282</sup> Both drugs improved QoL above the minimal important difference for the CDLQI and were adequately tolerated and there were no serious adverse events attributed to either medication. In addition, there was no significant impact on either treatment on renal tubular function, using sensitive tubular biomarkers.<sup>282</sup> In the short-term treatment of AE, higher ciclosporin dosages (5 mg/kg per day) lead to a more rapid response and are more efficacious than lower dosages (2.5-3 mg/kg per day).<sup>265</sup> Longterm use of ciclosporin up to 1 year is possible, however, supporting evidence is limited.<sup>265</sup>

### **Dosage: acute flare, short term, long term**

- licensed  $\geq$  16 years of age
- standard dosage adults: 2.5-5 mg/kg per day in two single doses
  - Acute flare, short-term: 4-5 mg/kg body weight per day
  - Long-term: 2.5-3 mg/kg body weight per day
- commonly used dosage children: 2.5-5 mg/kg per day in two single doses
- We recommend combining ciclosporin, as any systemic treatment, with emollients and, whenever needed, topical anti-inflammatory treatment in AE patients.

### **Safety**

Ciclosporin has a narrow therapeutic index and requires a close follow-up for blood pressure and signs of renal impairment. To note, clinically relevant increase of creatinine seems less common than expected, as recently confirmed in the TREAT trial, which showed no abnormal renal profiles due to ciclosporin, even when sensitive tubular function biomarkers were used (see above).<sup>268, 277, 282</sup> Oral hygiene is important to prevent gingival hyperplasia.

### **Screening and monitoring**

- Screening for hepatitis B/C and HIV before therapy should be considered (see also section 8.1 Introduction conventional immunomodulatory drugs)

- Screening and follow up monitoring: Blood pressure, full blood count, renal and liver profile (including GGT) according to national guidelines (e.g. at baseline, 4 weeks and then 3-monthly).

### **Combination with other treatments**

We recommend combining ciclosporine, as any systemic treatment, with emollients and, whenever needed, topical anti-inflammatory treatment in AE patients. Because of a potentially increased risk to develop skin cancer, ciclosporin should not be combined with UV light (UVA, UVB, PUVA).



### **Special considerations**

Ciclosporin has been shown to be effective in and is better tolerated by children and adolescents.<sup>276, 278, 283</sup>

Ciclosporin can be considered in pregnant woman with severe AE. So far, no increased risk of congenital malformations or fetal death compared to the background populations have been reported. An increased risk of low birthweight cannot be ruled out.<sup>136</sup> Where systemic therapy is likely to be needed throughout pregnancy, ciclosporin is first choice therapy.<sup>136</sup>

Ciclosporin is an inhibitor of CYP3A4, the multidrug efflux transporter P-glycoprotein (P-gp), and the organic anion transporters (OATP). Concurrent use of drugs that are substrates of CYP3A4, P-gp, and OATP with ciclosporin can therefore lead to increased plasma concentrations of these co-administered drugs, which are substrates of these enzymes and/or transporters

## 8.4. Methotrexate

<p>We <b>suggest</b> using methotrexate in AE patients who are candidates for systemic treatment.</p>		<p style="text-align: center;"><b>100%</b></p> <div style="text-align: center;">  </div> <p style="text-align: center;">Evidence and consensus based see, Evidence Report</p>
---	--	--

methotrexate: off-label; commonly used dosage  
 adults: initial dose: 10-15 mg per week; maximum dose: 25 mg per week  
 children: 0.3–0.4 mg/kg per week; maximum dose: 25mg per week

Certainty of evidence: Network meta-analysis from 2022<sup>2,3</sup>:

Short term (up to 16 weeks) vs placebo (NMA medications used in clinical practice or likely to be approved soon)

⊕⊕○○ LOW for standardized mean difference change in signs -0.6 (-1, -0.2), QoL -0.4 (-0.9, 0.1), itch -0.6 (-1.2, 0)

*For methotrexate versus other drugs, see Evidence Report*

### Mechanisms of action and efficacy

MTX is a folic acid antagonist that impedes cell division, DNA/RNA synthesis and repair and protein synthesis, altogether suppressing the activity of the immune system. Although its exact action in AE is not fully understood, inhibition of the JAK/STAT pathway has been proposed.<sup>284</sup>

MTX has been used in the treatment of moderate and severe AE for years, but clinical trial evidence is limited. Consequently, recommendations have been primarily based on expert consensus<sup>285-288</sup>, but there is one controlled study comparing MTX with AZA in adults<sup>269, 289, 290</sup>, one investigator-blinded randomised controlled trial comparing MTX with ciclosporin in children (TREAT trial)<sup>278</sup> and an open-label randomised multi-centre study in children, again comparing MTX with ciclosporin.<sup>291</sup> Altogether these studies support that MTX can be considered effective, relatively safe, and well-tolerated treatments for severe AE both in children and adults - findings also in keeping with recent retrospective studies.<sup>292-294</sup>

In the TREAT trial (n=103) ciclosporin showed a better response after 12 weeks (4 mg/kg/day), but MTX (0.4 mg/kg/week) was superior after this time point, with more sustained disease control seen up to week 60, even after treatment was stopped at 36 weeks (lower disease severity measured by EASI and o-SCORAD, as well as less patient-reported flares and reduced need for the use of topical anti-inflammatory treatment), suggesting potential disease modification through MTX. Both MTX and ciclosporin improved QoL above the minimally important difference for the CDLQI. Importantly, ciclosporin was significantly more expensive than MTX (£0.55 per week) vs ciclosporin (£24.33 per week, UK National Health Service prices 2023), which should be taken into account when treatment with either drug is considered.<sup>278</sup>

In the living network meta-analysis, which only included adults, the efficacy of MTX was comparable to AZA and lower than dupilumab and ciclosporin in clearing clinical signs of AE at week 16. In addition, the UK-Irish Atopic Eczema Systemic TherAPy register (A-STAR) recently published a real-world comparison of MTX versus ciclosporin and dupilumab.<sup>264, 295</sup> Ciclosporin and dupilumab were superior to MTX with regard to treatment effectiveness, while all three medications had a similar impact on QoL. It is important to keep in mind that gradual up-dosing was commonly used in those receiving MTX in the A-STAR analysis, while the TREAT trial regimen involved patients receiving the full treatment dose from the outset.<sup>285-287</sup> One adult study suggests that patients who do not benefit from a moderate weekly dose (10–15 mg) of MTX over a three-month treatment period will probably not benefit from an increased dosage. However, slow gradual up-dosing of MTX might underestimate the therapeutic potential of the drug in AE. In children 0.4 mg/kg/week is recommended, which is significantly higher than dosing in adults.<sup>285</sup> 25 mg per week are the widely used maximum treatment dose for adult and paediatric AE patients.<sup>288</sup>

### **Dosage: acute flare, short term, long term**

- off licence
- commonly used dosage
  - adults: initial dose: 10-15 mg per week; maximum dose: 25 mg per week (given in a single, weekly dose). No test dose is needed.
  - children: 0.2–0.4 mg/kg per week acute flare and short-term: no relevant dosing
- Oral and subcutaneous delivery are considered equivalent options of administration. For patients in whom MTX 15 to 25 mg orally once weekly is ineffective or poorly tolerated, a trial of subcutaneous MTX administration is an alternative.
- We recommend combining MTX, as any systemic treatment, with emollients and, whenever needed, topical anti-inflammatory treatment in AE patients.
- Concomitant use of folic acid should be considered to reduce gastrointestinal and other side-effects related to the folic acid antagonistic effect of the drug.<sup>296</sup>

### **Safety**

As MTX is a commonly used drug in dermatology, the safety profile is well recognized, with nausea, fatigue and raised liver enzymes as main side effects, while pancytopenia and idiopathic pulmonary fibrosis is of key concern but only very rarely seen.

MTX is generally well tolerated and is considered safe for long-term treatment, based on experience and multiple studies including both adults and children suffering from psoriasis and rheumatologic disease.<sup>297, 298</sup>

### **Screening and monitoring**

Screening for chronic infections (e.g. hepatitis B-/C, HIV, tuberculosis) before therapy should be considered (see also section 8.1 Introduction conventional immunomodulatory drugs).

Screening and follow up monitoring: Complete blood count, renal and liver profile before and every 4 weeks for the first 3 months or, after increasing the dose, then every 8-12 weeks.

In patients undergoing long-term MTX therapy, a fibroscan may be considered as an option to monitor liver fibrosis in accordance with national and local guidelines. An emerging alternative is the fibrosis-4 index, combining age, AST, ALT and platelet count to identify those at increased risk of liver fibrosis.<sup>299</sup>

Any noteworthy impact on liver or bone marrow function should give cause to dose reduction or transient or total discontinuation of treatment.

### **Combination with other treatments**

We recommend combining methotrexate, as any systemic treatment, with emollients and, whenever needed, topical anti-inflammatory treatment in AE patients. There is experience from rheumatoid arthritis for combining with the JAK-Inhibitor baricitinib.


### **Special considerations**

MTX may be used for treatment of AE in both adults and children.


Subcutaneous administration increases bioavailability and tolerability, as well as adherence, compared to oral treatment.

MTX affects fertility and is highly teratogenic. Effective contraception is advised for women of childbearing potential. According to the SmPC, the same applies to men treated with MTX who could potentially father a child.

## 8.5. Systemic glucocorticosteroids

<p>We <b>suggest</b> using systemic glucocorticosteroids <i>only</i> as rescue therapy for acute flares in AE patients.</p>	↑	<p>100%</p>  <p>100 % Agreement</p> <p>Expert Consensus</p>
---	---	--

systemic glucocorticosteroids: general licence for adults and children; starting dose 0.5mg/kg per day; dosage maximum: 1 mg/kg per day

<p>We <b>recommend against</b> the long-term use of systemic glucocorticosteroids in AE patients.</p>	↓↓	<p>100%</p>  <p>100 % Agreement</p> <p>Expert Consensus</p>
---	----	--

### Mechanisms of action and efficacy

Glucocorticoids are a class of steroid hormones that bind to the glucocorticoid receptor. The activated glucocorticoid receptor complex upregulates the expression of anti-inflammatory proteins and suppresses the expression of pro-inflammatory proteins, leading to broad anti-inflammatory property.<sup>300</sup>

There are only few studies in adult and paediatric AE patients, despite the regular use of systemic glucocorticosteroids in clinical practice. In studies conducted on children and adults, systemic glucocorticosteroids do not induce long-term remission and swift rebound is common. Systemic glucocorticosteroids have significantly inferior efficacy than ciclosporin.<sup>276, 301</sup>

### Dosage: acute flare, short term, long term

- Acute flare: Starting dose is usually 0.5 mg/kg bodyweight per day. Treatment should be discontinued or tapered as soon as possible.
- Short-term and long-term: no relevant dosing
- We recommend combining systemic glucocorticosteroids, as any systemic treatment, with emollients and, whenever needed, topical anti-inflammatory treatment in AE patients.

### Safety

Systemic glucocorticosteroids have a wide therapeutic index. Toxicity is related to the mean dose, cumulative dose and duration of use. At high doses and with long-term use (typically >0.5 mg/kg/day) important side effects include skin atrophy, weight gain, sleep disturbance, mood changes, hyperglycaemia or new onset diabetes, peptic ulcers/gastritis, osteoporosis, and increased susceptibility to infections.<sup>302</sup> In particular with long-term use, patients can also develop adrenal suppression and

together with a high risk of rebound flares when tapering the treatment dose, cessation can be challenging. Systemic glucocorticosteroids must therefore be avoided as a long-term treatment in adults and children. Even a fairly high dose can simply be stopped without tapering when used for no longer than three weeks.<sup>303</sup>

### **Screening and monitoring**

No standard set of variables are recommended when used for acute rescue therapy, but patients' individual needs for monitoring may apply.

### **Combination with other treatments**

We recommend combining systemic glucocorticoids, as any systemic treatment, with emollients and, whenever needed, topical anti-inflammatory treatment in AE patients. There are none of the other treatments in AE that are contraindicated when using systemic glucocorticosteroids.

### **Special considerations**

Treatment of acute flares of AE with oral glucocorticosteroids is moderately effective.<sup>276, 301</sup>


Systemic glucocorticosteroids have an unfavourable risk/benefit ratio for the long-term treatment of adult and paediatric AE.

## 9. Interleukin-13-Inhibitors

### 9.1. Interleukin-13-Inhibitors Introduction

Dupilumab, tralokinumab, and lebrikizumab are monoclonal antibodies that target signalling pathways involved in type 2 inflammation, a central driver of AE. **Dupilumab** blocks the shared IL-4 receptor alpha subunit, thereby inhibiting both IL-4 and IL-13 signalling. In contrast, **tralokinumab** and **lebrikizumab** selectively bind to **IL-13**, specifically disrupting its pro-inflammatory effects. All three biologics are effective in reducing skin inflammation, itch, and barrier dysfunction, and thus offer targeted treatment options tailored to individual inflammatory profiles.

### 9.2. Dupilumab

<p>We <b>recommend</b> dupilumab in AE patients who are candidates for systemic treatment.</p>	<p>↑↑</p>	<p style="text-align: center;"><b>100%</b></p> <div style="text-align: center;">  <p><b>100 % Agreement</b></p> </div> <p style="text-align: center;">Evidence and consensus based, see Evidence Report</p>
--	-----------	--

dupilumab: in licence for  $\geq 6$  months of age;

age 6 months-6 years: from 5kg <15 kg 200 mg Q4W, 15kg <30 kg 300 mg Q4W

age 6-11: from 15kg <60kg, initially 300 mg s.c. day 1 and 15 followed by 300 mg Q4W, when  $\geq 60$  kg, initially 600 mg s.c. day 1 followed by 300 mg Q2W

age 12-17: <60 kg: initially 400 mg s.c. day 1 followed by 200 mg Q2W, when  $\geq 60$  kg: initially 600 mg s.c. day 1 followed by 300 mg Q2W

adults: initially 600 mg s.c. day 1 followed by 300 mg Q2W

Certainty of evidence: Network meta-analysis from 2024<sup>3, 4</sup>:

Short term (up to 16 weeks) vs placebo (NMA medications used in clinical practice)

⊕⊕⊕⊕ HIGH for mean difference **EASI** -10.5 (-11.9, -9.2); **POEM** -7.3 (-8, -6.7); **peak pruritus NRS** -2.1 (-2.3, -1.8); **DLQI** (-4.9 (-5.4, -4.3)

*For dupilumab versus other drugs, see Evidence Report*

### Mechanisms of action and efficacy

Dupilumab was the first marketed fully human IgG4 monoclonal antibody (mAb) in the treatment of AE and has been available for treatment of adults for more than 6 years in many countries. It is now also approved for children from 6 months of age. Dupilumab binds to the  $\alpha$ -subunit of the IL-4 receptor, which is part of both the IL-4 and IL-13 receptor complex. The safety and efficacy of dupilumab was primarily established in placebo-controlled studies in moderate-to-severe AE<sup>185</sup>. Dupilumab showed

significant clinical effects across 3 distinct severity assessment tools: Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), and SCORing Atopic Dermatitis (SCORAD). Moreover, dupilumab treatment significantly reduced pruritus. Dupilumab has shown efficacy in both intrinsic and extrinsic AE.<sup>304</sup> Dupilumab is also registered for treatment of moderate-to-severe asthma, eosinophilic esophagitis, and chronic rhinosinusitis with nasal polyps, thereby covering several type 2 inflammatory diseases.

### **Dosage: acute flare, short term, long term**

The approved dosing of dupilumab in adults consists of a 600 mg subcutaneous loading dose followed by maintenance doses of 300 mg every other week (Q2W). For children the following dosing regimens are used: licensed for  $\geq 6$  months; age 6 months-6 years: from 5kg <15 kg 200 mg Q4W, 15kg <30 kg 300 mg Q4W. Age 6-11: from 15kg <60kg, initially 300 mg s.c. day 1 &15 followed by 300 mg Q4W, when  $\geq 60$  kg, initially 600 mg s.c. day 1 followed by 300 mg Q2W. Age 12-17: <60 kg: initially 400 mg s.c. day 1 followed by 200 mg Q2W, when  $\geq 60$  kg: initially 600 mg s.c. day 1 followed by 300 mg Q2W.

Dupilumab has been used in an open label study for up to 5 years in adults with moderate-to-severe AE<sup>305,306</sup>, but some former trial patients have continued open label on the medication much longer. Safety data were consistent with previously reported trials and the known dupilumab safety profile.

### **Safety**

Dupilumab treatment is in general well tolerated, and routine blood tests are not necessary, but a substantial number of patients develops ocular surface disease (over 30% in some 'real world' settings report conjunctivitis), of which most are mild-to-moderate.<sup>307-310</sup> Key risk factors are pre-existing eyelid eczema, pre-existing allergic eye disease, pre-existing conjunctivitis, dry eye disease, and elevated IgE/eosinophil levels.<sup>311</sup> Topical treatment with anti-inflammatory eyedrops is often sufficient, without need to discontinue treatment.<sup>312</sup> There is now also more detailed guidance on how to deal with dupilumab-related ocular surface disorders.<sup>313</sup> In addition, a subset of patients may experience dupilumab-associated facial erythema after treatment initiation, which is usually mild and self-limiting.<sup>314</sup> Transient blood eosinophilia<sup>307</sup> can also occur, typically without clinical consequences. There have also been reports of arthralgia or arthritis-like symptoms developing during dupilumab therapy.<sup>315</sup>

### **Screening and monitoring**


The guideline committee considers that biochemical or instrumental investigations are not required for screening or treatment monitoring. This is consistent with the manufacturer's information.**Combination with other treatments**

We recommend combining dupilumab, as any systemic treatment, with emollients and, whenever needed, topical anti-inflammatory treatment in AE patients

### **Special considerations**

AE patients with type 2 comorbidities such as prurigo nodularis, asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and/or eosinophil esophagitis may also have beneficial effects of dupilumab treatment on these diseases.

### 9.3. Lebrikizumab

<p>We <b>recommend</b> lebrikizumab in AE patients who are candidates for systemic treatment.</p>	<p>↑↑</p>	<p style="text-align: center;"><b>100%</b></p> <div style="text-align: center;">  <p><b>100% Agreement</b></p> </div> <p style="text-align: center;">Evidence and consensus based, see Evidence Report</p>
---	-----------	---

lebrikizumab: in licence for  $\geq 12$  years of age (with bodyweight  $\geq 40$ kg);  
dosage: initially 500 mg s.c. day 1 and 15 followed by 250 mg s.c. Q2W up to week 16-24  
once clinical response is achieved, the recommended maintenance dose is 250 mg every Q4W. From week 24 onwards, generally Q4W

Certainty of evidence: Network meta-analysis from 2024<sup>3, 4</sup>:

Short term (up to 16 weeks) vs placebo (NMA medications used in clinical practice)

⊕⊕⊕⊕ HIGH for mean difference **POEM** -6.2 (-7.4, -5.1)

⊕⊕⊕○ MODERATE for mean difference **EASI** -8.5 (-10.4, -6.5); **DLQI** -4.7 (-6.4, -2.8)

⊕⊕○○ LOW for mean difference **peak pruritus NRS** -2.1 (-2.6, -1.7)

*For lebrikizumab versus other drugs, see Evidence Report*

#### Mechanisms of action and efficacy

Lebrikizumab is a high-affinity humanized IgG4 mAb that binds specifically to soluble interleukin 13 and selectively prevents formation of the IL-13R $\alpha$ 1/IL-4R $\alpha$  heterodimer receptor signaling complex.

In two identically designed randomised, double-blind, placebo-controlled monotherapy phase 3 studies (ADvocate1 and ADvocate2), adolescents (aged 12 years and older) and adult AE patients received either lebrikizumab at a dose of 250 mg Q2W (loading dose of 500 mg at baseline and week 2) or placebo.<sup>316</sup> After 16 weeks, 43.1% (lebrikizumab arm) vs. 12.7% (placebo arm) in ADvocate1 and 33.2% vs. 10.8% in ADvocate2 achieved the primary endpoint of IGA score of 0 or 1 with a reduction of at least 2 points.<sup>316</sup> Patients who responded to lebrikizumab at the end of the 16-week induction period were re-randomized 2:2:1 to receive lebrikizumab 250 mg Q2W, Q4W or placebo (lebrikizumab withdrawal) for 36 additional weeks. After 52 weeks, an IGA of 0 or 1 with a  $\geq 2$ -point improvement was maintained by 71.2% and 76.9% of patients treated with lebrikizumab Q2W or Q4W, respectively. In the lebrikizumab withdrawal arm only 47.9% maintained their response.<sup>317</sup> In a further placebo-controlled phase 3 study, in which the effect of lebrikizumab was investigated together with topical corticosteroids, the drug also proved to be clearly superior to placebo.<sup>318</sup>

#### Dosage: acute flare, short term, long term

The recommended dosage is an induction therapy of 500 mg at week 0 and week 2, followed by 250 mg Q2W until week 16. In patients with an initial partial response, 250 mg Q2W can be continued until week

24. Once a clinical response is achieved, the recommended maintenance dose of lebrikizumab is 250 mg Q4W. From week 24 onwards, Q4W is mandatory according to the drug approval.

### **Safety**

Stein Gold et al. investigated the safety of lebrikizumab by analyzing data from eight phase 2 and phase 3 studies. Overall, the frequency of adverse events was comparable between patients receiving lebrikizumab and those given a placebo. Conjunctivitis and AE were the most frequently reported events, with AE reported more frequently in the placebo groups than in the Q2W groups (18.4% versus 6.0%) and conjunctivitis reported more frequently in lebrikizumab in the Q2W groups than in the placebo groups (6.5% versus 1.8%). Nasopharyngitis, headache, allergic conjunctivitis, dry eye, and allergic rhinitis were reported more frequently in the lebrikizumab group.<sup>319</sup>

Simpson et al. reported injection site reactions (1.3%), herpes infection (3.8%), eosinophilia (3.2%) with no associated clinical symptoms, and conjunctivitis (9.6%) as adverse events in patients treated with lebrikizumab.<sup>320</sup>


Notably, based on the currently available clinical trial data lebrikizumab appears to have lower rates of ocular complications than dupilumab. 'Real world' comparisons, for instance through national registers, are still awaited.

### **Screening and monitoring**

The guideline committee considers that biochemical or instrumental investigations are not required for screening or treatment monitoring. This is consistent with the manufacturer's information. **Combination with other treatments**

We recommend combining Lebrikizumab, as any systemic treatment, with emollients and, whenever needed, topical anti-inflammatory treatment in AE patients

## 9.4. Tralokinumab

<p>We <b>recommend</b> tralokinumab in AE patients who are candidates for systemic treatment.</p>	↑↑	<p>100%</p>  <p>100 % Agreement</p> <p>Evidence and consensus based, see Evidence Report</p>
---	----	---

tralokinumab: in licence for ≥ 12 years of age;

age 12-17: initially 600 mg s.c. day 1 followed by 300 mg Q2W

adults: initially 600 mg s.c. day 1 followed by 300 mg Q2W

At prescriber's discretion, every fourth week dosing may be considered for patients who achieve clear or almost clear skin after 16 weeks of treatment.

Certainty of evidence: Network meta-analysis from 2024<sup>3,4</sup>:

Short term (up to 16 weeks) vs placebo (NMA medications used in clinical practice)

⊕⊕⊕⊕ HIGH for mean difference **POEM** -4.2 (-5, -3.4)

⊕⊕⊕○ MODERATE for mean difference **peak pruritus NRS** -1 (-1.2, -0.7); **DLQI** -2.4 (-3.1, -1.6)

⊕⊕○○ LOW for mean difference **EASI** -6.2 (-7.8, -4.7)

*For tralokinumab versus other drugs, see Evidence Report*

### Mechanisms of action and efficacy

Tralokinumab is a fully human, high affinity IgG4 mAb, which neutralizes IL-13, and has been approved by the EMA in summer 2021.<sup>321</sup> In two 52-week, double-blind, placebo-controlled, phase III trials, adults with moderate-to-severe AE were randomized to subcutaneous tralokinumab 300 mg every 2 weeks or placebo.<sup>189</sup> Tralokinumab monotherapy was superior to placebo at 16 weeks of treatment. Co-primary endpoints were IGA score of 0 or 1 and EASI 75 at week 16. Patient achieving an IGA score of 0/1 and/or EASI 75 with tralokinumab at week 16 were re-randomized to tralokinumab Q2W or every 4 weeks or placebo for 36 weeks. The majority of week 16 tralokinumab-responders maintained response at week 52 with continued tralokinumab treatment without any rescue medication. In a randomised, double-blind, phase 3 trial 301 adolescent patients received either 300 mg or 150 mg of tralokinumab or placebo. After 16 weeks, significantly more patients in the tralokinumab arms showed an EASI 75 response (27.8%, 28.6%, 6.4%) or an IGA of 0 or 1 (17.5%, 21.4%, 4.3%). Subjects achieving a clinical response (IGA = 0, 1; or EASI75) at week 16 without use of rescue medication were re-randomized to maintenance dosing regimens. At 52 weeks, EASI-75 response ranged from 44.4% to 63.3% in the different maintenance dosing regimens.<sup>322</sup>

### Dosage: acute flare, short term, long term

The recommended dosage is 300 mg every 2 weeks after a loading dose of 600 mg at treatment onset. At prescriber's discretion, every fourth week dosing may be considered for patients who achieve clear or almost clear skin after 16 weeks of treatment.

Phase III trials have also investigated what happens when patients who do well for 16 weeks on tralokinumab continue treatment as labelled, reduce treatment frequency, or discontinue treatment.

After 16 weeks, patients who reached EASI 75 or IGA success were re-randomized to continue treatment every two weeks, titrate down to every four weeks, or use placebo. At 52 weeks, without TCS, more than 55% of patients who continued twice-monthly treatment maintained EASI 75, as did approximately 50% of patients treated monthly. More than 51% of patients who stayed on twice-monthly dosing maintained IGA 0 or 1, versus 39% and 45% of patients who switched to monthly dosing.

### **Safety**

In the two studies, adverse events were reported in 76.4% and 61.5% of patients receiving tralokinumab and in 77.0% and 66.0% of patients receiving placebo in the 16-week initial period.

Notably, based on the currently available clinical trial data, tralokinumab appears to have lower rates of ocular complications than dupilumab.<sup>189</sup>

The combination therapy with TCS, TCI and UV light treatment is possible.

### **Screening and monitoring**

The guideline committee considers that biochemical or instrumental investigations are not required for screening or treatment monitoring. This is consistent with the manufacturer's information.

### **Combination with other treatments**


We recommend combining tralokinumab, as any systemic treatment, with emollients and, whenever needed, topical anti-inflammatory treatment in AE patients

## 10. Interleukin-31-Inhibitors

### 10.1 Interleukin-31-Inhibitors Introduction

Nemolizumab is a monoclonal antibody that targets the interleukin-31 receptor A (IL-31RA), a key driver of pruritus (itch) and inflammation in AE. By blocking IL-31 signalling, nemolizumab reduces itch intensity and skin inflammation. As such, Nemolizumab represents a novel, targeted approach that complements existing biologics focused on IL-4 and IL-13 pathways.

### 10.2 Nemolizumab

<p>We <b>recommend</b> nemolizumab in AE patients who are candidates for systemic treatment.</p>	↑↑	<p>100%</p>  <p>100 % Agreement</p> <p>Evidence and consensus based, see Evidence Report</p>
--	----	--

nemolizumab: in licence for  $\geq 12$  years of age

dosage: initially 60 mg s.c. day 1 followed by 30 mg s.c. Q4W

After 16 weeks of treatment, for patients who achieve clinical response, the recommended maintenance dose is 30 Q8W

Certainty of evidence: Network meta-analysis from 2025<sup>3</sup>

Short term (up to 16 weeks) vs placebo (NMA medications used in clinical practice)

⊕⊕⊕○ MODERATE for mean difference **EASI** -4.4 (-6.5, -2.4); **POEM** -3.9 (-5.1, -2.8); **DLQI** -2.4 (-3.4, -1.3); **peak pruritus NRS** -2 (-2.4, -1.6)

*For nemolizumab versus other drugs, see Evidence Report*

### Mechanisms of action and efficacy

Nemolizumab is a humanized mAb targeting the IL-31 receptor alpha chain (IL-31RA), which was initially developed for the treatment of AE-related pruritus.

In two randomized, double-blind, placebo-controlled phase 3 trials (ARCADIA 1 and 2), a total of 1,728 adults and adolescents (aged  $\geq 12$  years) with moderate-to-severe AE and associated pruritus were enrolled. All participants had previously shown an inadequate response to TCS treatment. Patients received either 30 mg nemolizumab Q4W, with an initial loading dose of 60 mg, or placebo injections, alongside TCS and, in some cases, TCI. Randomization was conducted in a 2:1 ratio for nemolizumab versus placebo. At week 16, 44% (270/620) and 42% (220/522) of patients treated with nemolizumab

achieved an EASI-75 response compared to 29% (93/321) and 30% (80/265) of patients receiving placebo. Similarly, the proportion of patients achieving IGA success (defined as an IGA score of 0 or 1 with a reduction of at least 2 points) was significantly higher in the nemolizumab groups than in the placebo groups. Significant benefits were also observed for secondary endpoints, with consistent improvements in pruritus and sleep disturbance.<sup>323</sup>

Patients who achieved a clinical response (IGA success or EASI-75) at week 16 were re-randomized (1:1:1) to receive nemolizumab 30 mg Q4W, nemolizumab 30 mg Q8W, or placebo for additional 32 weeks. During this period, additional topical anti-inflammatory therapy was also permitted. At week 48, a higher proportion of patients maintained IGA success in the nemolizumab Q4W (61.5%) and Q8W (60.4%) groups compared to the placebo group (49.7%). Similarly, EASI-75 response rates were higher in the nemolizumab Q4W (76.3%) and Q8W (75.7%) groups compared to placebo (63.9%).<sup>324</sup>

### **Dosage: acute flare, short term, long term**

Global phase III trials investigated the nemolizumab 30 mg Q4W dose administered up to week 16 with a loading dose of 60 mg at baseline and showed positive outcomes. After week 16, clinical responders did not show a clinical difference with the Q4W and Q8W maintenance regimen.<sup>323</sup>

### **Safety**

In the two mentioned phase 3 trials the frequency of adverse events was comparable between patients receiving nemolizumab and those given a placebo.<sup>323</sup>

The most common treatment-emergent adverse event was worsening of AE in 12% (75/616) participants in the nemolizumab group vs 11% (34/321) in the placebo group in ARCADIA 1; and 7% (37/519) vs 6% (15/263), respectively, in ARCADIA 2.

Asthma events occurred in both groups in both studies. However, it should be noted that more than 30% of all included patients reported pre-existing asthma.

In both studies, hypersensitivity reactions (urticaria) were noted. Non-serious and mild urticaria was reported in 1% and 2% patients receiving nemolizumab vs <1% patient receiving placebo in ARCADIA 1 and ARCADIA 2. Nemolizumab was not discontinued due to any of these events.<sup>323</sup>

### **Screening and monitoring**

The guideline committee considers that biochemical or instrumental investigations are not required for screening or treatment monitoring. This is consistent with the manufacturer's information.

### **Combination with other treatments**

We recommend combining nemolizumab, as any systemic treatment, with emollients and, whenever needed, topical anti-inflammatory treatment in AE patients

## 11. JAK-Inhibitors

### 11.1 JAK-Inhibitors introduction

The janus kinase (JAK) family, constituting JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2), are a class of cytoplasmic tyrosine kinases.<sup>325</sup> JAKs dock to the intracellular part of cytokine receptor chains to generate functional signalling complexes and regulate the inflammatory process through activating the cytoplasmic transcription factors termed as signal transducer and activator of transcription (STAT). When activated, STAT proteins produce dimers, which translocate into the nucleus and either positively or negatively regulate downstream target gene expression of inflammatory mediators, suggesting that inhibiting JAK activity may be more effective than targeting a single cytokine. Beyond interrupting cytokine-driven inflammatory responses in the skin, JAK inhibition has been reported to attenuate chronic itch and improve skin barrier function by regulating the expression of skin barrier protein filaggrin.<sup>326, 327</sup>

#### Special considerations

JAK-Inhibitors are also effective in certain other inflammatory diseases and are approved for their treatment in some cases. Therefore, patients with AE and with concomitant inflammatory diseases, such as alopecia areata, rheumatoid and juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis or inflammatory bowel diseases are likely to experience additional beneficial effects for these concomitant diseases, but the effect size may vary according to the JAK-Inhibitor used.

#### General safety issues

Following a review of the benefit-risk balance of oral JAK-Inhibitors, which confirmed, that tofacitinib (oral JAK-Inhibitor; not approved for AE) increases the risk of major cardiovascular problems, cancer, venous thromboembolism and serious infections compared to TNF-alpha inhibitors<sup>328</sup>, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) proposed measures to minimize the risk of serious side effects associated with JAK-Inhibitors in 2022.<sup>329, 330</sup> It was recommended that oral JAK-Inhibitors should only be used in patients aged  $\geq 65$  years or with a history of atherosclerotic cardiovascular disease, other risk factors for cardiovascular disease (e.g. long-term smoking) or with increased risk of cancer if no suitable treatment alternatives are available, and with caution in patients at risk of pulmonary embolism or deep vein thrombosis.<sup>329, 330</sup> If treatment with JAK-Inhibitors is initiated in these patients, this should be done with the lower dose in each case. The PRAC concluded that these safety findings apply to all approved uses of JAK inhibitors in dermatological, rheumatological or gastroenterological chronic inflammatory diseases.<sup>329, 330</sup>


#### Screening and monitoring

The label's requirements for monitoring are mentioned per JAK-Inhibitor. In practice, the guideline group considers the same baseline screening and treatment monitoring investigations applicable to all JAK-Inhibitors. For baseline screening this is a full blood count, renal, liver and lipid profile and hepatitis, HIV and TBT. For monitoring purposes during treatment we propose a full blood count, renal, liver and lipid profile at four weeks into treatment and then three-monthly while on therapy. The guideline group does not advocate for mandatory monitoring of creatinine phosphokinase levels in asymptomatic patients.

**Pregnancy**

All JAK-Inhibitors are considered strictly contraindicated during pregnancy. Safe contraception should be ensured for women of childbearing age.

## 11.2 Abrocitinib

<p>We <b>recommend</b> abrocitinib in AE patients, who are candidates for systemic treatment.</p>	↑↑	<p style="text-align: center;"><b>100%</b></p> <div style="text-align: center;">  <p><b>100 % Agreement</b></p> </div> <p>Evidence and consensus based, see Evidence Report</p>
---	----	--

abrocitinib: in licence for  $\geq 12$  years of age;  
dosage  $\geq 12$  years: 100 or 200 mg per day based on disease burden and risk factors;  
dosage adults age  $\geq 65$ : 100 mg per day

Certainty of evidence: Network meta-analysis from 2024<sup>3, 4</sup>.

Short term (up to 16 weeks) vs placebo (NMA medications used in clinical practice)

100 mg

⊕⊕⊕⊕ HIGH for mean difference **EASI** -8.5 (-10.3, -6.7); **POEM** -5.1 (-6.1, -4.1)

⊕⊕⊕○ MODERATE for mean difference **peak pruritus NRS** -1.6 (-2.1, -1.1); **DLQI** -3.4 (-4.3, -2.6)

200 mg

⊕⊕⊕⊕ HIGH for mean difference **EASI** -12.8 (-14.6, -11.1); **POEM** -8.4 (-9.3, -7.5); **DLQI** -5.6 (-6.3, -4.8)

⊕⊕⊕○ MODERATE for mean difference **peak pruritus NRS** -2.4 (-3, -1.8)

*For abrocitinib versus other drugs, see Evidence Report*

### Mechanisms of action and efficacy

Abrocitinib is an oral JAK1 selective inhibitor, approved from the age of 12, that has shown efficacy in patients with moderate-to-severe AE when used as a monotherapy (MONO-1 and -2 studies) and in combination with topical therapies in achieving treatment response in comparison to placebo (COMPARE study), as measured using IGA and EASI-75 response. For instance, the proportion of patients with EASI-75 response at week 12 was significantly higher with abrocitinib 100 mg (~40-45%) and abrocitinib 200 mg (~61-63%) compared to placebo (~10-12%) in the MONO studies. In the COMPARE study the proportion of patients with EASI-75 response was significantly higher with abrocitinib 100 mg (~59%) and abrocitinib 200 mg (~70%) compared to placebo (27%).<sup>264</sup> Similar efficacy has been demonstrated in the adolescent JADE TEEN trial for both the 100mg and 200mg doses, in combination with topical therapies.<sup>331</sup> Importantly, in the COMPARE study (which had dupilumab as a comparator arm) higher responder rates were observed with abrocitinib 200 mg compared to dupilumab (p-values not calculated) after 16 weeks of treatment. The efficacy of abrocitinib 100 mg and dupilumab was similar in this subgroup. The results indicate that abrocitinib 200 mg may provide a higher probability of treatment response compared to dupilumab in patients with severe AE.<sup>332</sup>

### Dosage: acute flare, short term, long term

Abrocitinib is licenced at the 100 mg and the 200 mg daily doses, with the lower dose recommended for adolescents as a starting dose. Starting with the higher dose usually leads to a faster clinical response, better drug survival and adherence, and may therefore be advisable in younger adults and in otherwise

healthy patients. One study assessed flare prevention, i.e. the risk and probability of flares and recapture of treatment response following a flare. Of 1233 patients, 798 responders to induction with abrocitinib 200 mg (64.7%) were randomly assigned to dose maintenance, dose reduction or treatment withdrawal (placebo). The flare probability during maintenance was 18.9%, 42.6%, and 80.9% with abrocitinib 200 mg, abrocitinib 100 mg, and placebo, respectively by week 52. Among patients with flare in the abrocitinib 200 mg, abrocitinib 100 mg, and placebo groups, 36.6%, 58.8%, and 81.6% regained IGA 0/1 response, respectively, and 55.0%, 74.5%, and 91.8% regained EASI index response, respectively, with rescue treatment of abrocitinib 200 mg plus medicated topical therapy.<sup>333</sup>

### **Safety**

Based on long-term follow up of patients from the phase II and III trials as well as one long-term extension study, with a total n of 2856 (1614 patient-years (PY); total exposure in the all-abrocitinib cohort was  $\geq 24$  weeks in 1248 patients and  $\geq 48$  weeks in 606 (maximum 108 weeks). In the placebo-controlled cohort (n = 1540), dose-related adverse events (200 mg, 100 mg, placebo) were nausea (14.6%, 6.1%, 2.0%), headache (7.8%, 5.9%, 3.5%), and acne (4.7%, 1.6%, 0%). Platelet count was reduced transiently in a dose-dependent manner; 2/2718 patients (200-mg group) had confirmed platelet counts of  $< 50 \times 10^3/\text{mm}^3$  at week 4. Incidence rates (IRs) were 2.33/100PY and 2.65/100 PY for serious infection, 4.34/100PY and 2.04/100PY for herpes zoster, and 11.83/100PY and 8.73/100PY for herpes simplex in the 200-mg and 100-mg groups, respectively.<sup>334</sup>

### **Screening and monitoring**

For baseline screening, the manufacturer's label laboratory monitoring recommendations are full blood count including platelet count, absolute lymphocyte count (ALC), absolute neutrophil count (ANC), and haemoglobin (Hb) as well as lipid parameters. Infection screening for HIV, hepatitis B and C as well as TB is advisable before initiation of therapy.

In practice, the guideline group considers the same baseline screening and treatment monitoring investigations applicable to all JAK-Inhibitors. For baseline screening this is a full blood count, renal, liver and lipid profile and hepatitis B and C, HIV and TB screen.

For follow up monitoring we propose a full blood count, renal, liver and lipid profile at four weeks into treatment and then three-monthly while on therapy. The guideline group does not advocate for mandatory monitoring of creatinine phosphokinase levels in asymptomatic patients.


### **Combination with other treatments**

We recommend combining abrocitinib, as any systemic treatment, with emollients and, whenever needed, topical anti-inflammatory treatment in AE patients

### **Special considerations**

Abrocitinib is a new JAK-Inhibitor and has not been formally tested in other inflammatory diseases. Please refer to the special considerations in the JAK-Inhibitor introduction chapter.

### 11.3 Baricitinib

<p>We <b>recommend</b> baricitinib in AE patients, who are candidates for systemic treatment.</p>	<p>↑↑</p>	<p>&gt;75%</p>  <p>Evidence and consensus based, see Evidence Report</p>
<p>baricitinib in licence for for <math>\geq 2</math> years of age;  dosage age 2-18y: from 10kg&lt;30kg: 2 mg per day; from 30kg: 4 mg per day  dosage adults: 4 mg per day  reduction to half dosage per day possible, depending on treatment response  dosage adults <math>\geq 65</math>y: 2 mg per day</p> <p>Certainty of evidence: Network meta-analysis from 2024<sup>3, 4</sup>:</p> <p>Short term (up to 16 weeks) vs placebo (NMA medications used in clinical practice)</p> <p>2 mg  ⊕⊕⊕○ MODERATE for mean difference <b>EASI</b> -5.1 (-6.9, -3.4); <b>POEM</b> -3.8 (-4.9, -2.7); <b>peak pruritus NRS</b> -1.2 (-1.6, -0.9); <b>DLQI</b> -2.3 (-3.1, -1.4)</p> <p>4 mg  ⊕⊕⊕⊕ HIGH for mean difference <b>POEM</b> -5.4 (-6.6, -4.2); <b>peak pruritus NRS</b> -1.6 (-2, -1.3)  ⊕⊕⊕○ MODERATE for mean difference <b>EASI</b> -7.5 (-9.4, -5.6); <b>DLQI</b> -3.5 (-4.4, -2.6)</p> <p><i>For baricitinib versus other drugs, see Evidence Report</i></p>		

#### Mechanisms of action and efficacy

Baricitinib is an oral selective JAK1 and JAK2 Inhibitor. The drug has been tested in one phase 2 and several phase 3 trials in adults with moderate-to-severe AE at 1mg, 2mg and 4mg once daily against placebo, showing significant improvement with regard to EASI from baseline to 16 weeks, in particular in the two higher doses (2 mg daily (mean difference, 5.1-point reduction; 95% CI, -6.9, -3.4 [GRADE assessment: moderate certainty]) and 4 mg daily (mean difference, 7.5-point reduction; 95% CI, -9.4, -5.6 [GRADE assessment: moderate certainty]).<sup>4</sup> Similar efficacy has been shown in these studies with regard to the IGA and itch scores. The concomitant use of topical corticosteroids was allowed in one trial.<sup>335</sup>

In October 2023, baricitinib was approved by the EMA for the treatment of children (2 years and older) and adolescents with AE. Data from a phase 3 study (BREEZE-AD PEDS) had previously been published, in which 483 children and adolescents received baricitinib 0.5 mg or 1 mg or 2 mg or 4 mg or placebo over 16 weeks. The drug was convincing with regard to the primary endpoint Investigator Global Assessment of 0/1 with a  $\geq 2$ -point improvement at week 16 as well as the secondary endpoints EASI-75, EASI-90, mean change from baseline in EASI score, SCORAD 75 and 4-point improvement in the Itch Numeric Rating scale.<sup>336</sup>

#### Dosage: acute flare, short term, long term

At present, Baricitinib data is available up to 68 weeks follow up<sup>337,338</sup>, demonstrating sustained efficacy.

The recommended dose of baricitinib for adult patients is 4 mg once daily. A dose of 2 mg once daily should be considered for patients who have achieved sustained control of disease activity with 4 mg once daily and are eligible for dose tapering.

A dose of 2 mg once daily is recommended for patients at higher risk of venous thromboembolism, major adverse cardiovascular events and malignancy, as well as for patients aged  $\geq 65$  years and for patients with a history of chronic or recurrent infections.<sup>339</sup> A dose of 4 mg once daily may be considered for these patients who do not achieve adequate control of disease activity with 2 mg once daily dose.

For children and adolescents the recommended dose of baricitinib is 4 mg once daily for patients weighing 30 kg or more. For patients weighing 10– $\leq$  30 kg, the recommended dose is 2 mg once daily. A reduction to half the dose should be considered for patients who have achieved sustained control of disease activity with the standard recommended dose and are eligible for dose tapering.

Starting with the higher dose usually leads to a faster clinical response, better drug survival and adherence, and may therefore be advisable in younger, otherwise healthy patients.

## **Safety**

The most common side effects with baricitinib in clinical trials include an increase in LDL cholesterol, upper respiratory tract infections, and headache. Acne is less common than with other JAK-Inhibitors. Infections reported with baricitinib include herpes simplex. However, the rate of these events reported in a recent combined safety study including 2531 patients with AE from 8 RCTs who were given baricitinib for 2247 patient-years (median duration 310 days) was overall low: eczema herpeticum (n = 11), cellulitis (n = 6) and pneumonia (n = 3). There were four opportunistic infections reported.<sup>340</sup> A transient increase of CPK may be seen, especially after extensive bodily exercise. No malignancies, gastrointestinal perforations, positively adjudicated cardiovascular events or tuberculosis were reported in the placebo-controlled period in baricitinib-treated patients. The frequency of herpes simplex was higher in the 4 mg group (6.1%) compared to the 2 mg (3.6%) and placebo groups (2.7%).<sup>340</sup> Analyses of long-term safety data are still pending in patients with AE. For use in rheumatoid arthritis, data is available from an integrated data base with 9 phase III/II/Ib and 1 long-term extension covering 3,770 patients for up to 9.3 years of baricitinib treatment (14 744 patient-years of exposure). Patients who received at least one dose of baricitinib in the incorporated studies were included in the uncontrolled analysis set.<sup>341</sup> The incidence rate for serious infections was reported with 2.6 per 100 patient years, while the incidence rate for herpes zoster was reported with 3 per 100 patient years. The incidence rate for major cardiovascular events was 0.5 per 100 patient years, rising slightly to 0.77 in those patients over 50 with at least one cardiovascular risk factor. Incidence rates for deep vein thrombosis or pulmonary embolism were reported with 0.5 per 100 patient years.<sup>341</sup>

In the children and adolescents BREEZE-AD PEDS study abdominal pain, acne and headache were the most frequently reported adverse events. Few patients discontinued the study drug due to AEs (1.6% placebo and 0.6% baricitinib-treated).<sup>336</sup>

## **Screening and monitoring**

For baseline screening, the manufacturer advises that patients with suspected hepatitis B consult a liver specialist for advice before initiation of treatment. Lipid and liver profiles need to be regularly monitored following treatment initiation. Screening for any haematological abnormalities is also advised.

In practice, the guideline group considers the same baseline screening and treatment monitoring investigations applicable to all JAK-Inhibitors. For baseline screening this is a full blood count, renal, liver and lipid profile and hepatitis B and C, HIV and TB screen.

For follow up monitoring we propose a full blood count, renal, liver and lipid profile at four weeks into treatment and then three-monthly while on therapy. The guideline group does not advocate for mandatory monitoring of creatinine phosphokinase levels in asymptomatic patients.

### **Combination with other treatments**


We recommend combining baricitinib, as any systemic treatment, with emollients and, whenever needed, topical anti-inflammatory treatment in AE patients. No studies assessing the use of baricitinib with other systemic therapies in AE patients have been published to date, but the combination therapy with MTX is an established combination regimen in the management of rheumatoid arthritis.<sup>342</sup>

### **Special considerations**

JAK-Inhibitors are also effective for certain other inflammatory diseases and are approved for their treatment in some cases. Therefore, patients with AE and with concomitant inflammatory diseases, such as AA, rheumatoid and juvenile idiopathic arthritis, ankylosing spondylitis and psoriatic arthritis and inflammatory bowel diseases are likely to experience additional beneficial effects for these concomitant diseases. Baricitinib is already licensed for most of these indications.

Please refer to the special considerations in the JAK-Inhibitor introduction chapter.

## 11.4 Upadacitinib

<p>We <b>recommend</b> upadacitinib in AE patients who are candidates for systemic treatment.</p>	<p>↑↑</p>	<p style="text-align: center;"><b>100%</b></p> <div style="text-align: center;">  </div> <p style="text-align: center;">Evidence and consensus based, see Evidence Report</p>
---	-----------	--

upadacitinib: in licence for ≥ 12 years of age;  
adults: 15 or 30 mg per day; age ≥ 65: 15 mg per day  
age 12-17 (≥ 30 kg bw): 15 mg per day

Certainty of evidence: Network meta-analysis from 2024<sup>3,4</sup>:  
Short term (up to 16 weeks) vs placebo (NMA medications used in clinical practice)

15 mg

⊕⊕⊕⊕ HIGH for mean difference **EASI** -11 (-12.6, -9.4)

⊕⊕⊕○ MODERATE for mean difference **POEM** -7 (-11.2, -2.9); **peak pruritus NRS** -2.4 (-2.8, -2)

30 mg

⊕⊕⊕⊕ HIGH for mean difference **EASI** -13.5 (-15.2, -11.9); **POEM** -10.7 (-14.8, -6.5); **peak pruritus NRS** -3.3 (-3.6, -3.1)

*For upadacitinib versus other drugs, see Evidence Report*

### Mechanisms of action and efficacy

Upadacitinib is a relatively selective and reversible Janus Kinase (JAK) 1 inhibitor, approved from age 12. In phase 3 studies (Measure Up 1/2 and AD Up), upadacitinib with and without concomitant topical corticosteroid therapy was superior to in achieving efficacy endpoints, including the proportion achieving EASI75 response after 16 weeks of treatment in patients aged 12 years and older with moderate to severe AE.<sup>192, 343</sup>

In a direct head-to-head trial enrolling adult AE patients randomized to receive upadacitinib (n=342) and dupilumab (n=331) 248 patients receiving upadacitinib (72.4%) and 207 patients receiving dupilumab (62.6%) achieved EASI75 at 16 weeks ( $p=0.007$ ). All ranked secondary end points also demonstrated the superiority of upadacitinib vs dupilumab, including improvement in Worst Pruritus NRS as early as week 1, achievement of EASI75 as early as week 2, and EASI100 at week 16. Rates of serious infection, eczema herpeticum, herpes zoster, and laboratory-related adverse events were higher for patients who received upadacitinib, whereas rates of conjunctivitis and injection-site reactions were higher for patients who received dupilumab.<sup>344</sup>

### Dosage: acute flare, short term, long term

Upadacitinib is licensed at the 15 mg and 30 mg doses for AE. Starting with the higher dose usually leads to a faster clinical response, better drug survival and adherence, and may therefore be advisable in younger adults, otherwise healthy patients. Follow up until week 52 is now available, showing long-term

efficacy and safety profiles similar to the 16-week trials.<sup>345</sup> There is no study that has looked at acute flare treatment, and there are currently early phase AE trials in children >6 months.

### **Safety**

The cumulative incidence rates of adverse events were 78.6% for 30 mg, 76.2% for 15 mg, 73.8% for 7.5 mg and 62.5% for placebo in the phase 2 trial and have been similar in the studies reported since.<sup>346</sup> Upper respiratory tract infections and acne were the most frequently reported adverse events for upadacitinib. The cumulative incidence rates of severe adverse events were 0% for 30mg, 2.4% for 15mg, 4.8% for 7.5mg and 2.4% for placebo. Low withdrawal rates were reported in the placebo and upadacitinib groups (n<5 for each group).

In a phase 3 trial, 272 Japanese patients (age 12-75 years) with moderate-to-severe AE were randomized in a 1:1:1 ratio to receive 15 mg upadacitinib, 30 mg upadacitinib or placebo (each in combination with a TCS) to evaluate the safety of upadacitinib in combination with TCS. Treatment-emergent adverse event (TEAEs) were reported for 56.0%, 63.7% and 42.2% of participants, respectively at week 16. The most frequently reported TEAEs were acne (13.2%, 19.8%, 5.6%), nasopharyngitis (13.2%, 15.4%, 15.6%), and herpes zoster infection (0%, 4.4%, 0%). No thromboembolic events, malignancies, gastrointestinal perforations or deaths occurred.<sup>347</sup> At week 16, patients receiving placebo were re-randomized (1:1) to upadacitinib 15 mg or 30 mg. Through week 160, TEAE rates were 28.4 and 34.3 events per 100 patient-years for upadacitinib 15 mg (n = 133) and 30 mg (n = 136), respectively. The most common adverse events remained acne (11.6 and 22.3 per 100 patient-years), nasopharyngitis (12.7 and 16.5 per 100 patient-years), and herpes zoster (8.2 and 12.3 per 100 patient-years) for the 15 mg and 30 mg groups, respectively.<sup>348</sup>

### **Screening and monitoring**

The manufacturer advises that patients are screened for viral hepatitis B and C and TB. Lipid and liver profiles need to be measured at baseline and regularly following treatment initiation. Screening and monitoring for any haematological abnormalities is also advised, no later than 12 weeks.

In practice, the guideline group considers the same baseline screening and treatment monitoring investigations applicable to all JAK-Inhibitors. For baseline screening this is a full blood count, renal, liver and lipid profile and hepatitis B and C, HIV and TB screen.

For follow up monitoring we propose a full blood count, renal, liver and lipid profile at four weeks into treatment and then three-monthly while on therapy. The guideline group does not advocate for mandatory monitoring of creatinine phosphokinase levels in asymptomatic patients.

### **Combination with other treatments**

We recommend combining upadacitinib, as any systemic treatment, with emollients and, whenever needed, topical anti-inflammatory treatment in AE patients. No studies assessing the use of upadacitinib with other systemic therapies in AE patients have been published to date, but the combination therapy with MTX is an established combination regimen in the management of rheumatoid arthritis, albeit only with the 15mg once a day dose.<sup>349</sup>

### **Special considerations**

JAK-Inhibitors are also effective for certain other inflammatory diseases and are approved for their treatment in some cases. Therefore, patients with AE and with concomitant inflammatory diseases, such

as AA, rheumatoid and juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis and inflammatory bowel diseases are likely to experience additional beneficial effects for these concomitant diseases. Upadacitinib is already licensed for most of these indications. Upadacitinib is also approved for the treatment of giant cell arteritis.

Please refer to the special considerations in the JAK-Inhibitor introduction chapter.

## 12. Other systemic treatment

### 12.1 Alitretinoin

#### **Mechanisms of action and efficacy**

Alitretinoin is a retinoid binding both retinoic acid (RAR) and retinoic X (RXR) receptors, thus delivering anti-inflammatory and anti-proliferative effects. It is licensed in some European countries for the treatment of chronic hand eczema irrespectively of its pathogenesis.

There is one large, multicenter randomized, placebo controlled clinical trial involving 1032 patients with chronic hand eczema, about one third of which were probably atopic hand eczema patients.<sup>350</sup> Improvement of eczema was seen in 75% of the patients. The patient group suffering from atopic hand eczema was not analyzed separately, and extrapalmar symptoms have not been assessed in this trial.

Six patients with AE and prominent hand involvement were treated with alitretinoin for twelve weeks in an uncontrolled, open label trial.<sup>351</sup> Both, palmar and extrapalmar lesions improved during the trial, as shown by the modified Total Lesion Symptom Score (mTLSS) hand eczema score and the SCORAD.

#### **Dosage: acute flare, short term, long term**

According to the mode of action, alitretinoin is suitable for long-term treatment. An alitretinoin treatment course should be planned for 3 to 6 months.

The dosage of alitretinoin is 10-30 mg per day.

#### **Safety**

As alitretinoin is highly teratogenic, all females of childbearing potential must adhere to a strict birth control programme.

#### **Screening and monitoring**

Before and during therapy: liver enzymes (aspartate aminotransferase (ASAT), aspartate aminotransferase (ALAT), gamma-glutamyl transpeptidase (GGT)), cholesterol, triglycerides, basal thyroid stimulating hormone (TSH), free thyroxine (fT4) peripheral blood levels; pregnancy test in women with childbearing potential.

#### **Combination with other treatments**

Concomitantly to alitretinoin, topical therapy with corticosteroids, calcineurininhibitors and emollients can be applied.

#### **Special considerations**

A retrospective analysis of children treated with alitretinoin because of hand eczema and other diagnoses including two severe AE patients, revealed that the response to alitretinoin was moderate in one subject, whereas the other patient failed to improve even after extending treatment to up to 11 months.<sup>352</sup>

Alitretinoin may be a treatment option for patients with chronic hand eczema and concomittant AE as in-label use, whereas there is no good rationale for its use in patients without chronic hand eczema.

## 12.2 Treatments under investigation

### Ox40-Inhibitors

Ox40 and its ligand (Ox40L) are co-stimulatory molecules involved in T-cell activation and survival, playing a key role in sustaining chronic inflammation in AE. The Ox40–Ox40L pathway enhances the proliferation of Th2 and Th22 cells, which are central to AE pathogenesis. Targeting this pathway offers a novel therapeutic approach aimed at modulating the immune response more upstream than current IL-4/IL-13 inhibitors. Early-phase trials of Ox40 or Ox40L inhibitors have shown promise in reducing inflammation and pruritus in moderate-to-severe AE.<sup>353, 354</sup> Recent clinical investigations have evaluated several Ox-40/Ox-40L inhibitors - telazolimab, rocatinlimab, and amlitelimab - in adults with moderate-to-severe AE. In a phase 2a trial, telazolimab (GBR 830/ISB 830) induced EASI-50 in 77% of patients by day 71 (compared to ~38% with placebo), with 23% achieving IGA 0/1. The treatment was well tolerated, with headache, mild infection, and myalgia among the most common adverse events.<sup>355, 356</sup> In a larger phase 2b study (NCT03568162), telazolimab 300 mg or 600 mg every 2 weeks led to significantly greater EASI score reductions (-54.4% to -59.0%) versus placebo (-34.2% to -41.8%) at week 16, with favourable safety profiles.<sup>357</sup> Similarly, rocatinlimab (AMG 451/KHK 4083) demonstrated efficacy, with early-phase data showing a ~74% mean reduction in EASI by day 155, and the phase 2b STREAM-AD trial confirmed sustained EASI-75 rates and transcriptomic reversal of Th2/Th1/Th17/Th22 pathway activation, lasting well beyond treatment cessation.<sup>358, 359</sup> Lastly, amlitelimab (SAR445229/KY1005), targeting Ox-40L, achieved ~80% mean EASI reduction at week 16 in its phase 2a trial (low-dose arm) versus ~49% with placebo. IGA 0/1 responses reached 44% versus 8% in placebo, with the most common side effects being headache and upper respiratory infections.<sup>360, 361</sup>

These results underscore the potential of Ox40–pathway blockade as a novel, upstream immunomodulatory strategy in AE.

None of the Ox40-Inhibitors is currently (November 2025) licensed for the treatment of AE in any country.

## 12.3 Therapies that were used in past

### Mycophenolate mofetil / mycophenolic acid

Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), inhibits inosine-5'-monophosphate dehydrogenase, depleting guanosine nucleotides in B and T lymphocytes and inhibiting their proliferation. It was used off-label in patients with refractory or intolerant AE. There are no high-quality randomized controlled trials to support its use.<sup>362</sup>

### Omalizumab

Omalizumab, an anti-IgE antibody, binds free IgE and prevents its interaction with high-affinity receptors on mast cells, basophils, and epidermal dendritic cells, potentially reducing inflammation in AE. While it is approved for example for asthma and chronic spontaneous urticaria (CSU), its use in AE remains off-label. Despite some observational studies and a clinical trial<sup>363</sup> showing moderate efficacy in improving AE symptoms, the evidence is conflicting, with no predictive markers for a better response.<sup>364</sup>

Omalizumab's safety profile is excellent, but its unpredictable and modest efficacy does not support its widespread use for AE treatment.

### **Immunoabsorption**

Immunoabsorption has been used in patients with AE and elevated total IgE levels based on the assumption that a reduction in IgE might result in disease improvement.<sup>365</sup> Immunoabsorption was reviewed in the previous AE guidelines, but is expected to be scarcely used in the future, as multiple newer effective and safe treatments are available.

### **Mast cell stabilizers**

Mast cell stabilizers block mast cell degranulation preventing the release of histamine and related mediators. Mast cell stabilizers were reviewed in the previous AE guidelines, but they are expected to be scarcely used in the future, as multiple newer effective and safe treatments are available.

### **Intravenous immunoglobulin**

Intravenous immunoglobulin (IVIG) provides immunomodulatory therapy in inflammatory and autoimmune diseases.<sup>366</sup> IVIG was reviewed in the previous AE guidelines, but is expected to be scarcely used in the future, as multiple newer effective and safe treatments are available.




### **Leukotriene antagonists**

Montelukast is a cysteinyl leukotriene receptor antagonist that blocks the action of LTD<sub>4</sub>, LTC<sub>4</sub> and LTE<sub>4</sub>.<sup>367</sup> Montelukast was reviewed in the previous AE guidelines but is scarcely used, as multiple newer effective and safe treatments are available.

### **Apremilast**


Apremilast is a small molecule phosphodiesterase (PDE) 4 inhibitor that has been approved for the treatment of psoriasis arthritis and moderate-to-severe plaques psoriasis. Apremilast was reviewed in the previous AE guidelines but is expected to be scarcely used in the future, as multiple newer effective and safe treatments are available. The apremilast clinical program in the treatment of AE has been discontinued.<sup>368-371</sup>

### 13. Avoidance techniques in atopic eczema

<p>We <b>recommend</b> to identify individual trigger factors in patients with AE, to avoid these in the future, with the aim of prolonging remission or clearance.</p>	↑↑	<p style="text-align: center;">&gt;75%</p>  <p style="text-align: center;">(16/17) Expert Consensus</p>
<p>We <b>recommend</b> to avoid pollen, house dust mite and animal dander as much as possible to prevent exacerbation of AE in sensitized patients with a clear history of disease flares secondary to these triggers.</p>	↑↑	<p style="text-align: center;">&gt;75%</p>  <p style="text-align: center;">(14/15) Expert Consensus</p>
<p>There is no need to restrict normal everyday physical activity in patients with AE.</p>	Statement	<p style="text-align: center;">&gt;75%</p>  <p style="text-align: center;">(17/19) Expert Consensus</p>
<p>We <b>recommend</b> avoiding irritant clothing (e.g. wool with coarse fibers) to prevent an exacerbation of AE in patients with sensitive skin.</p>	↑↑	<p style="text-align: center;">&gt;75%</p>  <p style="text-align: center;">(16/17) Expert Consensus</p>
<p>We <b>suggest</b> that patients with AE learn strategies to cope with stress (e.g. educational programmes). In selected cases, counselling or psychotherapy is <b>suggested</b>.</p>	↑	<p style="text-align: center;">100%</p>  <p style="text-align: center;">(16/16) Expert Consensus</p>

We **recommend** the avoidance of tobacco smoke for the prevention of AE.

↑↑



### Pollen avoidance

Pollen-related flares can be observed in sensitized atopic patients. Exacerbation of AE may occur after either direct skin contact or inhalation of pollen allergens.<sup>372</sup> Whether pollen avoidance leads to the prevention of flares in AE, has formally not been shown yet.

A reduced concentration of pollen indoors may help to prevent flares in patients highly sensitized to pollen. Keeping windows closed during high pollen peaks or the restrictions of outdoor activities in high pollen containing areas (e.g. lawn mowing) may be helpful. Frequently ventilated indoor spaces in rainy weather or at night/early morning, as well as the use of special pollen filters in air conditioners may also be advised. Skin contact with pollen-vectorized clothes or pets should be avoided. High-altitude climate may be recommended due to its lower pollen count compared to average living areas.<sup>40, 69</sup> These measures may however be difficult to maintain.<sup>69</sup>

### House dust mite avoidance

House dust mite (HDM) -related flares may occur in AE patients. Some house dust mite allergens identified by specific IgE or skin prick testing are enzymatically active compounds, which can destroy the cutaneous permeability barrier and may evoke the development of eczematous inflammation in sensitized atopic individuals.

The evidence on HDM avoidance techniques in the prevention of atopic flares is somewhat controversial.<sup>373-375</sup> Measures of reducing exposure include mattress encasing, the use of adequate indoor ventilation (filter, well-aeration), and the avoidance of wall washing on high temperature.<sup>69</sup> HDM, a common indoor allergen occurring in dust, may be reduced by cleaning regularly. Complete eradication by e.g. encasing is not possible.

### Animal dander avoidance

When allergies to furry animals are evident, their avoidance is recommended.<sup>69</sup> Particularly the exposure to cat allergens may be a risk factor for the development of inflammatory skin lesions as well as respiratory symptoms in sensitized patients with AE.<sup>376</sup> There may be an exception for dogs due to a suggested general protective effect of dog-keeping in the development of AE.<sup>377</sup>

### Exercise/perspiration/physical activity

In AE patients heat and excessive sweating is one of the main factors reported to exacerbate itch.<sup>378</sup> When excessive sweat is left on the skin it can lead to occlusion of the sweat pores and formation of keratin plugs which in turn may cause local inflammation and itch. Some of the components of sweat include histamin, antimicrobial peptides and proteases which can induce itch. Sweat can also facilitate the penetration of allergens through the defective atopic skin barrier leading to mast cell degranulation.<sup>379, 380</sup> As sweat is important for skin homeostasis it is not possible to avoid sweating

completely. However, it should be washed off with consistent application of emollients as soon as possible to avoid inducing itch. The evidence concerning physical activity as a trigger for AE is conflicting and incomplete.<sup>378</sup> Although physical activity often leads to sweating, it is important for both physical and mental health, and AE patient should not be advised to avoid it.

### **Clothing**

In patients with AE certain fabrics such as wool can cause a tingling sensation, skin irritation and itch. The evidence is not completely clear on which fabrics to recommend for use and which to avoid. Clothing-related exacerbation can be subjective.<sup>381</sup> There is no evidence from high quality studies that certain fabrics improve the severity of AE.<sup>381, 382</sup> In general, textiles with course fibres, such as certain wool garments and occlusive clothing leading to overheating should be avoided. Otherwise, the choices of clothing should be based on individual preferences. Most AE patients tolerate silk and cotton well, whereas contact with wool is frequently irritating.

### **Psychological stress**

There is good evidence that AE is associated with depression, anxiety and reduced QoL.<sup>383, 384</sup> It is difficult to investigate whether the psychological stress is a cause or consequence of the AE exacerbation, and in many case it is probably both. There is a positive correlation between maternal stress and offspring AE.<sup>385, 386</sup> Although evidence from larger studies is lacking, patients report that stress induces itch and flaring of the disease.<sup>387, 388</sup> (see chapter psychological intervention)


### **Pollution**


In a systematic review of environmental epidemiologic studies about air pollution and AE acceptable evidence was found that, based on small-scale exposure measurements (so-called PM 2.5., i.e. particles with less than 2.5 µm diameter) , especially truck traffic emissions increased AE prevalence. PM 2.5 are primarily comprised of organic carbon compounds, nitrates, and sulfates. For large-scale exposures to larger particles (PM10) or SO<sub>2</sub> the review did not find an effect on AE prevalence.<sup>389, 390</sup> Additional environmental risk factors for AE identified in single studies<sup>391</sup> were carbon monoxide (CO) exposure during first trimester, CO exposure within past 12 months to CO level > 1 ppm above annual CO, high total volatile organic compounds (TVOC) in infant's bedrooms at 6 months and AE at 36 months, and nitric oxide (NO<sub>2</sub>); the latter found as risk factor for AE in four different studies. So far the role of pollutants as trigger factor of pre-existing AE has not properly been described.

### **Tobacco smoke**


The association of AE with active smoking was found to be significant in a metaanalysis (OR 1.87, 95% confidence interval 1.32-2.63). This association remained significant when looking at only children, only adults and by geographic region. Moreover, the effect of exposure to passive smoke on AE flares is small but also significant (OR 1.18, 95% confidence interval 1.01-1.38). Passive smoke was associated with the prevalence and severity of AE both in children and adults.<sup>392</sup> The results of a recent registry study of 908 patients with AE suggest that the intensity of lesions and the Patient Global Assessment Score (PGA) were higher in smoking patients (n=352) than in non-smoking patients (n=556). However, physician-assessed disease severity (o-SCORAD and EASI scores) did not differ between smokers and non-smokers in this study.<sup>393</sup>


## 14. Dietary interventions in atopic eczema


<p>We <b>recommend</b> to identify individual dietary trigger factors in patients with AE, to avoid these in the future, with the aim of prolonging remission or clearance.</p>	↑↑	<p style="text-align: center;">&gt;75%</p>  <p style="text-align: center;">(16/17) Expert Consensus</p>
---	----	--


<p><u>IgE-mediated food allergy (immediate reactions):</u></p> <p>We <b>recommend</b> diagnostic procedures for the elucidation of IgE-mediated food allergy (food specific IgE and/or SPT, diagnostic elimination diets and challenge tests) in AE patients with a history of <i>food-induced immediate symptoms</i>.</p>	↑↑	
<p><u>IgE-mediated food allergy (immediate reactions) plus food-induced AE “delayed hypersensitivity”:</u></p> <p>We <b>recommend</b> diagnostic procedures for the elucidation of combined reactions to foods (immediate reactions plus food-induced eczema (food specific IgE and/or SPT, diagnostic elimination diets and challenge tests)) in AE patients with a history of <i>food-induced symptoms, including worsening of AE</i>.</p>	↑↑	<p style="text-align: center;">&gt;75%</p>  <p style="text-align: center;">(16/18)<sup>1</sup> Expert Consensus</p>
<p><u>History or suspicion of food-triggered AE “delayed hypersensitivity”:</u></p> <p>We <b>suggest</b> diagnostic procedures for the elucidation of food as a trigger factor of AE (food specific IgE and/or SPT, diagnostic elimination diets and challenge tests) in patients with moderate-to-severe AE and with a <i>history or suspicion of food-triggered AE</i>.</p>	↑	


<sup>1</sup> Abstention

<p>A therapeutic elimination diet is <b>recommended</b> after the individual diagnosis of food allergy or food-induced eczema in AE.</p>	<p>↑↑</p>	<p>100%</p> <div style="text-align: center;">  <p>100 % Agreement</p> </div> <p>(17/17) Expert Consensus</p>
--	-----------	---

<p>We <b>recommend</b> re-evaluation of a child's IgE mediated food allergy after one to two years after strict elimination diet.</p>	<p>↑↑</p>	<p>100%</p> <div style="text-align: center;">  <p>100 % Agreement</p> </div> <p>(17/17) Expert Consensus</p>
---	-----------	---

<p>We <b>recommend against</b> general dietary interventions (e.g. other supplements, general avoidance of certain foods e.g. cow's milk, gluten) for the management of AE.</p>	<p>↓↓</p>	<p>100%</p> <div style="text-align: center;">  <p>100 % Agreement</p> </div> <p>(19/19) Expert Consensus</p>
---	-----------	---

<p>We <b>cannot make a recommendation</b> on probiotics for the management of AE.</p>	<p>0</p>	<p>100%</p> <div style="text-align: center;">  <p>100 % Agreement</p> </div> <p>(19/19) Expert Consensus</p>
---	----------	---

<p>We <b>recommend against</b> vitamins as a treatment for AE.</p>	<p>↓↓</p>	<p>100%</p> <div style="text-align: center;">  <p>100 % Agreement</p> </div> <p>(17/17) Expert Consensus</p>
--	-----------	---

### Food allergens, pre- and probiotics

Food allergy has been documented in approximately one-third of children with moderate-to-severe AE.<sup>394, 395</sup> Among food allergens, cow's milk, hen's egg, peanut, soya, nuts and fish are most frequently responsible for immediate-type food allergy and AE exacerbation in young children, with age-dependent variations in causally incriminated food.<sup>396</sup> In older children, adolescents and adults pollen-associated food allergy should also be taken into account.<sup>397-399</sup>

### Response patterns to food allergens

Three different clinical reaction patterns in patients with AE have been described, depending on the type of symptoms and their time of onset.<sup>396, 400</sup>

Immediate-type, non-eczematous reactions are usually IgE-mediated, occur within a maximum of 2 hours after the administration of the allergen, with skin manifestations such as urticaria, angioedema, flushing and pruritus or other immediate-type reactions of the gastrointestinal tract, the respiratory tract or the cardiovascular system in the case of anaphylaxis. Cutaneous manifestations occur in 74% of patients. In addition, children might develop a transient morbilliform rash 6–10 h after the initial immediate reaction, disappearing within a few hours and considered as 'late-phase' IgE-mediated response.<sup>400, 401</sup>

Isolated eczematous delayed-type reactions typically occur 6–48 h after the ingestion of the allergen, including flares of eczema in predilection sites of AE. However, such isolated eczematous reactions are rare.<sup>397</sup>

A combination of the two above-mentioned patterns with an immediate-type reaction followed by an eczematous delayed-type reaction has been described in approximately 40% of children with food and adolescents /adults with birch pollen associated reactions.<sup>399, 402</sup>

Sensitization to food should be identified by means of a detailed clinical history in combination with *in vivo* tests (skin prick tests - SPT) and *in vitro* tests (serum-specific IgE), as described in detail in food allergy guidelines.<sup>403</sup> *In vitro* tests are particularly valuable when SPT material for certain food is not available for routine diagnostics or when SPT cannot be applied (e.g. dermatographism or UV- and drug-induced skin hyporeactivity, widespread eczema, or the inability to stop antihistamines). Moreover, *in vitro* specific IgE to food allergens may give better quantitative data for the grade of sensitization, which helps to estimate the probability of the risk of a clinical reaction. However, precise decision points are not available, but it offers the opportunity to test single recombinant allergens, which may have a better diagnostic specificity than testing with food extracts for some foods (e.g., Gly m 4 in pollen-related soya allergy, Ara h2 in peanut allergy).

Atopy patch tests (APT) are not considered a routine instrument since standardised test materials are still not available. APT are performed with self-made food material using a 1/10 dilution in saline of the fresh food applied for 24–48 h on non-lesional skin.<sup>404</sup> So far, APTs have demonstrated to improve the accuracy of skin testing in the diagnosis of allergy to cow's milk, hen's eggs, cereals and peanuts in patients with AE.<sup>405-408</sup> Whereas immediate-type reactions are associated with SPT positivity, delayed reactions are related to positive responses to APTs. However, double-blind placebo-controlled food challenge (DBPCFC) remains the 'gold standard' for the diagnosis of food allergy.<sup>403</sup>

Oral food challenge should be performed under medical supervision with emergency equipment available, particularly after long-term removal of the culprit food from the diet. Home introduction for

cow's milk may be considered in the absence of evidence of sensitisation and without active eczema. In practice, oral food challenge should be performed according to standardized protocols.<sup>409</sup> In AE, the major flaw is that it might not offer the opportunity to exclude placebo reactions or coincidental influences of other trigger factors of AE during the challenge period. Therefore, the evaluation of delayed reactions after 24 h or 48 h by trained personell is mandatory.<sup>402, 403</sup> Challenge tests based on repeated exposure to food enable the assessment of delayed adverse responses.<sup>402</sup>

All foods that are associated with immediate reactions should be avoided. It is suggested, however, to re-evaluate cow's milk and hen's egg allergy in infants and young children with AE after one to two years, as these might have been outgrown. According to the the Milk Allergy in Primary (iMAP) Care guideline reintroduction of cow's milk should be between 9-12 months of age or at least 6 months after diagnosis is made: <https://gpifn.files.wordpress.com/2019/10/imap-treatment-algorithm.pdf>.

In a systematic review<sup>410</sup>, eight randomized controlled studies examined the effect of an elimination diet on existing AE. Based on this, there is no convincing evidence that a cow's milk- or hen's egg-free diet is beneficial in general, when unselected groups of patients with AE were studied. There is also no evidence for a benefit in the use of elementary or few food-restricted diets in unselected patients with AE. This comes with the caveat that elimination diets are difficult to carry out even in a motivating atmosphere during a clinical study and the dropout rate in AE studies is particularly high in studies on diets.

A Cochrane systematic review based on nine randomized controlled trials concluded that eliminating hen's egg from the diet in those who had evidence of significant sensitisation to hen's egg proved beneficial to AE control.<sup>411</sup> Accordingly, the American Academy of Dermatology recommends hen's egg restriction in the subset of patients with AE, who were found to be clinically allergic to hen's egg.<sup>412</sup> This approach should also be followed for other food allergens proven relevant in individual patients.

### **Pre- and probiotics and dietary supplements**

Probiotics such as lactobacillus mixtures have been studied in AE and have been shown to induce improvement in some settings.<sup>413</sup> Other studies failed to show significant effects.<sup>414, 415</sup> In a study with 800 infants, the effect of a prebiotic mixture was investigated and found to have beneficial effects in preventing the development of AE.<sup>416</sup> A recent Cochrane review identified 39 randomised controlled trials involving 2599 randomised participants.<sup>417</sup> The authors concluded that compared with no probiotic, currently available probiotic strains probably make little or no difference in improving patient-rated eczema symptoms. However, in 2020, the systematic review by Tan-Lim et al found that certain probiotic preparations (Bifidobacterium animalis subsp lactis CECT 8145, Bifidobacterium longum CECT 7347, and Lactobacillus casei CECT 9104); Lactobacillus casei DN-114001) show benefit in reducing allergic symptoms in paediatric AE.<sup>418</sup>

A systemic review on dietary supplements including fish oil, vitamin D or vitamin E came to the conclusion that there is no convincing evidence of the benefit of dietary supplements in AE.<sup>419</sup>

### **Vitamins**



A double blind, randomized clinical trial evaluated the effects of multistrain synbiotic (prebiotic+probiotic) versus vitamin D3 supplements or conventional therapy (topical steroid, emollients, antihistamine) on the severity of atopic eczema among 81 infants under 1 year of age for a period of two months; results showed a significant difference in SCORAD reduction between synbiotic

( $p < 0.001$ ) and vit D3 ( $p = 0.001$ ) groups compared to control group and no significant difference between vit D3 and synbiotic groups ( $p = 0.661$ ).<sup>420</sup>

In another randomized, controlled, investigator -blinded study on 26 young patients a product containing Licochalcone A lotion (LA+omega6+ceramide3+glycerin) was compared with an hydrocortisone lotion twice daily for 4 weeks in an inpatient comparison. A significant reduction of SCORAD was observed in the LA side ( $p < 0.001$ ), but no statistical significant difference between the two sides ( $p = 0.199$ ) were found. Relapses were lower in the LA side; patients satisfaction was high with both therapies but HC lotion induced a faster resolution of oedema, erythema, excoriation and pruritus (no statistical difference between two sides).<sup>421</sup>

The effects of pre-natal folic acid and iron supplementation was studied by administering standardized questionnaire to 344 women who delivered babies in an Italian hospital. Women were supplemented before childbirth with iron only, folic acid only, iron+folic acid or no supplements. Results of this study showed that iron+folic acid supplementation during pregnancy had protective effect for AE in the offspring while smoking during pregnancy and family history of AE increased risk of AE in the offspring. No association between AE and body mass index, psychological distress condition, maternal food antigen avoidance during pregnancy, vegetables and fruit as antioxidants intake was found.<sup>422</sup>

## 15. Allergen-specific immunotherapy

We <b>recommend against</b> allergen-specific immunotherapy as a routine treatment option for AE.	↓↓	<p style="text-align: center;">&gt;50%</p>  <p style="text-align: center;">(8/13) Expert Consensus</p>
We <b>suggest</b> that AIT is considered for selected patients with aeroallergen sensitization and a history of clinical exacerbation after exposure to the causative allergen	↑	<p style="text-align: center;">100%</p>  <p style="text-align: center;">100 % Agreement</p> <p style="text-align: center;">(11/11) Expert Consensus</p>

**Introduction**

The cause of symptoms in allergic patients is that the sensitized individual reacts with an allergic immune response to an otherwise harmless allergen. The aim of allergen-specific immunotherapy (AIT) is to theoretically cure allergic diseases. The idea behind it is that an immune tolerance is achieved in the sensitized patient by modifying the immune response and re-gaining regulatory capacities of humoral and cellular immune components.<sup>423</sup> Such changes may lead to the clinical improvement of allergic symptoms, reduced use of symptomatic rescue medications and improve QoL. The first promising and successful results were established and published in 1911.<sup>424</sup>

According to recent recommendations, ASIT is advised for a minimum period of 3 years, however according to long-term efficacy data, the longer the treatment the better. For AIT purified, non-allergenic, highly-immunogenic modified allergen extracts have been recommended. The routes of AIT may be of sublingual, oral, subcutaneous, or even transdermal and intralymphatic forms have recently been introduced.<sup>423</sup> Among these the sublingual (SLIT) and subcutaneous (SCIT) ways of application are the most commonly used forms, both being equally efficacious and safe, however SLIT formulation ensures greater liberty for the patient, while the SCIT secures better compliance and treatment adherence. Both SCIT and SLIT have seen low overall therapy compliance as well as varying levels of treatment literacy. In one meta-analysis, SCIT discontinuation ranged from 6 to 84% whereas SLIT discontinuation ranged from 21 to 93%.<sup>425</sup>

The role of allergen sensitization in AE pathogenesis has been investigated, but remains to be fully elucidated.

Inflammatory processes seem to be mediated by both an immediate-type reaction, initiated by the internalization of the complex IgE specific/allergens from epidermal dendritic cells, and a delayed T cell reactivity, characterized by a Th2 inflammatory pattern.<sup>7</sup>

One of the most important allergen sources in AE are house dust mites due to the perennial exposure. Recent studies focused the attention also on the role of pollen allergens as trigger for AE flare-ups.

AIT consists of administering increasing doses of allergen in order to modulate the response and promote peripheral immune tolerance mechanisms. AIT induces a shift from a Th2 to a Th1 immune response pattern, a decrease of mediator release from mast cells and the production of blocking antibodies IgG4 .

Favourable effects of AIT on disease symptoms of AE appear to be higher if accompanying relevant type I sensitizations are present, but only house dust mite-sensitized patients have been studied in larger studies in AE patients.

Here, the data for subcutaneous immunotherapy are stronger when compared to sublingual therapy and patients with severe AE (SCORAD > 50) showed better results.<sup>426</sup>

### **Systematic Reviews**

In recent years, different attempts to perform systematic review and meta-analysis on ASIT in AE were made. The first systematic review of the literature analyzed 10 studies in 2007 [distinguishing among placebo-controlled and observational studies].<sup>427</sup> The authors concluded that the overall effect was in favor of AIT, but no conclusion and recommendation could be formulated at that moment. In 2013 Bae et al.<sup>428</sup> performed a meta-analysis including 8 studies. The authors concluded that their meta-analysis provided moderate-level evidence for the efficacy of SIT against atopic dermatitis. They stated however that there is only a moderate quality of the evidence supporting the use of AIT.

Gendelman and Lang<sup>429</sup> analysed the double-blinded controlled trials published about SCIT and SLIT until 2013, including 8 studies, using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. Based on finding serious methodological problems, the authors concluded that only a weak recommendation could be given for use of AIT in patients with AE.

There has been recent data published on the efficacy of adjuvant SLIT treatment in AE patients in a small pilot study. The results indicated good efficacy and clinical response in mild-to-moderate AE. Furthermore AIT improved skin permeability barrier functions as well.<sup>430</sup>


Finally, a Cochrane systematic review was published in 2016.<sup>431</sup> The authors included 12 studies and stated that this small number of studies was insufficient to give conclusive results .

The most recent guidelines of dermatological societies suggest to evaluate AIT in patients with AE and sensitization to aeroallergens, and not fully responding to symptomatic treatment, leaving the final decision to the clinician

AIT prescription should be considered individually for each patient, evaluating the risk/benefit ratio, and discussed with the patient.<sup>432</sup>

Based on this evidence, we **suggest** that AIT may be considered for selected patients with house dust mite, birch or grass pollen sensitization, and a history of clinical exacerbation after exposure to the causative allergen or a positive corresponding atopy patch test. Moreover, AIT shall be applied in patients with respiratory atopic diseases and an approved indication of that therapeutical procedure with AE as a comorbidity.

## 16. Complementary medicine

<p>We <b>recommend against</b> acupuncture as standard therapy for AE.</p>	<p>↓↓</p>	<p>100%</p> <p style="text-align: center;"><b>100 % Agreement</b></p> <p>(13/13) Expert Consensus</p>
<p>We <b>recommend against</b> phytotherapy as standard therapy for AE.</p>	<p>↓↓</p>	<p>100%</p> <p style="text-align: center;"><b>100 % Agreement</b></p> <p>(14/14) Expert Consensus</p>
<p>We <b>recommend against</b> blood autologous serum as standard therapy for AE.</p>	<p>↓↓</p>	<p>100%</p> <p style="text-align: center;"><b>100 % Agreement</b></p> <p>(12/12) Expert Consensus</p>
<p>We <b>recommend against</b> Chinese herbal medicine as standard therapy for AE.</p>	<p>↓↓</p>	<p>100%</p> <p style="text-align: center;"><b>100 % Agreement</b></p> <p>(12/12) Expert Consensus</p>
<p>We <b>cannot make a recommendation</b> with respect to alpine climate therapy for AE.</p>	<p>0</p>	<p>&gt;75%</p>  <p>(11/12) Expert Consensus</p>

Complementary medicine describes a wide variety of healthcare practices used alongside standard medical treatment. These include alternative health approaches such as traditional Chinese medicine, acupuncture and others.

### **Acupuncture**

Acupuncture has been widely applied for the treatment of many chronic diseases, especially dermatological conditions.<sup>433, 434</sup> Some clinical trials have demonstrated that acupuncture can significantly reduce itch intensity and allergen-induced basophil activation in patients with AE.<sup>435, 436</sup>

A recent systematic review by Jiao et al<sup>437</sup> included eight RCTs (with 434 participants) compared the efficacy of acupuncture versus no treatment/placebo/conventional medicine in patients with chronic eczema. One included RCT showed that acupuncture was better than no treatment at reducing itch intensity but the results were not considered as reliable because of the low number of patients included (10 patients). The combined results of six RCTs showed that acupuncture was better than conventional medicine at reducing the eczema area and severity index (EASI) and the combined results of seven RCTs showed that acupuncture was better than conventional medicine in terms of global symptom improvement in AE. A meta-analysis of six and seven RCTs found a reduction in EASI (MD: -1.89, 95% CI: -3.04 to -0.75, I<sup>2</sup>: 78%) when acupuncture was compared to conventional medicine, and in global symptom improvement (RR: 1.59, 95% CI: 1.20 to 2.11, I<sup>2</sup>: 55%), respectively. No data on QoL and AE recurrence rate were available. No severe adverse events were found related to acupuncture.

The certainty of evidence of all outcomes was graded as low, because of high risk of bias, too small sample sizes and indirectness (due to studies having included patients with chronic, not explicitly atopic, eczema). The effects of acupuncture may have been exaggerated in these trials.

### **Phytotherapy**

We searched for studies examining the efficacy of phytotherapy in atopic eczema and we found only four studies including a small number of patients.

Fermented rice flour containing *Lactobacillus paracasei* CBA L74 (heat-killed probiotic lactobacilli) 7g/day diluted in a liquid in 10 young patients (6 months-6 years old) for 12 weeks in combination with topical corticosteroids and emollients was able to reduce the need of steroid application in half of the patients and the stop of steroid application in the other half.<sup>438</sup>

A single-center, open-label, pilot study on 20 adult patients with moderate-severe AE found that the application of a cream containing SOD 100000IU+combination of plant extracts twice daily in monotherapy for 30 days decreased the overall SCORAD of 67% from baseline.<sup>439</sup>

A double-blinded, randomized, placebo-controlled trial on 45 pediatric patients compared the efficacy of a cream containing an extract of *Ficus carica* L. (Melfi cream) versus hydrocortisone or placebo: both Melfi cream and hydrocortisone cream after 14 days of application determined a significant reduction of SCORAD compared to placebo.<sup>440</sup>

In another controlled study the efficacy and skin biophysiology of a cream and cleanser containing lipid complex with shea butter extract was compared with a ceramide product on a total of 58 AE patients, for 4 weeks of therapy. The treatment was well accepted, with improvement of SCORAD values and DLQI but no significant differences between the two products were found.<sup>441</sup>

There is lack of well defined RCT and it should be noted that plant extracts may cause contact sensitization.<sup>442</sup>

### **Autologous Blood Therapy**

A randomized double-blind placebo-controlled trial on 22 patients evaluated the clinical efficacy of intramuscular autologous plasma therapy and autologous high-molecular-weight plasma protein fraction therapy (AHPT) for 8 weeks in adult patients with recalcitrant atopic eczema. At the end of treatment patients in the AHPT group had a significant reduction in SCORAD and DLQI; no significant changes in the autologous plasma therapy group. Long term results were not maintained in either AHPT or autologous plasma therapy group.<sup>443</sup>

In another trial including 16 AE patients sensitized to HDM (*Dermatophagoides farinae*) the effects of intramuscular administration of autologous total immunoglobulin G twice weekly for 4 weeks were evaluated. Results showed a significant reduction of specific IgE and increase in specific IgG, showing a potential anti-allergic immunomodulatory effects in AE patients of autologous total IgG injections. No adverse events were declared.<sup>444</sup>

Long-term changes of clinical severity and laboratory parameters after intramuscular autologous IgG (Autologous ImmunoGlobulin Therapy: AIGT) for 4 weeks were studied in 3 AE adult patients and followed up for 2 years. In all cases a clinical improvement and a decrease in IgE levels were seen, with one patient who experienced a clinical improvement at week 40 until the end of follow up and the other two patients who had faster clinical improvement but a shorter duration of the response.

Authors concluded that AIGT had long-term favorable effects on both clinical severity and laboratory parameters in selected patients with severe recalcitrant AE. No adverse events emerged during the observation period.<sup>445</sup>

There is only very limited evidence supporting autologous blood therapy in the treatment of AE.

### **Chinese herbal medicine**

Chinese herbs have traditional been used in Chinese medicine for many years.

Recent systematic reviews could not find conclusive evidence to demonstrate that topical application of CHM for AE was superior to other control interventions due to methodological weaknesses of the included randomised controlled trial<sup>446</sup> and could not find conclusive evidence that CHM taken by mouth or applied topically to the skin could reduce the severity of eczema in children or adults.<sup>447</sup>

Well-designed, adequately powered RCTs are needed to evaluate the efficacy and safety of CHM for managing eczema.

### **High altitude alpine climate**

Fifteen observational studies were included in a recent review concerning 40.148 patients. Four studies concerning 2.670 patients presented follow-up data over a period of 1 year.<sup>375</sup> Quality assessment showed serious study limitations, therefore resulting in a very low level of evidence for the described outcomes.


Patient characteristics were not well described, and data on other pharmacological therapy were not provided. In most studies, style of reporting was very global and details were often lacking, making it

difficult to interpret the data. Because no trials have been conducted and no control groups were included in the observational studies, there is no reliable data on which elements of alpine climate treatment are responsible for the observed effect.

The results of this systematic review provide very low quality evidence that alpine climate therapy results in decreased disease activity and reduced corticosteroid requirement.

A small study including 7 patients with atopic eczema, who spent 5 days in a moderate altitude mountain region, reported no changes in SCORAD.<sup>448</sup>

## 17. Psychological and educational interventions

<p>We <b>suggest</b> that therapeutic patient education programmes with proven efficacy in children and adults with AE are widely implemented.</p>	<p>↑</p>	<p>100%</p>  <p>100 % Agreement</p> <p>(14/14) Expert Consensus</p>
--	----------	--

### Introduction to therapeutic patient education (TPE)/ complex interventions

Psychological and emotional factors as well as psychodynamic structures within the family are well-known elements that may influence the clinical course of AE.<sup>449</sup> Stress can elicit severe exacerbations of the disease and perpetuate the itch-scratch cycle. Anxiety or depression are acknowledged comorbidities in AE patients.<sup>450</sup> Furthermore, poor QoL and adherence to treatment are key issues in these patients.<sup>451</sup> As a multidimensional phenomenon, low treatment adherence is influenced among others by the disease itself, its chronicity but also by the patient's beliefs and characteristics. It can be improved by introducing specific strategies after understanding the patient's adherence pattern.<sup>451</sup> Therapeutic patient education (TPE) programmes were originally designed to enable people with chronic diseases to manage their illness (increasing autonomy and decreasing medical complications). They can help patients and their families to better understand and accept their disease and cope with treatment in order to improve QoL and treatment adherence. The aim of TPE is not simply to provide information by leaflets, but entails the transfer of skills (e.g. disease self-management strategies, knowledge of treatments, relaxation and behavioral therapy techniques) from a trained healthcare professional to the patient or their parents.<sup>452</sup> Additionally, as TPE is a patient-centered holistic care, it should facilitate a better partnership between doctors and their patients/caregivers. TPE can also help restore family dynamics. Parents with negative treatment experiences in the past and poor coping abilities regarding scratch control are likely to benefit most from TPE programmes.<sup>453</sup>

High-quality TPE programmes should ideally be evidence-based, tailored to patient's needs, taking into account the individual educational and cultural background (rather than being standardized in form and content). It should also have a well-defined content and activities that are provided by an interdisciplinary health care team.<sup>454</sup>

In terms on efficacy on disease severity outcomes, a recent meta-analysis including 7 RCTs that evaluated the effect of parental education with a total of 1853 children showed a significant difference in the SCORAD scores between the TPE and non-TPE groups (standardized mean difference = - 8.22, 95% CI = - 11.29, - 5.15;  $p < 0.01$ ).<sup>455</sup> The quality of evidence was assessed by Grading of Recommendations Assessment, Development and Evaluation (GRADE). However no significant differences in terms of QoL between groups were identified. A wide variety of interventions programmes are used depending of cultural backgrounds and health care systems (individual psychosomatic counseling, individual nurse or psychologist-led sessions, single or multiple interdisciplinary group sessions, written action plans, lectures, online videos etc.) and optimal delivery mode needs to be determined.<sup>456</sup> Although evidence remains limited regarding the efficacy of each of these interventions in the management of AE, the best

efficacy results and level of evidence are provided by interdisciplinary well structured age related group programmes in adults and children.<sup>454, 457</sup>

### **Nurse or psychologist-led programmes**

There is some evidence that eczema workshops lead to an improvement in severity scores with greater adherence in AE management, itch-scratching cognition, and additional psychological benefit.<sup>454</sup> Nurse led programmes result in more effective use of topical therapies, improvement of severity scores and may be sparing doctor's time compared to standard care.<sup>458</sup> The relative effectiveness of nurse led programs compared to multidisciplinary age related, structured programmes is unclear.

### **E-health**

There is some evidence that a direct-access, online model for follow-up dermatologic care is equivalent to classical in-person care in terms of efficacy but less costly.<sup>456</sup>

### **Other approaches**

As adjunctive therapies and in order to cope with AE, different psychological interventions can be useful. They can have a positive effect on the severity of the disease and on itching and scratching behaviors. A systematic review including 8 RCT, revealed that 5 showed a significant reduction in eczema severity.<sup>459</sup> Autogenic training (a systematic form of relaxation involving increasing awareness of the body), cognitive-behavioral therapy, habit reversal and behavioral therapies seems to be more effective rather than aromatherapy, brief dynamic psychotherapy and stress management programme. An effect on itching intensity has been found in all different kind of interventions evaluated except for habit reversal behavioral therapy.

### **Conclusion**


Structured interdisciplinary high quality education programmes should be implemented regardless of the severity of AE. They can improve the efficacy of topical treatment and be particularly helpful in evaluating the next treatment steps like the necessity of introducing systemic treatments. Psychological interventions, for example autogenic training, relaxation, cognitive-behavioral therapy, habit reversal and behavioral therapies have a positive effect on different aspects of AE.


## 18. Pregnancy, breastfeeding, and family planning


The current ethical framework of GCP guidelines deems it unethical to perform clinical trials in pregnant women. Therefore, there is no high-level evidence data on the efficacy and safety in this patient population. On the other hand, AE is the most common general skin disease in pregnancy. AE may either (i) worsen in women with a chronic condition, or (ii) may be reactivated in patients with a past AE history or (iii) may occur in women with no AE history (atopic eruption of pregnancy, AEP). Worsening of AE is mostly reported during the second and third trimesters, while AEP typically occurs during the first trimester.<sup>136</sup> There are no major clinical differences between classical AE worsening and AEP. Physiological skewness of the immune system towards a Th2-dominated response during pregnancy as well as physical and psychological stress during this period may contribute to AE worsening during pregnancy.

Little is known about treatment patterns during pregnancy, but patients and caregivers tend to reduce the use of topical and systemic therapies during pregnancy to avoid presumed harm to the fetus.<sup>460</sup> Consequently, undertreatment of AE during pregnancy may lead to serious QoL impairment but also to complications such as eczema herpeticum or staphylococcus aureus skin infections, and should therefore be avoided. We make recommendations based on the currently available evidence in relation to both topical and systemic therapies for the mother to ensure the health and well-being of the mother and the child throughout pregnancy.


### 18.1 Pregnant Women


In pregnant women with AE, we <b>recommend</b> TCS class II or III.	↑↑	<p>100%</p>  <p>100 % Agreement</p> <p>Expert Consensus</p>
---	----	--


In pregnant women with AE, we <b>suggest</b> that TCI may preferably be used on the face and intertriginous areas and on abdominal, breast and thigh skin, where the risk of striae formation increases with excessive use of TCS.	↑	<p>&gt;75%</p>  <p>&gt;75% Agreement</p> <p>Expert Consensus</p>
--	---	---


In pregnant women with AE, when topical treatments are insufficient, we <b>recommend</b> narrow-band UVB (311)	↑↑	<p>&gt;75%</p>  <p>&gt;75% Agreement</p> <p>Expert Consensus</p>
--	----	---

<p>nm) or broad spectrum UVB therapy if NB-UVB is unavailable.</p>		
--	--	--

<p>In pregnant women with AE who require systemic treatment we <b>suggest</b> ciclosporin.</p>	↑	<p style="text-align: center;"><b>100%</b></p> <div style="text-align: center;">  <p><b>100 % Agreement</b></p> </div> <p style="text-align: center;">Expert Consensus</p>
--	---	---

<p>In pregnant women with AE, we <b>recommend against</b> long term use of systemic corticosteroids - as we do in all AE patients.</p>	↓↓	<p style="text-align: center;"><b>100%</b></p> <div style="text-align: center;">  <p><b>100 % Agreement</b></p> </div>
<p>In pregnant women with AE, we <b>suggest</b> prednisolone only as short term rescue therapy for acute flares.</p>	↑	<p style="text-align: center;">Expert Consensus</p>

<p>In pregnant women with AE, we <b>recommend against</b> the use of abrocitinib, baricitinib, upadacitinib and methotrexate.</p>	↓↓	<p style="text-align: center;"><b>100%</b></p> <div style="text-align: center;">  <p><b>100 % Agreement</b></p> </div> <p style="text-align: center;">Expert Consensus</p>
---	----	---

<p>In pregnant women with AE, we <b>cannot make a recommendation</b> regarding the use of lebrikizumab, nemolizumab and tralokinumab due to the current lack of clinical data.</p>	0	<p style="text-align: center;"><b>100%</b></p> <div style="text-align: center;">  <p><b>100 % Agreement</b></p> </div>
<p>In pregnant women with AE, who require systemic treatment, we <b>suggest</b> dupilumab if the potential benefit justifies the potential risk to the fetus.</p>	↑	<p style="text-align: center;">Expert Consensus</p>

### First line treatments

*Emollients.* Basic emollient therapy is key in the treatment of AE also during pregnancy and must be proposed to pregnant women with AE as a basic daily therapy. There is no firm evidence on which emollient should be used. However, emollients with a high lipid content and as few potentially harmful agents as possible are typically favored. Using emollients in a wet wrap technique is encouraged.<sup>40</sup>

*TCS.* Reactive or proactive use of TCS class II or III according to the fingertip unit rule (see chapter 3) is recommended. A Cochrane systematic review updated in 2015 including 14 studies (5 cohort and 9 case-control studies) with 1,601,515 study subjects has examined the risk of TCS use in pregnancy. Overall, it has been deemed safe, with no causal associations between maternal exposure to TCS of all potencies and pregnancy outcomes including mode of delivery, congenital abnormalities, preterm delivery, fetal death, and low Apgar score, although the use of very potent topical corticosteroids, particularly in high doses, may be associated with low birthweight.<sup>461</sup> Proactive, twice weekly TCS application as maintenance therapy is regarded as safe, but caution is necessary if using potent TCS over large body surface areas, or sensitive areas as breast and thigh skin, on a more regular basis. Some experts suggest that class IV may be used as rescue therapy, or over longer periods on limited skin areas, but this is controversial. Fluticasone propionate should be avoided as it is the only TCS that is known not to be metabolized by the placenta.<sup>136</sup> There is experimental data that there is zero degradation of Fluticasone propionate at the placental barrier, whereas the degradation of hydrocortisone is high and the degradation of betamethasone is low.<sup>462, 463</sup> Therefore, the use of fluticasone propionate in pregnant women is generally avoided.<sup>136</sup>

*TCI.* Reactive and proactive use of TCI may be preferable on the face and intertriginous areas, and on abdominal, breast and thigh skin, where the risk of striae formation increases with excessive use of TCS.

*Antiseptics.* Antiseptics, except triclosan, may be used by pregnant women if clinically needed to prevent recurring skin infections, but are not used as a general routine measure.

*UV phototherapy.* Therapy with narrow-band UVB (311 nm) and broad-spectrum UVB does not impose a risk to the fetus in pregnant woman. However, oral psoralen should not be used preconceptionally (3 months) or in pregnant women.

### Second- and third-line treatments

Second- and third-line treatments are generally reserved for pregnant women with AE who remain inadequately controlled with TCS class II or III.

Systemic corticosteroids should not be used in the long-term in AE in general and even more so not during pregnancy, as it is associated with an increased risk of fetal complications, including gestational diabetes.<sup>461</sup> Only short courses of prednisolone (maximum 0.5 mg/kg/day) may be used with strict indication.

Ciclosporin may be used off-label in severe uncontrolled AE during pregnancy if topical anti-inflammatory treatment alone or in combination with UV treatment fails, and there is a clear need for

better long-term disease control. However, extra attention should be given to the renal function and blood pressure of the mother. There is no evidence of teratogenicity. Ciclosporin crosses the placenta<sup>464</sup> and should not be used during pregnancy, unless the potential benefit to the mother justifies the potential risk to the fetus.

AZA may be used off-label in pregnant women with severe uncontrolled AE, who are already receiving this treatment at the time of conception (see also chapter 8.2). There is no evidence for teratogenicity from studies with patients with inflammatory bowel diseases. Close consultation with an experienced obstetrician is generally considered important when prescribing this in pregnant women.<sup>136</sup>

MTX and Alitretinoin are teratogenic and therefore strictly contra-indicated during pregnancy.

As for dupilumab, the guideline group suggests considering use during pregnancy if the potential benefits outweigh the potential risks to the fetus, and emphasizes that the decision to use or withhold the medication must be made on a case-by-case basis. This is in keeping with the label and mounting evidence of the safety of dupilumab. The medication has been administered in well over 1,000 pregnant atopic eczema sufferers.<sup>465-471</sup> A propensity-matched cohort study, using data from the Collaborative Network of TriNetX, included 243 women treated with dupilumab before pregnancy, 293 treated during pregnancy and 300 treated during pregnancy and postpartum for type 2 chronic inflammatory diseases (atopic eczema, asthma, chronic rhinosinusitis with nasal polyps, prurigo nodularis, or eosinophilic esophagitis) and matched these patients with pregnant patients with type 2 chronic inflammatory diseases who were not exposed to dupilumab. Patients with outcomes occurring prior to the respective index events were excluded. Based on the data evaluated, the authors of the study conclude that there is no increased risk of adverse events for either the mother or the child. Of the 293 patients treated with dupilumab during pregnancy, 92 received the treatment for AD.<sup>472</sup> The authors of another retrospective multicenter case series, which reported on maternal and fetal outcomes in 85 cases of dupilumab exposure during pregnancy across 18 countries, also conclude that dupilumab is a good therapeutic option for the treatment of AD in women of childbearing potential.<sup>473</sup> On the other hand, an analysis examining reports documented between 1980 and 2023 in VigiBase that mentioned pregnancy- or fetus-related adverse reactions associated with drugs indicated for asthma, was published in 2025.<sup>474</sup> A total of 2,894 cases involving dupilumab were identified. The authors reported that, compared with medications other than biologics, the use of dupilumab during pregnancy was associated with a higher reporting odds ratio (ROR) for abortion or stillbirth (ROR 4.33; 95% CI, 3.16–5.94), spontaneous fetal death (ROR 5.34; 95% CI, 3.90–7.32), and spontaneous abortion (ROR 7.25; 95% CI, 5.26–9.99). Low ROR values were reported for pregnancy complications, gestational hypertension and related disorders, delivery complications, preterm birth and neonatal complications.<sup>474</sup> However, it is important to consider the limitations of the Vigibase database, including that reports do not prove causation. Reporting bias has been recognised as an important concern, as reporting is spontaneous and voluntary. In addition, the database lacks information on how many people in total were exposed to the medication, how often and how long, which means that it is not possible to calculate reliable incidence rates or risk probabilities from Vigibase alone.

For lebrikizumab, tralokinumab and nemolizumab the guideline group cannot recommend any of these medications, as there is currently no clinical data available to inform about any potential drug-associated risks.


Abrocitinib, baricitinib and upadacitinib are contraindicated during pregnancy according to label. There is no clinical data but single case reports supporting its safety in pregnant women. However, teratogenic effects have been described in animal models.<sup>475</sup>

Antihistamines are of limited efficacy in AE (see chapter antipruritic treatment). In case of need, loratadine or cetirizine should preferentially be used because of the broad experience with this drug in pregnant women.<sup>476-478</sup>

Due to lack of experience with crisaborole during pregnancy, this drug should not be used preconceptionally, in pregnancy or during lactation.

If antibiotic treatment is required for superinfected AE during pregnancy, all penicillins, cephalosporins, and erythromycin are considered safe and may be prescribed as needed.<sup>479, 480</sup>

**18.2 Breastfeeding women**

In breastfeeding women with AE, we <b>recommend</b> TCS II or III.	↑↑	 <p>100% 100 % Agreement Expert Consensus</p>
In breastfeeding women with AE, we <b>suggest</b> prednisolone only as short-term rescue therapy for acute flares.	↑	
In breastfeeding women with AE, we <b>suggest against</b> abrocitinib, baricitinib, upadacitinib, ciclosporin and methotrexate.	↓	
In breastfeeding women with AE, we <b>cannot make a recommendation</b> regarding the use of dupilumab, lebrikizumab, nemolizumab and tralokinumab due to the current lack of clinical data.	0	

TCS and TCI: No studies have examined the safety of TCS and TCI use during lactation but no harmful effect is suspected. Nevertheless, topical treatment is generally applied to the nipple region immediately after nursing, allowing the drug to be absorbed into the skin before the next feeding.<sup>136</sup>

Systemic corticosteroids: Treatment with a short course of a systemic corticosteroids during lactation is safe, since <0.1% of the mother's ingested dosage is secreted into breastmilk.

With regard to biologics (dupilumab, lebrikizumab, nemolizumab and tralokinumab), current evidence is insufficient to make a clear recommendation for or against their use in breastfeeding mothers with AE. Limited data suggests that the concentration of biologics in general (not just IL4 and IL13 inhibitors) appears to be low in breast milk.<sup>481</sup> Being protein-based therapeutics, biologics are expected to be degraded by gastric acid and proteolytic enzymes in the infant's gastrointestinal tract, which may further limit systemic absorption. Nevertheless, given the very limited clinical experience, caution should be exercised, and the decision to use biologics during lactation should be made on a case-by-case basis by clinical experts.

MTX, AZA, ciclosporin, and JAK-Inhibitors are secreted in breastmilk and may induce immunosuppression in the neonate. MTX, AZA, ciclosporin, and JAK-Inhibitors are generally not suggested for lactating mothers.<sup>136</sup>

## 18.3 Family planning

### Preconception recommendations for women

TCS and TCI: Although the literature on this subject is very sparse, all currently licensed topical AE therapies can be used without concern in women wishing to conceive.

MTX: Local labels in different countries suggest a contraindication range spanning from 1 month to 6 months before conception. European Medicines Agency (EMA) recommends 6 months as a means of precaution. The practice of the guideline group differs from this and we recommend stopping methotrexate 3 months before a planned conception.

Since JAK-inhibitors are contraindicated during pregnancy, the use of abrocitinib, baricitinib and upadacitinib should generally be avoided during periods of active family planning.

With regard to dupilumab, lebrikizumab, nemolizumab and tralokinumab, see chapter on pregnancy. Decisions regarding the administration of these drugs during active family planning, and potential exposure in early pregnancy, need to be made on a case-by-case basis, taking into account the respective half-lives of the drugs.

### Preconception recommendations for men

TCS and TCI: Although the literature on this subject is extremely sparse, all topical AE therapies in men wishing to father a child can be used without concern.

Ciclosporin may be used in the treatment of AE in men at the time of conception, as there is no evidence for harm or decreased fertility.

MTX: Following the European S3-guideline on systemic treatment of psoriasis vulgaris a 3-month MTX pause prior to conception is recommended. However, (inadvertent) exposure beyond this time does not justify termination of pregnancy, because there is no scientific evidence of male teratogenicity.<sup>136</sup> Some data suggest that methotrexate (MTX) may potentially impair sperm quality, for example by altering sperm DNA or motility, although the evidence is contradictory.<sup>482</sup>

AZA and JAK-Inhibitors: there is no contraindication for the use of AZA and JAK-Inhibitors in men wishing to father a child.

Dupilumab, lebrikizumab, nemolizumab, tralokinumab: There is currently no evidence that men need to abstain from fathering a child while on therapy. Further data is awaited to clearly demonstrate evidence of no harm.

## 19. Considerations for paediatric and adolescent patients

### Important phenotypic and diagnostic differences

AE may appear during the first months of life and most patients develop the condition before the age of 5 years. Around 60% of children outgrow AE in some cases. However, significant numbers either represent with AE or hand eczema as adults.<sup>483</sup>

Severe early disease and a family history of AE may predict a more persistent course of the disease.<sup>41</sup>

During infancy (0-2 years) the predilection areas are the cheeks, head, trunk, and extensor surfaces of the extremities, although flexural involvement is also common, which becomes an even more prominent feature during later childhood.

The first clinical signs often appear on the cheeks in form of erythematous, oozing, crusted plaques. The symptoms may then generalize and spread to the scalp, forehead, trunk, and limbs. Centrofacial pallor along with spared area of the nose and paranasal skin cause the „headlight sign“ appearance. The diaper area is also usually intact in infancy. The facial symptoms usually decrease by the end of the first year.<sup>484</sup>

Prematurity causes barrier dysfunction with higher transepidermal water loss (TEWL) and increased percutaneous absorption of chemicals. This is an important factor at planning local treatment dosage, body area, and duration. Infants are more susceptible to percutaneous toxicity. Their high surface area-to-volume ratio, immature drug metabolism systems, and decreased subcutaneous fat stores increase the absorption potential of the skin, while decreasing the volume of distribution of a drug or toxin. In full-term infants skin barrier development continues also during the first year of life.

Bathing an infant provides important psychological benefits between parent and child. Bathing of infants with AE should be brief to maintain the microbial flora, which is changing with age, avoiding harsh soaps and detergents and using bath emollients to aid skin hydration and emollients as soap substitutes to aid barrier function.<sup>485</sup>

Wet wraps can be a useful treatment approach where additional hydration of the skin is needed, in particular in young children.<sup>76</sup>

### Prevention

In children with AE we suggest to pay particular attention to emerging concomitant allergic diseases. About half of patients with moderate-to-severe AE develop food allergies (FA), asthma, and allergic rhinitis.

Skin care interventions, such as the regular use of emollients during the first year of life, have not shown convincing evidence of a reduction in AE development up to 2 years of age (see also emollient section).

### Topical anti-inflammatory treatment

As for adults, a stepped approach of TCS potency is recommended. Mild potency TCS is typically sufficient for mild atopic eczema in the face and neck (for 5-7 days). Moderate potency TCS are used for moderate atopic eczema, and potent for severe atopic eczema. Moderate or potent preparations are used for short periods (7 to 14 days) for flares. In vulnerable sites such as axillae and groin, less potent topical corticosteroids or TCI are desirable. Topical corticosteroids are recommended to apply once or twice daily for children under 12 years. Adolescents and adults will generally be instructed to apply a topical steroid 1-2 times a day for short bursts of treatment, and then stop or step down use when the

AE flare-up settles. Potent or very potent topical corticosteroids in children aged under 12 months should only be applied under specialist dermatological supervision.<sup>42</sup>


TCS are applied once or twice daily to all the affected areas, one of the times ideally shortly after a bath. The most common way to measure the amount of medication needed is by fingertip unit (FTU). This means the amount of medication that covers the finger from its tip to the first joint.


To treat the face of a 3-month-old infant, 1 FTU will suffice. To fully cover an entire leg of a 6-year-old, a 4 FTU dose is used.

With mild disease activity, maintenance use of topical corticosteroid twice to thrice weekly (monthly amounts in the mean range of 15 g in infants, 30 g in children and up to 60–90 g in adolescents and adults, adapted to affected body surface area) with a liberal use of emollients do not result in adverse systemic or local effects.<sup>41</sup>

TCI may effectively and safely be used as anti-inflammatory agents in the treatment of AE, especially on sensitive skin areas (e.g. face), from age two. The use of TCI in younger children is common (Ref. 349). Daily application (BID) recommended during relapses on the affected area, following the FTU rules, while according to the pro-active regimen they may also be applied twice a week on the symptom-free areas.<sup>41</sup> TCI are also used off label under 2 years of age in many centres.

## 20. Occupational aspects

<p>AE can have a negative impact on work life and is associated with a higher risk of hand eczema.</p>	<b>State- ment</b>	<p style="text-align: center;">100%</p> <div style="text-align: center;">  </div> <p style="text-align: center;">(15/15) Expert Consensus</p>
--	------------------------	--

<p>We <b>suggest</b> individual pre-employment counselling regarding choice of profession, including risk assessment, avoidance strategies and protective measures.</p>	↑	<p style="text-align: center;">100%</p> <div style="text-align: center;">  </div> <p style="text-align: center;">(23/23) Expert Consensus</p>
---	---	--

A number of occupational aspects are relevant to AE patients, as they are running a significant risk of developing occupational contact dermatitis. Atopy amplifies the effects of irritant and allergen exposure in several professions such as hairdressers, nurses, metalworkers, mechanics and cleaners, where hand eczema is a very common disease.<sup>7</sup> The risk for hand eczema in AE patients is increased about 4-fold.<sup>486</sup> Physicians should inform AE patients about the increased risk, and provide good guidance about prophylactic skin protection and irritant/contact allergen avoidance. All dermatologists treating adolescent patients with AE should advise these early on occupational aspects of their skin disease and suitable career choices.<sup>7</sup>

### Impact of atopic eczema on work life

AE has an adverse impact on QoL of patients and families, but may also impact work life and career choice. Knowledge is scarce though the socio-economic and individual costs due to loss of work activity is likely to be considerable.

The systematic review of Nørreslet et al. examined the literature up to February 2017 regarding impact on work life for AE patients, with a specific focus on choice of education and occupation, sick leave, change of job and disability pensions due to AE.<sup>487</sup> No meta-analysis could be performed due to wide methodological heterogeneity of included publications. Quality assessment was performed by the authors based on a validated list of criteria.<sup>487</sup> 23 papers were found eligible, including 26 studies with 103,343 participants from 12 different countries comprising 7,789 AE patients. Supplementary Table 4 provides an overview of these 26 studies.

### *Influence on job choice*

Out of five studies on the influence of AE on job choice, only one study in three of moderate/high quality showed significant influence on job choice.<sup>488-490</sup> Two studies of low quality demonstrated influence on job.<sup>491, 492</sup> Thus, no consistent conclusion can be drawn.

### *Influence on sick leave*

For the nine studies on sick leave, only one was of moderate/high quality,<sup>493</sup> the rest of low/moderate quality.<sup>490, 491, 494-499</sup> Sick leave was assessed indirectly as work-loss costs, lost work productivity or days away from work. In all studies sick leave was self-reported, proposing a risk of recall bias. Eight out of nine studies found increased sick leave due to AE.<sup>490, 491, 494-499</sup>

### *Social compensations due to AE*

The two low quality studies on social compensations showed a negative impact.<sup>491, 500</sup>

### *Influence on work life*

For the twelve studies assessing influence on work life due to AE, nine were of moderate or moderate/high quality<sup>490, 493, 501-507</sup> and three of low/moderate or low quality.<sup>508-510</sup> Objectives, outcomes and study designs were very heterogeneous. Overall, three studies reported significant influence of AE on change or loss of job,<sup>490, 501, 509</sup> while five reported no marked association.<sup>493, 502, 505, 506, 510</sup> The remaining studies did not assess this outcome.

This systematic review strongly suggests that AE negatively affects sick leave and possibly also job choice, change or loss of job and disability pensions.

After publication of the systematic review by Nørreslet et al.,<sup>487</sup> several studies have been undertaken regarding the economic burden of AE. All studies report similar results with reduced work productivity and activity in AE patients.<sup>11, 511-516</sup> One study estimated annual costs of productivity loss at \$2400 higher for employed US adult AE patients vs. employed non-AE controls.<sup>511</sup> A Dutch study estimated costs of productivity loss at €6886 per patient per year (PPY) for controlled AE patients and €13.702 PPY for uncontrolled AE patients.<sup>513</sup>

## **Risks in atopic eczema patients when starting / during work life**

Apart from the risks mentioned above, another risk when starting or during work life may be the onset of hand eczema (HE). Ruff et al. conducted a systematic review and meta-analyses to establish the association estimate between AE and the point, 1-year and lifetime prevalence of HE compared to controls.<sup>486</sup> Thirty-five studies were included with 168.311 participants, of which twenty-six in the meta-analyses with 90.336 participants. Of these 26, 10 were considered of high quality, 15 of moderate quality and one of low quality.

Prevalence of HE was significantly increased and associated with AE (point prevalence OR 2.35 (95% CI 1.47-3.76), 1-year prevalence OR 4.29 (95% CI 3.13-5.88), lifetime prevalence OR 4.06 (95% CI 2.72-6.06)). Positive significant associations between AE and occupational HE were found (1-year OR 4.31 (95% CI 2.08-8.91), lifetime prevalence OR 2.81 (95% CI 2.08-3.79)). In general population studies these results were confirmed (1-year prevalence of HE in individuals with and without AE - OR 4.19 (95% CI 3.46-5.08), lifetime prevalence OR 5.69 (95% CI 4.41-7.36)).

The systematic review was limited by different methods to diagnose both AE and HE (questionnaires versus clinical observation; only 5 of 26 studies used the validated U.K. working party's diagnostic criteria; risk of misclassification), lack of prospective studies for 1-year and lifetime prevalence of HE (only through questionnaires; risk of misclassification, reporting bias) and poor clinical phenotype descriptions.

Based on this systematic review AE patients have a three- to four-fold increase in prevalence of HE compared to controls. Therefore, special attention and individual guidance should be given to AE patients, both prior to and during active work life and when affected by occupational HE.

### Atopic eczema and counselling regarding work life

Several studies provide recommendations regarding counselling and follow-up of workers with AE,<sup>487, 514, 517</sup> based on the findings that AE is associated with HE and with a negative impact on work life. Pre-employment counselling with special attention on risk communication, avoidance strategies (see chapter avoidance techniques in AE) and protective measures (including higher need of emollients, see chapter basic emollients and moisturizers) is advised. Above all, guidance is recommended to be given to AE patients to avoid professions with skin irritating tasks or with contact with sensitizing substances, especially in patients with a history of persistent or relapsing HE. This includes a range of professions with wet-work, frequent use of gloves and exposure to sensitizing compounds, a non-exhaustive list is presented in Table 4.<sup>486-488, 501-503, 518, 519</sup> Secondary prevention is important, including frequent medical follow-up of the course of symptoms over the first few years on the job.<sup>519</sup> In case of problems, referral to a health and safety officer can be helpful to relieve the disease burden. However, no specific studies in the AE population were found regarding the effectiveness of such primary and secondary prevention measures.

**Table 4: Occupations with an elevated risk of hand eczema**

Job/occupation	Possible sensitizing compounds and atopic eczema triggers
Hairdresser	hair dyes, perm products, haircare products, rubber auxiliary materials, bleaching agents, detergents, wet-work, cosmetic preservatives
Beauticians	acrylics, acrylates, cosmetic preservatives, rubber auxiliary materials, wet-work
Cleaning and housekeeping	disinfectants, rubber auxiliary materials, abrasives, wet-work
Baker	flour and grain dust, rubber auxiliary materials, wet-work
Painter	paints, isocyanates, resins, turpentine, paint pigments, preservatives
Construction and cement worker	isocyanates, cement, concrete, glues, paints, resins, fiberglass, and metals
Carpenter	woods
Agricultural worker	animal particles, disinfectants, plants, rubber auxiliary materials

Florist and gardener	plants, rubber auxiliary materials, wet-work
Healthcare worker	latex, disinfectants, rubber auxiliary materials, medications, wet work
Veterinarian, animal lab worker, zookeeper	animal particles, disinfectants, rubber auxiliary materials, medications, tools, wet work
Catering and cooking employees	detergents, disinfectants, foods, rubber auxiliary materials, wet-work
Wind energy technician	solvents, glues, paints, epoxy, resins, fiberglass, acids and alkalis, detergents
Mechanic and metal worker	cutting fluids, coolants, detergents, metals, petroleum products, preservatives

## **XI. Strengths and limitations**

The vision of this guideline was to provide a comprehensive evidence-based update on all aspects of AE care with high relevance to practising clinicians across Europe. To reflect the latest methodological rigour in guideline development, the formal structure of the guideline document has been changed to follow the structure and style of the EuroGuiDerm guidelines. We assembled a guideline development group (GDG) that included clinical and methodological experts from across Europe, including patients. Our clear conflict of interest policy has created more transparency and was also reflected in the online voting procedures on standardised guideline statements.

While this regulated process of guideline formation has resulted in higher methodological rigour, independence, objectivity and quality of the content, we are conscious that the guideline document is already outdated regarding the fastest changing content, in particular the chapter on systemic therapy. However, we plan to update the content of this aspect of the guideline on a regular basis, creating a 'living' guideline for the systemic AE therapies.

## XII. References

1. Kaminski-Hartenthaler A, Meerpohl JJ, Gartlehner G, Kien C, Langer G, Wipplinger J et al. [GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations]. *Z Evid Fortbild Qual Gesundheitswes* 2014;108(7):413–20. GRADE Leitlinien: 14. Von der Evidenz zur Empfehlung: Die Bedeutung und Darstellung von Empfehlungen.
2. Drucker AM, Morra DE, Prieto-Merino D, Ellis AG, Yiu ZZN, Rochweg B et al. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis. *JAMA Dermatol* 2022;158(5):523–32.
3. Drucker AM. Systemic immunomodulatory treatments for atopic dermatitis: a living systematic review and network meta-analysis. 2022. Available at: <https://eczematherapies.com/research/> (last accessed 12 May 2025).
4. Drucker AM, Lam M, Prieto-Merino D, Malek R, Ellis AG, Yiu ZZN et al. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Living Systematic Review and Network Meta-Analysis Update. *JAMA Dermatol* 2024;160(9):936–44.
5. Drucker AM, Walwyn C, Chu C, Yiu ZZN, Rochweg B, Di Giorgio S et al. Living network meta-analysis to compare nemolizumab against other available targeted systemic treatments for atopic dermatitis. *Br J Dermatol* 2025;193(3):548–52.
6. Silverberg JI, Simpson EL, Armstrong AW, de Bruin-Weller MS, Irvine AD, Reich K. Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis. *Am J Clin Dermatol* 2022;23(1):1–11.
7. Wollenberg A, Christen-Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. *J Eur Acad Dermatol Venereol* 2020;34(12):2717–44.
8. Schünemann H, Brożek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. 2013. Available at: <https://gdt.gradeapro.org/app/handbook/handbook.html> (last accessed 03.08.2021).
9. Drucker AM, Flohr C, Ellis AG, Prieto-Merino D, Rochweg B, Bohdanowicz M et al. Systemic immunomodulatory treatments for atopic dermatitis: a living systematic review and network meta-analysis. 2025. Available at: <https://eczematherapies.com/research/>
10. Drucker AM, Lam M, Prieto-Merino D, Malek R, Ellis AG, Yiu ZZN et al. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Living Systematic Review and Network Meta-Analysis Update. *JAMA Dermatol* 2024;
11. Ring J, Zink A, Arents BWM, Seitz IA, Mensing U, Schielein MC et al. Atopic eczema: burden of disease and individual suffering - results from a large EU study in adults. *J Eur Acad Dermatol Venereol* 2019;33(7):1331–40.
12. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. *BMJ* 1996;312(7023):71–2.
13. Barbarot S, Stalder JF. Therapeutic patient education in atopic eczema. *Br J Dermatol* 2014;170 Suppl 1(44–8).
14. Arents BWM. Eczema treatment: it takes time to do no harm. *Br J Dermatol* 2017;177(3):613–4.
15. Andreassen TH, Christensen MO, Halling AS, Egeberg A, Thyssen JP. Placebo response in phase 2 and 3 trials of systemic and biological therapies for atopic dermatitis-a systematic review and meta-analysis. *J Eur Acad Dermatol Venereol* 2020;34(6):1143–50.
16. Zink AGS, Arents BWM, Fink-Wagner A, Seitz IA, Mensing U, Wettemann N et al. Out-of-pocket Costs for Individuals with Atopic Eczema: A Cross-sectional Study in Nine European Countries. *Acta Derm Venereol* 2019;99(3):263–7.

17. Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. *Lancet* 2020;396(10247):345–60.
18. Ring J. *Atopic dermatitis: eczema*. Springer; 2016.
19. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. *Nat Genet* 2006;38(4):441–6.
20. Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane ME, Moustafa M et al. Epidermal barrier dysfunction in atopic dermatitis. *J Invest Dermatol* 2009;129(8):1892–908.
21. Briot A, Deraison C, Lacroix M, Bonnart C, Robin A, Besson C et al. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. *J Exp Med* 2009;206(5):1135–47.
22. Draelos ZD. An evaluation of prescription device moisturizers. *J Cosmet Dermatol* 2009;8(1):40–3.
23. Elias PM, Wakefield JS, Man MQ. Moisturizers versus Current and Next-Generation Barrier Repair Therapy for the Management of Atopic Dermatitis. *Skin Pharmacol Physiol* 2019;32(1):1–7.
24. Gelmetti C, Wollenberg A. Atopic dermatitis - all you can do from the outside. *Br J Dermatol* 2014;170 Suppl 1(19–24).
25. Wollenberg A, Schnopp C. Evolution of conventional therapy in atopic dermatitis. *Immunol Allergy Clin North Am* 2010;30(3):351–68.
26. Abramovits W, Hebert AA, Boguniewicz M, Kempers SE, Tschen E, Jarratt MT et al. Patient-reported outcomes from a multicenter, randomized, vehicle-controlled clinical study of MAS063DP (Atopiclair) in the management of mild-to-moderate atopic dermatitis in adults. *J Dermatolog Treat* 2008;19(6):327–32.
27. Boralevi F, Saint Aroman M, Delarue A, Raudsepp H, Kaszuba A, Bylaite M et al. Long-term emollient therapy improves xerosis in children with atopic dermatitis. *J Eur Acad Dermatol Venereol* 2014;28(11):1456–62.
28. Eberlein B, Eicke C, Reinhardt HW, Ring J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). *J Eur Acad Dermatol Venereol* 2008;22(1):73–82.
29. Wilhelm K-P, Schölermann A, Bohnsack K, Wilhelm D, Rippke F. Wirksamkeit und Verträglichkeit einer topischen Zubereitung mit 10% Urea (Laceran® Salbe 10% Urea) bei Neurodermitis. *Aktuelle Derm* 1998;24(1-2):26–30.
30. Loden M, Andersson AC, Anderson C, Bergbrant IM, Frodin T, Ohman H et al. A double-blind study comparing the effect of glycerin and urea on dry, eczematous skin in atopic patients. *Acta Derm Venereol* 2002;82(1):45–7.
31. Darso U, Lübke J, Täieb A, Seidenari S, Wollenberg A, Calza AM et al. Position paper on diagnosis and treatment of atopic dermatitis. *J Eur Acad Dermatol Venereol* 2005;19(3):286–95.
32. Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. *J Eur Acad Dermatol Venereol* 2018;32(5):657–82.
33. van Zuuren EJ, Fedorowicz Z, Christensen R, Lavrijsen A, Arents BWM. Emollients and moisturisers for eczema. *Cochrane Database Syst Rev* 2017;2(CD012119).
34. Schram ME, Spuls PI, Leeflang MM, Lindeboom R, Bos JD, Schmitt J. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. *Allergy* 2012;67(1):99–106.
35. Akerstrom U, Reitamo S, Langeland T, Berg M, Rustad L, Korhonen L et al. Comparison of Moisturizing Creams for the Prevention of Atopic Dermatitis Relapse: A Randomized Double-blind Controlled Multicentre Clinical Trial. *Acta Derm Venereol* 2015;95(5):587–92.
36. Chiang C, Eichenfield LF. Quantitative assessment of combination bathing and moisturizing regimens on skin hydration in atopic dermatitis. *Pediatr Dermatol* 2009;26(3):273–8.

37. Dinkloh A, Worm M, Geier J, Schnuch A, Wollenberg A. Contact sensitization in patients with suspected cosmetic intolerance: results of the IVDK 2006-2011. *J Eur Acad Dermatol Venereol* 2015;29(6):1071–81.
38. Mengeaud V, Phulpin C, Bacquey A, Boralevi F, Schmitt AM, Taieb A. An innovative oat-based sterile emollient cream in the maintenance therapy of childhood atopic dermatitis. *Pediatr Dermatol* 2015;32(2):208–15.
39. Angelova-Fischer I, Rippke F, Richter D, Filbry A, Arrowitz C, Weber T et al. Stand-alone Emollient Treatment Reduces Flares After Discontinuation of Topical Steroid Treatment in Atopic Dermatitis: A Double-blind, Randomized, Vehicle-controlled, Left-right Comparison Study. *Acta Derm Venereol* 2018;98(5):517–23.
40. Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. *J Eur Acad Dermatol Venereol* 2018;32(5):657–82.
41. Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. *J Eur Acad Dermatol Venereol* 2018;32(6):850–78.
42. National Institute for Health and Care Excellence. NICE pathways: Eczema. 2020. Available at: <https://pathways.nice.org.uk/pathways/eczema>
43. Hlela C, Lunjani N, Gumedze F, Kakande B, Khumalo NP. Affordable moisturisers are effective in atopic eczema: A randomised controlled trial. *S Afr Med J* 2015;105(9):780–4.
44. Mandeau A, Aries MF, Boe JF, Brenk M, Crebassa-Trigueros V, Vaissiere C et al. Rhealba(R) oat plantlet extract: evidence of protein-free content and assessment of regulatory activity on immune inflammatory mediators. *Planta Med* 2011;77(9):900–6.
45. Gueniche A, Knautd B, Schuck E, Volz T, Bastien P, Martin R et al. Effects of nonpathogenic gram-negative bacterium *Vitreoscilla filiformis* lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study. *Br J Dermatol* 2008;159(6):1357–63.
46. Aries MF, Hernandez-Pigeon H, Vaissiere C, Delga H, Caruana A, Leveque M et al. Anti-inflammatory and immunomodulatory effects of *Aquaphilus dolomiae* extract on in vitro models. *Clin Cosmet Investig Dermatol* 2016;9(4):21–34.
47. Bamford JT, Ray S, Musekiwa A, van Gool C, Humphreys R, Ernst E. Oral evening primrose oil and borage oil for eczema. *Cochrane Database Syst Rev* 2013;2013(4):Cd004416.
48. Gehring W, Bopp R, Rippke F, Gloor M. Effect of topically applied evening primrose oil on epidermal barrier function in atopic dermatitis as a function of vehicle. *Arzneimittelforschung* 1999;49(7):635–42.
49. Simpson EL, Chalmers JR, Hanifin JM, Thomas KS, Cork MJ, McLean WH et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. *J Allergy Clin Immunol* 2014;134(4):818–23.
50. Horimukai K, Morita K, Narita M, Kondo M, Kitazawa H, Nozaki M et al. Application of moisturizer to neonates prevents development of atopic dermatitis. *J Allergy Clin Immunol* 2014;134(4):824–30 e6.
51. Chalmers JR, Haines RH, Bradshaw LE, Montgomery AA, Thomas KS, Brown SJ et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. *Lancet* 2020;395(10228):962–72.
52. Skjerven HO, Rehbinder EM, Vettukattil R, LeBlanc M, Granum B, Haugen G et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. *Lancet* 2020;395(10228):951–61.
53. Wollenberg A, Wetzel S, Burgdorf WH, Haas J. Viral infections in atopic dermatitis: pathogenic aspects and clinical management. *J Allergy Clin Immunol* 2003;112(4):667–74.

54. Fonacier LS, Aquino MR. The role of contact allergy in atopic dermatitis. *Immunol Allergy Clin North Am* 2010;30(3):337–50.
55. Thyssen JP, Linneberg A, Engkilde K, Menne T, Johansen JD. Contact sensitization to common haptens is associated with atopic dermatitis: new insight. *Br J Dermatol* 2012;166(6):1255–61.
56. Misery L, Belloni Fortina A, El Hachem M, Chernyshov P, von Kobyletzki L, Heratizadeh A et al. A position paper on the management of itch and pain in atopic dermatitis from the International Society of Atopic Dermatitis (ISAD)/Oriented Patient-Education Network in Dermatology (OPENED) task force. *J Eur Acad Dermatol Venereol* 2021;35(4):787–96.
57. Ring J, Mohrenschrager M. Allergy to peanut oil--clinically relevant? *J Eur Acad Dermatol Venereol* 2007;21(4):452–5.
58. Uehara M, Takada K. Use of soap in the management of atopic dermatitis. *Clin Exp Dermatol* 1985;10(5):419–25.
59. Blume-Peytavi U, Cork MJ, Faergemann J, Szczapa J, Vanaclocha F, Gelmetti C. Bathing and cleansing in newborns from day 1 to first year of life: recommendations from a European round table meeting. *J Eur Acad Dermatol Venereol* 2009;23(7):751–9.
60. Koutroulis I, Pyle T, Kopylov D, Little A, Gaughan J, Kratimenos P. The Association Between Bathing Habits and Severity of Atopic Dermatitis in Children. *Clin Pediatr (Phila)* 2016;55(2):176–81.
61. Denda M, Sokabe T, Fukumi-Tominaga T, Tominaga M. Effects of skin surface temperature on epidermal permeability barrier homeostasis. *J Invest Dermatol* 2007;127(3):654–9.
62. Hua T, Yousaf M, Gwillim E, Yew YW, Lee B, Hua K et al. Does daily bathing or showering worsen atopic dermatitis severity? A systematic review and meta-analysis. *Arch Dermatol Res* 2020;
63. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. *J Eur Acad Dermatol Venereol* 2012;26(9):1176–93.
64. Koutroulis I, Petrova K, Kratimenos P, Gaughan J. Frequency of bathing in the management of atopic dermatitis: to bathe or not to bathe? *Clin Pediatr (Phila)* 2014;53(7):677–81.
65. Santer M, Ridd MJ, Francis NA, Stuart B, Rumsby K, Chorozoglou M et al. Emollient bath additives for the treatment of childhood eczema (BATHE): multicentre pragmatic parallel group randomised controlled trial of clinical and cost effectiveness. *BMJ* 2018;361(k1332).
66. Maarouf M, Hendricks AJ, Shi VY. Bathing Additives for Atopic Dermatitis - A Systematic Review. *Dermatitis* 2019;30(3):191–7.
67. Ludwig G. On the topical effect of sea water tub-baths with and without addition of an oil emulsion. *Zeitschrift fur Haut-und Geschlechtskrankheiten* 1968;43(16):683–8.
68. Dittmar HC, Pflieger D, Schempp CM, Schopf E, Simon JC. [Comparison of balneophototherapy and UVA/B mono-phototherapy in patients with subacute atopic dermatitis]. *Hautarzt* 1999;50(9):649–53. Vergleichsstudie Solebader plus UVA/B versus UVA/B- Monotherapie bei Patienten mit subakuter atopischer Dermatitis.
69. Wollenberg A, Oranje A, Deleuran M, Simon D, Szalai Z, Kunz B et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. *J Eur Acad Dermatol Venereol* 2016;30(5):729–47.
70. Wollenberg A, Frank R, Kroth J, al. e. Proactive therapy of atopic eczema – an evidence-based concept with a behavioral background. *J Dtsch Dermatol Ges* 2009;7( 117–21.
71. Wollenberg A, Ehmann LM. Long term treatment concepts and proactive therapy for atopic eczema. *Ann Dermatol* 2012;24(3):253–60.
72. Schnopp C, Holtmann C, Stock S, Remling R, Folster-Holst R, Ring J et al. Topical steroids under wet-wrap dressings in atopic dermatitis--a vehicle-controlled trial. *Dermatology* 2002;204(1):56–9.
73. Gonzalez-Lopez G, Ceballos-Rodriguez RM, Gonzalez-Lopez JJ, Feito Rodriguez M, Herranz-Pinto P. Efficacy and safety of wet wrap therapy for patients with atopic dermatitis: a systematic review and meta-analysis. *Br J Dermatol* 2016;

74. Kohn LL, Kang Y, Antaya RJ. A randomized, controlled trial comparing topical steroid application to wet versus dry skin in children with atopic dermatitis (AD). *J Am Acad Dermatol* 2016;75(2):306–11.
75. Janmohamed SR, Oranje AP, Devillers AC, Rizopoulos D, van Praag MC, Van Gysel D et al. The proactive wet-wrap method with diluted corticosteroids versus emollients in children with atopic dermatitis: A prospective, randomized, double-blind, placebo-controlled trial. *J Am Acad Dermatol* 2014;
76. Cadmus SD, Sebastian KR, Warren D, Hovinga CA, Croce EA, Reveles LA et al. Efficacy and patient opinion of wet-wrap dressings using 0.1% triamcinolone acetonide ointment vs cream in the treatment of pediatric atopic dermatitis: A randomized split-body control study. *Pediatr Dermatol* 2019;36(4):437–41.
77. Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. *Br J Dermatol* 2002;147(3):528–37.
78. Berth-Jones J, Damstra RJ, Golsch S, Livden JK, Van Hooteghem O, Allegra F et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. *BMJ* 2003;326(7403):1367.
79. Niedner R. Therapie mit systemischen Glukokortikoiden. *Hautarzt* 2001;52(1062–71).
80. Barnes L, Kaya G, Rollason V. Topical corticosteroid-induced skin atrophy: a comprehensive review. *Drug Saf* 2015;38(5):493–509.
81. Van Der Meer JB, Glazenburg EJ, Mulder PG, Eggink HF, Coenraads PJ. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands Adult Atopic Dermatitis Study Group. *Br J Dermatol* 1999;140(6):1114–21.
82. Walsh P, Aeling JL, Huff L, Weston WL. Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids. *J Am Acad Dermatol* 1993;29(3):501–3.
83. Davallow Ghajar L, Wood Heickman LK, Conaway M, Rogol AD. Low Risk of Adrenal Insufficiency After Use of Low- to Moderate-Potency Topical Corticosteroids for Children With Atopic Dermatitis. *Clin Pediatr (Phila)* 2019;58(4):406–12.
84. Fishbein AB, Mueller K, Lor J, Smith P, Paller AS, Kaat A. Systematic Review and Meta-analysis Comparing Topical Corticosteroids With Vehicle/Moisturizer in Childhood Atopic Dermatitis. *J Pediatr Nurs* 2019;47(36–43).
85. Hengge UR. Topical Corticosteroids. In: Gaspari AA, Tyring SK, eds. *Clinical and Basic Immunodermatology*. Springer London; 2008:561–77.
86. Draelos ZD, Feldman SR, Berman B, Olivadoti M, Sierka D, Tallman AM et al. Tolerability of Topical Treatments for Atopic Dermatitis. *Dermatology and Therapy* 2019;9(1):71–102.
87. Siklar Z, Bostanci I, Atli O, Dallar Y. An infantile Cushing syndrome due to misuse of topical steroid. *Pediatr Dermatol* 2004;21(5):561–3.
88. Haeck IM, Rouwen TJ, Timmer-de Mik L, de Bruin-Weller MS, Bruijnzeel-Koomen CA. Topical corticosteroids in atopic dermatitis and the risk of glaucoma and cataracts. *J Am Acad Dermatol* 2011;64(2):275–81.
89. Chan HH, Salmon JF. Glaucoma caused by topical corticosteroid application to the eyelids. *Med J Aust* 2019;210(4):152–3.e1.
90. Sahni D, Darley CR, Hawk JLM. Glaucoma induced by periorbital topical steroid use – a rare complication. *Clin Exp Dermatol* 2004;29(6):617–9.
91. Hajar T, Leshem YA, Hanifin JM, Nedorost ST, Lio PA, Paller AS et al. A systematic review of topical corticosteroid withdrawal ("steroid addiction") in patients with atopic dermatitis and other dermatoses. *J Am Acad Dermatol* 2015;72(3):541–9 e2.
92. Queille C, Pommarede R, Saurat JH. Efficacy versus systemic effects of six topical steroids in the treatment of atopic dermatitis of childhood. *Pediatr Dermatol* 1984;1(3):246–53.

93. Charman C, Williams H. The use of corticosteroids and corticosteroid phobia in atopic dermatitis. *Clin Dermatol* 2003;21(3):193–200.
94. Meurer M, Eichenfield LF, Ho V, Potter PC, Werfel T, Hultsch T. Addition of pimecrolimus cream 1% to a topical corticosteroid treatment regimen in paediatric patients with severe atopic dermatitis: a randomized, double-blind trial. *J Dermatolog Treat* 2010;21(3):157–66.
95. Stalder JF, Aubert H, Anthoine E, Futamura M, Marcoux D, Morren MA et al. Topical corticosteroid phobia in atopic dermatitis: International feasibility study of the TOPICOP score. *Allergy* 2017;72(11):1713–9.
96. Aubert-Wastiaux H, Moret L, Le Rhun A, Fontenoy AM, Nguyen JM, Leux C et al. Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. *Br J Dermatol* 2011;165(4):808–14.
97. Lee JY, Her Y, Kim CW, Kim SS. Topical Corticosteroid Phobia among Parents of Children with Atopic Eczema in Korea. *Ann Dermatol* 2015;27(5):499–506.
98. Müller SM, Tomaschett D, Euler S, Vogt DR, Herzog L, Itin P. Topical Corticosteroid Concerns in Dermatological Outpatients: A Cross-Sectional and Interventional Study. *Dermatology* 2016;232(4):444–52.
99. Carr WW. Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations. *Paediatr Drugs* 2013;15(4):303–10.
100. Norris DA. Mechanisms of action of topical therapies and the rationale for combination therapy. *J Am Acad Dermatol* 2005;53(1, Supplement):S17–S25.
101. Ruzicka T, Bieber T, Schöpf E, Rubins A, Dobozy A, Bos J et al. A short-term trial of tacrolimus ointment for atopic dermatitis. *N Engl J Med* 1997;337(8):16–21.
102. Van Leent EJ, Graber M, Thurston M, Wagenaar A, Spuls PI, Bos JD. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. *Arch Dermatol* 1998;134(8):805–9.
103. Reitamo S, Wollenberg A, Schopf E, Perrot JL, Marks R, Ruzicka T et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. *Arch Dermatol* 2000;136(8):999–1006.
104. Meurer M, Folster-Holst R, Wozel G, Weidinger G, Junger M, Brautigam M et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. *Dermatology* 2002;205(3):271–7.
105. Reitamo S, Van Leent EJ, Ho V, Harper J, Ruzicka T, Kalimo K et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. *J Allergy Clin Immunol* 2002;109(3):539–46.
106. Cury Martins J, Martins C, Aoki V, Gois AF, Ishii HA, da Silva EM. Topical tacrolimus for atopic dermatitis. *Cochrane Database Syst Rev* 2015;7):CD009864.
107. Chen SL, Yan J, Wang FS. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials. *J Dermatolog Treat* 2010;21(3):144–56.
108. Wollenberg A, Reitamo S, Atzori F, Lahfa M, Ruzicka T, Healy E et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. *Allergy* 2008;63(6):742–50.
109. Thaci D, Reitamo S, Gonzalez Ensenat MA, Moss C, Boccaletti V, Cainelli T et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. *Br J Dermatol* 2008;159(6):1348–56.
110. Ho VC, Gupta A, Kaufmann R, Todd G, Vanaclocha F, Takaoka R et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. *J Pediatr* 2003;142(2):155–62.

111. Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. *J Am Acad Dermatol* 2002;46(4):495–504.
112. Patel RR, Vander Straten MR, Korman NJ. The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis. *Arch Dermatol* 2003;139(9):1184–6.
113. Reitamo S, Mandelin J, Rubins A, Remitz A, Makela M, Cirule K et al. The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitis. *Int J Dermatol* 2009;48(4):348–55.
114. Abędź N, Pawliczak R. Efficacy and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis: meta-analysis of randomized clinical trials. *Postępy Dermatol Alergol* 2019;36(6):752–9.
115. Reitamo S, Rustin M, Harper J, Kalimo K, Rubins A, Cambazard F et al. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. *Br J Dermatol* 2008;159(4):942–51.
116. Sigurgeirsson B, Boznanski A, Todd G, Vertruyen A, Schuttelaar ML, Zhu X et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. *Pediatrics* 2015;135(4):597–606.
117. Reitamo S, Rissanen J, Remitz A, Granlund H, Erkko P, Elg P et al. Tacrolimus ointment does not affect collagen synthesis: Results of a single-center randomized trial. *J Invest Dermatol* 1998;111(3):396–8.
118. Queille-Roussel C, Paul C, Duteil L, Lefebvre MC, Rapatz G, Zagula M et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. *Br J Dermatol* 2001;144(5):707–13.
119. Hong CH, Gooderham M, Bissonnette R. Evidence Review of Topical Calcineurin Inhibitors for the Treatment of Adult Atopic Dermatitis. *J Cutan Med Surg* 2019;23(4\_suppl):5s–10s.
120. Mandelin JM, Remitz A, Virtanen HM, Malmberg LP, Haahtela T, Reitamo S. A 10-year open follow-up of eczema and respiratory symptoms in patients with atopic dermatitis treated with topical tacrolimus for the first 4 years. *J Dermatolog Treat* 2010;21(3):167–70.
121. Lubbe J. Secondary infections in patients with atopic dermatitis. *Am J Clin Dermatol* 2003;4(9):641–54.
122. Wetzel S, Wollenberg A. Eczema molluscatum in tacrolimus treated atopic dermatitis. *Eur J Dermatol* 2004;14(1):73–4.
123. Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. *Pediatrics* 2002;110(1 Pt 1):e2.
124. Bornhovd E, Wollenberg A. Topische Immunmodulatoren zur Ekzembehandlung. *Allergo J* 2003;12(4):56–62.
125. Reitamo S, Ortonne JP, Sand C, Cambazard F, Bieber T, Folster-Holst R et al. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. *Br J Dermatol* 2005;152(6):1282–9.
126. Ohtsuki M, Morimoto H, Nakagawa H. Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: Review on safety and benefits. *The Journal of Dermatology* 2018;45(8):936–42.
127. Paller AS, Fölster-Holst R, Chen SC, Diepgen TL, Elmets C, Margolis DJ et al. No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. *J Am Acad Dermatol* 2020;
128. Ring J, Barker J, Behrendt H, Braathen L, Darsow U, Dubertret L et al. Review of the potential photo-carcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum. *J Eur Acad Dermatol Venereol* 2005;19(6):663–71.

129. Margolis DJ, Hoffstad O, Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. *Dermatology* 2007;214(4):289–95.
130. Thaci D, Salgo R. Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies. *Clin Dermatol* 2010;28(1):52–6.
131. Margolis DJ, Abuabara K, Hoffstad OJ, Wan J, Raimondo D, Bilker WB. Association Between Malignancy and Topical Use of Pimecrolimus. *JAMA Dermatol* 2015;151(6):594–9.
132. Deleuran M, Vestergaard C, Vølund A, Thestrup-Pedersen K. Topical Calcineurin Inhibitors, Topical Glucocorticoids and Cancer in Children: A Nationwide Study. *Acta Derm Venereol* 2016 96(6):834–5.
133. Asgari MM, Tsai AL, Avalos L, Sokil M, Quesenberry CP, Jr. Association Between Topical Calcineurin Inhibitor Use and Keratinocyte Carcinoma Risk Among Adults With Atopic Dermatitis. *JAMA Dermatol* 2020;
134. Castellsague J, Kuiper JG, Pottgard A, Anveden Berglind I, Dedman D, Gutierrez L et al. A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study). *Clin Epidemiol* 2018;10(299–310).
135. Czarnecka-Operacz M, Jenerowicz D. Topical calcineurin inhibitors in the treatment of atopic dermatitis – an update on safety issues. 2012;10(3):167–72.
136. Vestergaard C, Wollenberg A, Barbarot S, Christen-Zaech S, Deleuran M, Spuls P et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. *J Eur Acad Dermatol Venereol* 2019;33(9):1644–59.
137. McDowell L, Olin B. Crisaborole: A Novel Nonsteroidal Topical Treatment for Atopic Dermatitis. 2019;35(4):172–8.
138. Bissonnette R, Pavel AB, Diaz A, Werth JL, Zang C, Vranic I et al. Crisaborole and atopic dermatitis skin biomarkers: An inpatient randomized trial. *J Allergy Clin Immunol* 2019;144(5):1274–89.
139. Zebda R, Paller AS. Phosphodiesterase 4 inhibitors. *J Am Acad Dermatol* 2018;78(3, Supplement 1):S43–S52.
140. Yosipovitch G, Gold LF, Lebwohl MG, Silverberg JI, Tallman AM, Zane LT. Early Relief of Pruritus in Atopic Dermatitis with Crisaborole Ointment, A Non-steroidal, Phosphodiesterase 4 Inhibitor. *Acta Derm Venereol* 2018;98(5):484–9.
141. Fahrbach K, Tarpey J, Washington EB, Hughes R, Thom H, Neary MP et al. Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis. *Dermatol Ther (Heidelb)* 2020;
142. Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. *J Am Acad Dermatol* 2016;75(3):494–503.e6.
143. Eichenfield LF, Call RS, Forsha DW, Fowler J, Jr., Hebert AA, Spellman M et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. *J Am Acad Dermatol* 2017;77(4):641–9.e5.
144. Hanifin JM, Ellis CN, Frieden IJ, Fölster-Holst R, Stein Gold LF, Secci A et al. OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study. *J Am Acad Dermatol* 2016;75(2):297–305.
145. Ohba F, Matsuki S, Imayama S, Matsuguma K, Hojo S, Nomoto M et al. Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: An investigator-blinded, vehicle-controlled study. *J Dermatolog Treat* 2016;27(5):467–72.

146. Diaz A, Guttman-Yassky E. Topical agents for the treatment of atopic dermatitis. *Expert Rev Clin Immunol* 2019;15(4):369–82.
147. Bissonnette R, Papp KA, Poulin Y, Gooderham M, Raman M, Mallbris L et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. 2016;175(5):902–11.
148. Nakagawa H, Nemoto O, Igarashi A, Nagata T. Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study. *Br J Dermatol* 2018;178(2):424–32.
149. Kim BS, Howell MD, Sun K, Papp K, Nasir A, Kuligowski ME. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. *J Allergy Clin Immunol* 2020;145(2):572–82.
150. Peppers J, Paller AS, Maeda-Chubachi T, Wu S, Robbins K, Gallagher K et al. A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis. *J Am Acad Dermatol* 2019;80(1):89–98.e3.
151. Lee YW, Won C-H, Jung K, Nam H-J, Choi G, Park Y-H et al. Efficacy and safety of PAC-14028 cream – a novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild-to-moderate atopic dermatitis: a phase IIb randomized trial. *Br J Dermatol* 2019;180(5):1030–8.
152. Totté JE, van der Feltz WT, Hennekam M, van Belkum A, van Zuuren EJ, Pasmans SG. Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta-analysis. *Br J Dermatol* 2016;175(4):687–95.
153. Alexander H, Paller AS, Traidl-Hoffmann C, Beck LA, De Benedetto A, Dhar S et al. The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group. *Br J Dermatol* 2020;182(6):1331–42.
154. Cornelissen C, Marquardt Y, Czaja K, Wenzel J, Frank J, Luscher-Firzlaff J et al. IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. *J Allergy Clin Immunol* 2012;129(2):426–33, 33.e1–8.
155. Schlievert PM, Case LC, Strandberg KL, Abrams BB, Leung DYM. Superantigen profile of Staphylococcus aureus isolates from patients with steroid-resistant atopic dermatitis. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2008;46(10):1562–7.
156. George SM, Karanovic S, Harrison DA, Rani A, Birnie AJ, Bath-Hextall FJ et al. Interventions to reduce Staphylococcus aureus in the management of eczema. *Cochrane Database Syst Rev* 2019;2019(10):
157. Sawada Y, Tong Y, Barangi M, Hata T, Williams MR, Nakatsuji T et al. Dilute bleach baths used for treatment of atopic dermatitis are not antimicrobial in vitro. *J Allergy Clin Immunol* 2019;143(5):1946–8.
158. Juenger M, Ladwig A, Staecker S, Arnold A, Kramer A, Daeschlein G et al. Efficacy and safety of silver textile in the treatment of atopic dermatitis (AD). *Curr Med Res Opin* 2006;22(4):739–50.
159. Gauger A, Fischer S, Mempel M, Schaefer T, Foelster-Holst R, Abeck D et al. Efficacy and functionality of silver-coated textiles in patients with atopic eczema. *J Eur Acad Dermatol Venereol* 2006;20(5):534–41.
160. Wollenberg A, Zoch C, Wetzel S, Plewig G, Przybilla B. Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases. *J Am Acad Dermatol* 2003;49(2):198–205.
161. Seegräber M, Worm M, Werfel T, Svensson A, Novak N, Simon D et al. Recurrent eczema herpeticum - a retrospective European multicenter study evaluating the clinical characteristics of eczema herpeticum cases in atopic dermatitis patients. *J Eur Acad Dermatol Venereol* 2020;34(5):1074–9.
162. Ong PY, Leung DY. Bacterial and Viral Infections in Atopic Dermatitis: a Comprehensive Review. *Clin Rev Allergy Immunol* 2016;51(3):329–37.

163. Kreth HW, Hoeger PH. Safety, reactogenicity, and immunogenicity of live attenuated varicella vaccine in children between 1 and 9 years of age with atopic dermatitis. *Eur J Pediatr* 2006;165(10):677–83.
164. Schneider L, Weinberg A, Boguniewicz M, Taylor P, Oettgen H, Heughan L et al. Immune response to varicella vaccine in children with atopic dermatitis compared with nonatopic controls. *The Journal of allergy and clinical immunology* 2010;126(6):1306–7.e2.
165. Osier E, Eichenfield L. The Utility of Cantharidin for the Treatment of Molluscum Contagiosum. *Pediatr Dermatol* 2015;32(1):1–5.
166. Rush J, Dinulos JG. Childhood skin and soft tissue infections: new discoveries and guidelines regarding the management of bacterial soft tissue infections, molluscum contagiosum, and warts. *Curr Opin Pediatr* 2016;28(2):250–7.
167. Wollenberg A, Engler R. Smallpox, vaccination and adverse reactions to smallpox vaccine. *Curr Opin Allergy Clin Immunol* 2004;4(4):271–5.
168. Reed JL, Scott DE, Bray M. Eczema vaccinatum. *Clin Infect Dis* 2012;54(6):832–40.
169. Darsow U, Sbornik M, Rombold S, Katzer K, von Sonnenburg F, Behrendt H et al. Long-term safety of replication-defective smallpox vaccine (MVA-BN) in atopic eczema and allergic rhinitis. *J Eur Acad Dermatol Venereol* 2016;30(11):1971–7.
170. Mathes EF, Oza V, Frieden IJ, Cordero KM, Yagi S, Howard R et al. "Eczema coxsackium" and unusual cutaneous findings in an enterovirus outbreak. *Pediatrics* 2013;132(1):e149–57.
171. Neri I, Dondi A, Wollenberg A, Ricci L, Ricci G, Piccirilli G et al. Atypical Forms of Hand, Foot, and Mouth Disease: A Prospective Study of 47 Italian Children. *Pediatr Dermatol* 2016;33(4):429–37.
172. Lynch MD, Sears A, Cookson H, Lew T, Laftah Z, Orrin L et al. Disseminated coxsackievirus A6 affecting children with atopic dermatitis. *Clin Exp Dermatol* 2015;40(5):525–8.
173. Johnson VK, Hayman JL, McCarthy CA, Cardona ID. Successful treatment of eczema coxsackium with wet wrap therapy and low-dose topical corticosteroid. *J Allergy Clin Immunol Pract* 2014;2(6):803–4.
174. Sparber F, De Gregorio C, Steckholzer S, Ferreira FM, Dolowschiak T, Ruchti F et al. The Skin Commensal Yeast *Malassezia* Triggers a Type 17 Response that Coordinates Anti-fungal Immunity and Exacerbates Skin Inflammation. *Cell Host Microbe* 2019;25(3):389–403.e6.
175. Thammahong A, Kiatsurayanon C, Edwards SW, Rerknimitr P, Chiewchengchol D. The clinical significance of fungi in atopic dermatitis. *Int J Dermatol* 2020;59(8):926–35.
176. Glatz M, Bosshard PP, Hoetzenecker W, Schmid-Grendelmeier P. The Role of *Malassezia* spp. in Atopic Dermatitis. *Journal of clinical medicine* 2015;4(6):1217–28.
177. Kaffenberger BH, Mathis J, Zirwas MJ. A retrospective descriptive study of oral azole antifungal agents in patients with patch test-negative head and neck predominant atopic dermatitis. *J Am Acad Dermatol* 2014;71(3):480–3.
178. Svejgaard E, Larsen PO, Deleuran M, Ternowitz T, Roed-Petersen J, Nilsson J. Treatment of head and neck dermatitis comparing itraconazole 200 mg and 400 mg daily for 1 week with placebo. *J Eur Acad Dermatol Venereol* 2004;18(4):445–9.
179. Lorette G, Ermosilla V. Clinical efficacy of a new ciclopiroxolamine/zinc pyrithione shampoo in scalp seborrheic dermatitis treatment. *Eur J Dermatol* 2006;16(5):558–64.
180. Brodská P, Panzner P, Pizinger K, Schmid-Grendelmeier P. IgE-Mediated Sensitization to *Malassezia* in Atopic Dermatitis: More Common in Male Patients and in Head and Neck Type. *Dermatitis* 2014;25(3):120–6.
181. Glatz M, Buchner M, Von Bartenwerffer W, Schmid-Grendelmeier P, Worm M, Hedderich J et al. *Malassezia* spp.-specific immunoglobulin E level is a marker for severity of atopic dermatitis in adults. *Acta Derm Venereol* 2015;95(2):191–6.
182. Kamata Y, Tominaga M, Takamori K. Itch in Atopic Dermatitis Management. *Curr Probl Dermatol* 2016;50(86–93).

183. Sher LG, Chang J, Patel IB, Balkrishnan R, Fleischer AB, Jr. Relieving the pruritus of atopic dermatitis: a meta-analysis. *Acta Derm Venereol* 2012;92(5):455–61.
184. Reszke R, Krajewski P, Szepietowski JC. Emerging Therapeutic Options for Chronic Pruritus. *Am J Clin Dermatol* 2020;21(5):601–18.
185. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. *N Engl J Med* 2016;375(24):2335–48.
186. Silverberg JI, Yosipovitch G, Simpson EL, Kim BS, Wu JJ, Eckert L et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS. *J Am Acad Dermatol* 2020;82(6):1328–36.
187. Agache I, Song Y, Posso M, Alonso-Coello P, Rocha C, Solà I et al. Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines. *Allergy* 2021;76(1):45–58.
188. Worm M, Simpson EL, Thaçi D, Bissonnette R, Lacour JP, Beissert S et al. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial. *JAMA Dermatol* 2020;156(2):131–43.
189. Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). *Br J Dermatol* 2021;184(3):437–49.
190. Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet* 2020;396(10246):255–66.
191. Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. *Br J Dermatol* 2020;183(2):242–55.
192. Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. *Lancet* 2021;397(10290):2151–68.
193. Schommer A, Matthies C, Petersen I, Augustin M. Effektivität einer Polidocanol-Harnstoff-Kombination bei trockener, juckender Haut. Efficacy of a Polidocanol-Urea-Combination in Dry, Itching Skin. *Aktuelle Derm* 2007;33(01/02):33–8.
194. Hauss H, Proppe A, Matthies C. Vergleichende Untersuchungen zur Behandlung von trockener, juckender Haut mit einer Zubereitung aus Harnstoff und Polidocanol sowie mit einer Linolsäure-haltigen Fettcreme. Ergebnisse aus der Praxis. *Derm Beruf Umwelt* 1993;41(184–8).
195. Weisshaar E, Heyer G, Forster C, Handwerker HO. Effect of topical capsaicin on the cutaneous reactions and itching to histamine in atopic eczema compared to healthy skin. *Arch Dermatol Res* 1998;290(6):306–11.
196. Reimann S, Luger T, Metze D. [Topical administration of capsaicin in dermatology for treatment of itching and pain]. *Hautarzt* 2000;51(3):164–72. Topische Anwendung von Capsaicin in der Dermatologie zur Therapie von Juckreiz und Schmerz.
197. Garritsen FM, Brouwer MW, Limpens J, Spuls PI. Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research. *Br J Dermatol* 2014;170(3):501–13.

198. Jaworek A, Szafraniec K, Jaworek M, Matusiak Ł, Wojas-Pelc A, Szepietowski JC. Itch Relief in Atopic Dermatitis: Comparison of Narrowband Ultraviolet B Radiation and Cyclosporine Treatment. *Acta Derm Venereol* 2020;100(17):adv00291.
199. Doherty V, Sylvester DG, Kennedy CT, Harvey SG, Calthrop JG, Gibson JR. Treatment of itching in atopic eczema with antihistamines with a low sedative profile. *BMJ* 1989;298(6666):96.
200. Henz BM, Metzner P, O'Keefe E, Zuberbier T. Differential effects of new-generation H1-receptor antagonists in pruritic dermatoses. *Allergy* 1998;53(2):180–3.
201. Langeland T, Fagertun HE, Larsen S. Therapeutic effect of loratadine on pruritus in patients with atopic dermatitis. A multi-crossover-designed study. *Allergy* 1994;49(1):22–6.
202. La Rosa M, Ranno C, Musarra I, Guglielmo F, Corrias A, Bellanti JA. Double-blind study of cetirizine in atopic eczema in children. *Ann Allergy* 1994;73(2):117–22.
203. Wahlgren CF, Hägermark O, Bergström R. The antipruritic effect of a sedative and a non-sedative antihistamine in atopic dermatitis. *Br J Dermatol* 1990;122(4):545–51.
204. Munday J, Bloomfield R, Goldman M, Robey H, Kitowska GJ, Gwiedzinski Z et al. Chlorpheniramine is no more effective than placebo in relieving the symptoms of childhood atopic dermatitis with a nocturnal itching and scratching component. *Dermatology* 2002;205(1):40–5.
205. Hannuksela M, Kalimo K, Lammintausta K, Mattila T, Turjanmaa K, Varjonen E et al. Dose ranging study: cetirizine in the treatment of atopic dermatitis in adults. *Ann Allergy* 1993;70(2):127–33.
206. Chunharas A, Wisuthsarewong W, Wananukul S, Viravan S. Therapeutic efficacy and safety of loratadine syrup in childhood atopic dermatitis treated with mometasone furoate 0.1 per cent cream. *J Med Assoc Thai* 2002;85(4):482–7.
207. Kawakami T, Kaminishi K, Soma Y, Kushimoto T, Mizoguchi M. Oral antihistamine therapy influences plasma tryptase levels in adult atopic dermatitis. *J Dermatol Sci* 2006;43(2):127–34.
208. Mattered U, Böhmer MM, Weisshaar E, Jupiter A, Carter B, Apfelbacher CJ. Oral H1 antihistamines as 'add-on' therapy to topical treatment for eczema. *Cochrane Database Syst Rev* 2019;1(1):Cd012167.
209. Kawashima M, Tango T, Noguchi T, Inagi M, Nakagawa H, Harada S. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study. *Br J Dermatol* 2003;148(6):1212–21.
210. Simons FE. Safety of levocetirizine treatment in young atopic children: An 18-month study. *Pediatr Allergy Immunol* 2007;18(6):535–42.
211. Church MK, Maurer M, Simons FE, Bindslev-Jensen C, van Cauwenberge P, Bousquet J et al. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. *Allergy* 2010;65(4):459–66.
212. Adam K, Oswald I. The hypnotic effects of an antihistamine: promethazine. *Br J Clin Pharmacol* 1986;22(6):715–7.
213. Monroe EW. Efficacy and safety of nalmefene in patients with severe pruritus caused by chronic urticaria and atopic dermatitis. *J Am Acad Dermatol* 1989;21(1):135–6.
214. Burch JR, Harrison PV. Opiates, sleep and itch. *Clin Exp Dermatol* 1988;13(6):418–9.
215. Banerji D, Fox R, Seleznick M, Lockey R. 337 Controlled antipruritic trial of nalmefene (N) in chronic urticaria (CU) and atopic dermatitis (AD). *J Allergy Clin Immunol* 1988;81(1):252.
216. Metze D, Reimann S, Beissert S, Luger T. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. *J Am Acad Dermatol* 1999;41(4):533–9.
217. Malekzad F, Arbabi M, Mohtasham N, Toosi P, Jaberian M, Mohajer M et al. Efficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study. *J Eur Acad Dermatol Venereol* 2009;23(8):948–50.

218. Ständer S, Böckenholt B, Schürmeyer-Horst F, Weishaupt C, Heuft G, Luger TA et al. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. *Acta Derm Venereol* 2009;89(1):45–51.
219. Jekler J, Larko O. Combined UVA-UVB versus UVB phototherapy for atopic dermatitis: a paired-comparison study. *J Am Acad Dermatol* 1990;22(1):49–53.
220. Jekler J, Larko O. UVB phototherapy of atopic dermatitis. *Br J Dermatol* 1988;119(6):697–705.
221. Jekler J, Larko O. UVA solarium versus UVB phototherapy of atopic dermatitis: a paired-comparison study. *Br J Dermatol* 1991;125(6):569–72.
222. Jekler J, Larko O. Phototherapy for atopic dermatitis with ultraviolet A (UVA), low-dose UVB and combined UVA and UVB: two paired-comparison studies. *Photodermatol Photoimmunol Photomed* 1991;8(4):151–6.
223. Majoie IM, Oldhoff JM, van Weelden H, Laaper-Ertmann M, Bousema MT, Sigurdsson V et al. Narrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis. *J Am Acad Dermatol* 2009;60(1):77–84.
224. Der-Petrossian M, Seeber A, Honigsmann H, Tanew A. Half-side comparison study on the efficacy of 8-methoxypsoralen bath-PUVA versus narrow-band ultraviolet B phototherapy in patients with severe chronic atopic dermatitis. *Br J Dermatol* 2000;142(1):39–43.
225. Gambichler T, Othlinghaus N, Tomi NS, Holland-Letz T, Boms S, Skrygan M et al. Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study. *Br J Dermatol* 2009;160(3):652–8.
226. Legat FJ, Hofer A, Brabek E, Quehenberger F, Kerl H, Wolf P. Narrowband UV-B vs medium-dose UV-A1 phototherapy in chronic atopic dermatitis. *Arch Dermatol* 2003;139(2):223–4.
227. Reynolds NJ, Franklin V, Gray JC, Diffey BL, Farr PM. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. *Lancet* 2001;357(9273):2012–6.
228. Heinlin J, Schiffner-Rohe J, Schiffner R, Einsele-Kramer B, Landthaler M, Klein A et al. A first prospective randomized controlled trial on the efficacy and safety of synchronous balneophototherapy vs. narrow-band UVB monotherapy for atopic dermatitis. *J Eur Acad Dermatol Venereol* 2011;25(7):765–73.
229. Tzaneva S, Seeber A, Schwaiger M, Honigsmann H, Tanew A. High-dose versus medium-dose UVA1 phototherapy for patients with severe generalized atopic dermatitis. *J Am Acad Dermatol* 2001;45(4):503–7.
230. Dittmar HC, Pflieger D, Schopf E, Simon JC. [UVA1 phototherapy. Pilot study of dose finding in acute exacerbated atopic dermatitis]. *Hautarzt* 2001;52(5):423–7. UVA1-Phototherapie. Pilotstudie zur Dosisfindung bei der bei akut exazerbierten atopischen Dermatitis.
231. Krutmann J, Czech W, Diepgen T, Niedner R, Kapp A, Schopf E. High-dose UVA1 therapy in the treatment of patients with atopic dermatitis. *J Am Acad Dermatol* 1992;26(2 Pt 1):225–30.
232. Krutmann J, Diepgen TL, Luger TA, Grabbe S, Meffert H, Sonnichsen N et al. High-dose UVA1 therapy for atopic dermatitis: results of a multicenter trial. *J Am Acad Dermatol* 1998;38(4):589–93.
233. Tzaneva S, Kittler H, Holzer G, Reljic D, Weber M, Honigsmann H et al. 5-Methoxypsoralen plus ultraviolet (UV) A is superior to medium-dose UVA1 in the treatment of severe atopic dermatitis: a randomized crossover trial. *Br J Dermatol* 2010;162(3):655–60.
234. von Kobyletzki G, Pieck C, Hoffmann K, Freitag M, Altmeyer P. Medium-dose UVA1 cold-light phototherapy in the treatment of severe atopic dermatitis. *J Am Acad Dermatol* 1999;41(6):931–7.
235. Granlund H, Erko P, Remitz A, Langeland T, Helsing P, Nuutinen M et al. Comparison of cyclosporin and UVAB phototherapy for intermittent one-year treatment of atopic dermatitis. *Acta Derm Venereol* 2001;81(1):22–7.
236. Valkova S, Velkova A. UVA/UVB phototherapy for atopic dermatitis revisited. *J Dermatolog Treat* 2004;15(4):239–44.

237. Byun HJ, Lee HI, Kim B, Kim MN, Hong H, Choi Y et al. Full-spectrum light phototherapy for atopic dermatitis. *Int J Dermatol* 2011;50(1):94–101.
238. Qayyum S, Asad F, Agrawal R, Khurshid K, Rani Z, Pal SS. Comparison of efficacy and safety of ultraviolet A radiation versus ultraviolet B radiation in atopic dermatitis. *Journal of pakistan association of dermatologists* 2016;26(3):223–8.
239. Pacifico A, Iacovelli P, Damiani G, Ferraro C, Cazzaniga S, Conic RRZ et al. 'High dose' vs. 'medium dose' UVA1 phototherapy in italian patients with severe atopic dermatitis. *J Eur Acad Dermatol Venereol* 2019;33(4):718–24.
240. Collins P, Ferguson J. Narrowband (TL-01) UVB air-conditioned phototherapy for atopic eczema in children. *Br J Dermatol* 1995;133(4):653–5.
241. Jury CS, McHenry P, Burden AD, Lever R, Bilsland D. Narrowband ultraviolet B (UVB) phototherapy in children. *Clin Exp Dermatol* 2006;31(2):196–9.
242. Clayton TH, Clark SM, Turner D, Goulden V. The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy. *Clin Exp Dermatol* 2007;32(1):28–33.
243. Tay YK, Morelli JG, Weston WL. Experience with UVB phototherapy in children. *Pediatr Dermatol* 1996;13(5):406–9.
244. Sheehan MP, Atherton DJ, Norris P, Hawk J. Oral psoralen photochemotherapy in severe childhood atopic eczema: an update. *Br J Dermatol* 1993;129(4):431–6.
245. Mok ZR, Koh MJ, Chong WS. Is phototherapy useful in the treatment of atopic dermatitis in asian children? A 5-year report from singapore. *Pediatr Dermatol* 2014;31(6):698–702.
246. Pavlovsky M, Baum S, Shpiro D, Pavlovsky L, Pavlotsky F. Narrow band UVB: is it effective and safe for paediatric psoriasis and atopic dermatitis? *J Eur Acad Dermatol Venereol* 2011;25(6):727–9.
247. Darne S, Leech SN, Taylor AE. Narrowband ultraviolet B phototherapy in children with moderate-to-severe eczema: a comparative cohort study. *Br J Dermatol* 2014;170(1):150–6.
248. Dayal S, Pathak K, Sahu P, Jain VK. Narrowband UV-B phototherapy in childhood atopic dermatitis: efficacy and safety. *An Bras Dermatol* 2017;92(6):801–6.
249. Vermeulen FM, Gerbens LAA, Schmitt J, Deleuran M, Irvine AD, Logan K et al. The European TREATment of ATopic eczema (TREAT) Registry Taskforce survey: prescribing practices in Europe for phototherapy and systemic therapy in adult patients with moderate-to-severe atopic eczema. *Br J Dermatol* 2020;
250. Bedair K, Elhadad A, Hamad S, Ferguson J, Donnan P, Dawe RS. No association between whole-body ultraviolet A1 phototherapy and skin cancers in humans: a cancer registry linkage study. *Br J Dermatol* 2020;
251. Weischer M, Blum A, Eberhard F, Rocken M, Berneburg M. No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: A first retrospective study. *Acta Derm Venereol* 2004;84(5):370–4.
252. Lee E, Koo J, Berger T. UVB phototherapy and skin cancer risk: a review of the literature. *Int J Dermatol* 2005;44(5):355–60.
253. Archier E, Devaux S, Castela E, Gallini A, Aubin F, Le Maitre M et al. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. *J Eur Acad Dermatol Venereol* 2012;26 Suppl 3(22–31).
254. Stern RS, Liebman EJ, Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study. *J Natl Cancer Inst* 1998;90(17):1278–84.
255. Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. *N Engl J Med* 1997;336(15):1041–5.

256. Paul CF, Ho VC, McGeown C, Christophers E, Schmidtman B, Guillaume JC et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. *J Invest Dermatol* 2003;120(2):211–6.
257. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. *Lancet* 2001;358(9287):1042–5.
258. Schmitt J, Spuls PI, Thomas KS, Simpson E, Furue M, Deckert S et al. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. *J Allergy Clin Immunol* 2014;134(4):800–7.
259. Stadler PC, Renner ED, Milner J, Wollenberg A. Inborn Error of Immunity or Atopic Dermatitis: When to be Concerned and How to Investigate. *J Allergy Clin Immunol Pract* 2021;9(4):1501–7.
260. Eichenfield LF, Boguniewicz M, Lauren CT, Leung DYM, Levy ML, Schneider LC et al. Systemic Therapy for Atopic Dermatitis in Children and Adolescents: A US Expert Consensus. *Dermatology* 2024;240(5-6):897–909.
261. Fan R, Cohen JM. Vaccination Recommendations for Psoriasis and Atopic Dermatitis Patients on Biologic Therapy: A Practical Guide. *Yale J Biol Med* 2022;95(2):249–55.
262. Care AG-DoHaA. Australian Immunisation Handbook: Recommended timing of live vaccine administration for people receiving immunosuppressive therapies. 2025. Available at: <https://immunisationhandbook.health.gov.au/resources/tables/table-recommended-timing-of-live-vaccine-administration-for-people-receiving-immunosuppressive-therapies?> (last accessed 06.08.2025).
263. Lennard L. The clinical pharmacology of 6-mercaptopurine. *Eur J Clin Pharmacol* 1992;43(4):329–39.
264. Drucker AM, Ellis AG, Bohdanowicz M, Mashayekhi S, Yiu ZZN, Rochweg B et al. Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis: A Systematic Review and Network Meta-analysis. *JAMA Dermatol* 2020;156(6):659–67.
265. Roekevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. *J Allergy Clin Immunol* 2014;133(2):429–38.
266. Thomsen SF, Karlsmark T, Clemmensen KK, Graversgaard C, Ibler KS, Jemec GB et al. Outcome of treatment with azathioprine in severe atopic dermatitis: a 5-year retrospective study of adult outpatients. *Br J Dermatol* 2015;172(4):1122–4.
267. Garritsen FM, Roekevisch E, van der Schaft J, Deinum J, Spuls PI, de Bruin-Weller MS. Ten years experience with oral immunosuppressive treatment in adult patients with atopic dermatitis in two academic centres. *J Eur Acad Dermatol Venereol* 2015;29(10):1905–12.
268. van der Schaft J, van Zuilen AD, Deinum J, Bruijnzeel-Koomen CA, de Bruin-Weller MS. Serum creatinine levels during and after long-term treatment with cyclosporine A in patients with severe atopic dermatitis. *Acta Derm Venereol* 2015;95(8):963–7.
269. Gerbens LAA, Hamann SAS, Brouwer MWD, Roekevisch E, Leeflang MMG, Spuls PI. Methotrexate and azathioprine for severe atopic dermatitis: a 5-year follow-up study of a randomized controlled trial. *Br J Dermatol* 2018;178(6):1288–96.
270. Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. *Lancet* 2006;367(9513):839–46.
271. Meggitt SJ, Reynolds NJ. Azathioprine for atopic dermatitis. *Clin Exp Dermatol* 2001;26(5):369–75.
272. Taylor AE, Shuster S. Skin cancer after renal transplantation: the causal role of azathioprine. *Acta Derm Venereol* 1992;72(2):115–9.

273. Meggitt SJ, Anstey AV, Mohd Mustapa MF, Reynolds NJ, Wakelin S. British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine 2011. *Br J Dermatol* 2011;165(4):711–34.
274. Janssen NM, Genta MS. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. *Arch Intern Med* 2000;160(5):610–9.
275. Noguera-Morel L, Knöpfel N, Torreló A, Hernández-Martín A. A Retrospective Study of Systemic Treatment of Severe Atopic Dermatitis With Azathioprine: Effectiveness and Tolerance in 11 Pediatric Patients. *Actas Dermosifiliogr* 2019;110(3):227–31. Estudio retrospectivo del tratamiento sistémico de la dermatitis atópica grave con azatioprina. Eficacia y tolerancia en 11 pacientes pediátricos.
276. Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema - a systematic review and meta-analysis. *J Eur Acad Dermatol Venereol* 2007;21(5):606–19.
277. Seger EW, Wechter T, Strowd L, Feldman SR. Relative efficacy of systemic treatments for atopic dermatitis. *J Am Acad Dermatol* 2019;80(2):411–6.e4.
278. Flohr C, Rosala-Hallas A, Jones AP, Beattie P, Baron S, Browne F et al. Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial. *Br J Dermatol* 2023;189(6):674–84.
279. Alexander H, Malek R, Prieto-Merino D, Gribaleva E, Baden M, Beattie P et al. A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register. *Br J Dermatol* 2024;
280. Dal Bello G, Maurelli M, Schena D, Girolomoni G, Gisondi P. Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients. *Dermatol Ther* 2020;33(6):e13979.
281. Goujon C, Viguier M, Staumont-Sallé D, Bernier C, Guillet G, Lahfa M et al. Methotrexate Versus Cyclosporine in Adults with Moderate-to-Severe Atopic Dermatitis: A Phase III Randomized Noninferiority Trial. *J Allergy Clin Immunol Pract* 2018;6(2):562–9.e3.
282. Bruce G, Rosala-Hallas A, Jones AP, Turner C, Dalton N, Hilger E et al. The effects of ciclosporin and methotrexate on kidney function in the treatment of severe atopic dermatitis in children - results from the TREAT trial. *Br J Dermatol* 2024;
283. Berth-Jones J, Finlay AY, Zaki I, Tan B, Goodyear H, Lewis-Jones S et al. Cyclosporine in severe childhood atopic dermatitis: a multicenter study. *J Am Acad Dermatol* 1996;34(6):1016–21.
284. Alqarni AM, Zeidler MP. How does methotrexate work? *Biochem Soc Trans* 2020;48(2):559–67.
285. Weatherhead SC, Wahie S, Reynolds NJ, Meggitt SJ. An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. *Br J Dermatol* 2007;156(2):346–51.
286. Goujon C, Bérard F, Dahel K, Guillot I, Hennino A, Nosbaum A et al. Methotrexate for the treatment of adult atopic dermatitis. *Eur J Dermatol* 2006;16(2):155–8.
287. Lyakhovitsky A, Barzilai A, Heyman R, Baum S, Amichai B, Solomon M et al. Low-dose methotrexate treatment for moderate-to-severe atopic dermatitis in adults. *J Eur Acad Dermatol Venereol* 2010;24(1):43–9.
288. Caron AGM, van Huizen AM, Musters AAH, Gerbens LAA, Middelkamp Hup MA, Flohr C et al. International consensus on methotrexate dosing for patients with atopic dermatitis: An eDelphi study. *J Eur Acad Dermatol Venereol* 2025;39(2):331–9.
289. Schram ME, Roekevisch E, Leeflang MM, Bos JD, Schmitt J, Spuls PI. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. *J Allergy Clin Immunol* 2011;128(2):353–9.
290. Roekevisch E, Schram ME, Leeflang MMG, Brouwer MWD, Gerbens LAA, Bos JD et al. Methotrexate versus azathioprine in patients with atopic dermatitis: 2-year follow-up data. *J Allergy Clin Immunol* 2018;141(2):825–7.e10.

291. El-Khalawany MA, Hassan H, Shaaban D, Ghonaim N, Eassa B. Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt. *Eur J Pediatr* 2013;172(3):351–6.
292. Deo M, Yung A, Hill S, Rademaker M. Methotrexate for treatment of atopic dermatitis in children and adolescents. *Int J Dermatol* 2014;53(8):1037–41.
293. Taieb Y, Baum S, Ben Amitai D, Barzilai A, Greenberger S. The use of methotrexate for treating childhood atopic dermatitis: a multicenter retrospective study. *J Dermatolog Treat* 2019;30(3):240–4.
294. Shah N, Alhusayen R, Walsh S, Shear NH. Methotrexate in the Treatment of Moderate to Severe Atopic Dermatitis: A Retrospective Study. *J Cutan Med Surg* 2018;22(5):484–7.
295. Alexander H, Malek R, Prieto-Merino D, Gribaleva E, Baden M, Beattie P et al. A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register. *Br J Dermatol* 2024;191(6):988–99.
296. Ortiz Z, Shea B, Suarez-Almazor ME, Moher D, Wells GA, Tugwell P. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. *J Rheumatol* 1998;25(1):36–43.
297. Dogra S, Mahajan R. Systemic methotrexate therapy for psoriasis: past, present and future. *Clin Exp Dermatol* 2013;38(6):573–88.
298. Weinblatt ME. Methotrexate in rheumatoid arthritis: a quarter century of development. *Trans Am Clin Climatol Assoc* 2013;124(16–25).
299. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. *Gut* 2010;59(9):1265–9.
300. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. *N Engl J Med* 2005;353(16):1711–23.
301. La Rosa M, Musarra I, Ranno C, Maiello N, Negri L, del Giudice MM et al. A randomized, double-blind, placebo-controlled, crossover trial of systemic flunisolide in the treatment of children with severe atopic dermatitis. *Current Therapeutic Research* 1995;56(7):720–6.
302. Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. *Am J Med* 1994;96(2):115–23.
303. Richter B, Neises G, Clar C. Glucocorticoid withdrawal schemes in chronic medical disorders. A systematic review. *Endocrinol Metab Clin North Am* 2002;31(3):751–78.
304. Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. *N Engl J Med* 2014;371(2):130–9.
305. Beck LA, Bissonnette R, Deleuran M, Nakahara T, Galus R, Coleman A et al. Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study. *JAMA Dermatol* 2024;160(8):805–12.
306. Beck LA, Thaçi D, Deleuran M, Blauvelt A, Bissonnette R, de Bruin-Weller M et al. Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. *Am J Clin Dermatol* 2020;21(4):567–77.
307. Wollenberg A, Beck LA, Blauvelt A, Simpson EL, Chen Z, Chen Q et al. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). *Br J Dermatol* 2020;182(5):1120–35.
308. Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ et al. Conjunctivitis in dupilumab clinical trials. *Br J Dermatol* 2019;181(3):459–73.
309. Achten RE, Bakker DS, van Luijk CM, van der Wal M, de Graaf M, van Wijk F et al. Ocular surface disease is common in moderate-to-severe atopic dermatitis patients. *Clin Exp Allergy* 2022;52(6):801–5.

310. Ardern-Jones MR, Brown SJ, Flohr C, Hossain P, Irvine AD, Johnston GA et al. An expert consensus on managing dupilumab-related ocular surface disorders in people with atopic dermatitis 2024. *Br J Dermatol* 2024;
311. Schlösser AR, Bult L, Thelen JC, Thiadens A, Schappin R, Nijsten TEC et al. Higher prevalence of dupilumab-induced ocular adverse events in atopic dermatitis compared to asthma: A daily practice analysis. *Clin Transl Allergy* 2024;14(8):e12386.
312. Wollenberg A, Ariens L, Thureau S, van Luijk C, Seegräber M, de Bruin-Weller M. Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment. *J Allergy Clin Immunol Pract* 2018;6(5):1778–80.e1.
313. Ardern-Jones MR, Brown SJ, Flohr C, Hossain P, Irvine AD, Johnston GA et al. An expert consensus on managing dupilumab-related ocular surface disorders in people with atopic dermatitis 2024. *Br J Dermatol* 2024;191(6):865–85.
314. Jo CE, Finstad A, Georgakopoulos JR, Piguet V, Yeung J, Drucker AM. Facial and neck erythema associated with dupilumab treatment: A systematic review. *J Am Acad Dermatol* 2021;84(5):1339–47.
315. Napolitano M, Ruggiero A, Patruno C. Dupilumab-associated inflammatory arthritis: a literature review. *Clin Exp Dermatol* 2024;49(4):307–12.
316. Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A et al. Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. *N Engl J Med* 2023;388(12):1080–91.
317. Blauvelt A, Thyssen JP, Guttman-Yassky E, Bieber T, Serra-Baldrich E, Simpson E et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. *Br J Dermatol* 2023;188(6):740–8.
318. Simpson EL, Gooderham M, Wollenberg A, Weidinger S, Armstrong A, Soung J et al. Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere). *JAMA Dermatol* 2023;159(2):182–91.
319. Stein Gold L, Thaçi D, Thyssen JP, Gooderham M, Laquer V, Moore A et al. Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials. *Am J Clin Dermatol* 2023;24(4):595–607.
320. Simpson EL, Flohr C, Eichenfield LF, Bieber T, Sofen H, Taïeb A et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). *J Am Acad Dermatol* 2018;78(5):863–71.e11.
321. Popovic B, Breed J, Rees DG, Gardener MJ, Vinall LM, Kemp B et al. Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13R $\alpha$ 1 and IL-13R $\alpha$ 2. *J Mol Biol* 2017;429(2):208–19.
322. ClinicalTrials.gov. Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6). 2021. Available at: <https://clinicaltrials.gov/ct2/show/results/NCT03526861?term=ECZTRA+6&draw=2&rank=1> (last accessed 25.11.2022).
323. Silverberg JI, Wollenberg A, Reich A, Thaçi D, Legat FJ, Papp KA et al. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials. *Lancet* 2024;404(10451):445–60.
324. Silverberg JI, Wollenberg A, Legat FJ, Laquer VT, Armstrong AW, Herranz P et al. 667-Maintenance of efficacy and safety with nemolizumab at week 48: results from two global phase 3 pivotal studies (ARCADIA-1 and ARCADIA-2) in patients with moderate-to-severe atopic dermatitis. *Br J Dermatol* 2024;191(Supplement\_2):ljae266. 041.
325. Solimani F, Meier K, Ghoreschi K. Emerging Topical and Systemic JAK Inhibitors in Dermatology. *Front Immunol* 2019;10(2847).

326. Amano W, Nakajima S, Kunugi H, Numata Y, Kitoh A, Egawa G et al. The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling. *J Allergy Clin Immunol* 2015;136(3):667–77 e7.
327. Oetjen LK, Mack MR, Feng J, Whelan TM, Niu H, Guo CJ et al. Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch. *Cell* 2017;171(1):217–28 e13.
328. Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. *N Engl J Med* 2022;386(4):316–26.
329. Wollenberg A, Thyssen JP, Bieber T, Chan G, Kerkmann U. A detailed look at the European Medicines Agency's recommendations for use of Janus kinase inhibitors in patients with atopic dermatitis. *J Eur Acad Dermatol Venereol* 2023;37(10):2041–6.
330. European Medicines Agency (EMA). EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. 2022. Available at: <https://www.ema.europa.eu/en/news/ema-recommends-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic> (last accessed 28 August 2024).
331. Eichenfield LF, Flohr C, Sidbury R, Siegfried E, Szalai Z, Galus R et al. Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial. *JAMA Dermatol* 2021;157(10):1165–73.
332. Bieber T, Simpson EL, Silverberg JI, Thaçi D, Paul C, Pink AE et al. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. *N Engl J Med* 2021;384(12):1101–12.
333. Blauvelt A, Silverberg JI, Lynde CW, Bieber T, Eisman S, Zdybski J et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. *J Am Acad Dermatol* 2022;86(1):104–12.
334. Simpson EL, Silverberg JI, Nosbaum A, Winthrop KL, Guttman-Yassky E, Hoffmeister KM et al. Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program. *Am J Clin Dermatol* 2021;22(5):693–707.
335. Reich K, Kabashima K, Peris K, Silverberg JI, Eichenfield LF, Bieber T et al. Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial. *JAMA Dermatol* 2020;156(12):1333–43.
336. Torrelo A, Rewerska B, Galimberti M, Paller A, Yang CY, Prakash A et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). *Br J Dermatol* 2023;189(1):23–32.
337. Silverberg JI, Simpson EL, Wollenberg A, Bissonnette R, Kabashima K, DeLozier AM et al. Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials. *JAMA Dermatol* 2021;157(6):691–9.
338. Silverberg JI, Simpson EL, Thyssen JP, Werfel T, Cardillo TE, Colvin S et al. Long-term efficacy (up to 68 weeks) of Baricitinib in combination with topical corticosteroids in adult patients with moderate-to-severe atopic dermatitis: Analysis of treatment responders, partial responders and nonresponders originating from study BREEZE-AD7. *J Eur Acad Dermatol Venereol* 2023;37(5):1036–45.
339. Taylor PC, Bieber T, Alten R, Witte T, Galloway J, Deberdt W et al. Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications. *Adv Ther* 2023;40(4):1867–83.
340. Bieber T, Thyssen JP, Reich K, Simpson EL, Katoh N, Torrelo A et al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. *J Eur Acad Dermatol Venereol* 2021;35(2):476–85.

341. Taylor PC, Takeuchi T, Burmester GR, Durez P, Smolen JS, Deberdt W et al. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. *Ann Rheum Dis* 2022;81(3):335–43.
342. Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M et al. Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment. *Arthritis Rheumatol* 2017;69(3):506–17.
343. Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2021;397(10290):2169–81.
344. Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S et al. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. *JAMA Dermatol* 2021;157(9):1047–55.
345. Silverberg JI, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, Costanzo A et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results. *J Allergy Clin Immunol* 2022;149(3):977–87 e14.
346. Guttman-Yassky E, Thaci D, Pangan AL, Hong HC, Papp KA, Reich K et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. *J Allergy Clin Immunol* 2020;145(3):877–84.
347. Katoh N, Ohya Y, Murota H, Ikeda M, Hu X, Ikeda K et al. A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis. *JAAD Int* 2022;6(27–36).
348. Katoh N, Ikeda M, Ohya Y, Murota H, Hu X, Liu J et al. Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: Analysis of the 3-Year Phase 3 Rising Up Study. *Dermatol Ther (Heidelb)* 2024;14(1):213–32.
349. Fleischmann RM, Genovese MC, Enejosa JV, Mysler E, Bessette L, Peterfy C et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. *Ann Rheum Dis* 2019;78(11):1454–62.
350. Ruzicka T, Lynde CW, Jemec GB, Diepgen T, Berth-Jones J, Coenraads PJ et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. *Br J Dermatol* 2008;158(4):808–17.
351. Grahovac M, Molin S, Prinz JC, Ruzicka T, Wollenberg A. Treatment of atopic eczema with oral alitretinoin. *Br J Dermatol* 2010;162(1):217–8.
352. Luchsinger I, Vogler T, Schwieger-Briel A, Knöpfel N, Wälchli R, Weibel L et al. Safe and effective use of alitretinoin in children with recalcitrant hand eczema and other dermatoses - a retrospective analysis. *J Eur Acad Dermatol Venereol* 2020;34(5):1037–42.
353. Croft M, Esfandiari E, Chong C, Hsu H, Kabashima K, Kricorian G et al. OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target. *Am J Clin Dermatol* 2024;25(3):447–61.
354. Lé AM, Torres T. OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis-Focus on Rocatinlimab and Amlitelimab. *Pharmaceutics* 2022;14(12):
355. Guttman-Yassky E, Pavel AB, Zhou L, Estrada YD, Zhang N, Xu H et al. GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. *J Allergy Clin Immunol* 2019;144(2):482–93.e7.
356. Sher L, Rewerska B, Acocella A, Gudi G, Salhi Y, Mbow M et al. 472 Telazorlimab in atopic dermatitis: phase 2b study shows improvement at 16 weeks. *J Invest Dermatol* 2021;141(5):S82.

357. Rewerska B, Sher LD, Alpizar S, Pauser S, Pulka G, Mozaffarian N et al. Phase 2b randomized trial of OX40 inhibitor telazolimab for moderate-to-severe atopic dermatitis. *J Allergy Clin Immunol Glob* 2024;3(1):100195.
358. Nakagawa H, Iizuka H, Nemoto O, Shimabe M, Furukawa Y, Kikuta N et al. Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis. *J Dermatol Sci* 2020;99(2):82–9.
359. Guttman-Yassky E, Simpson EL, Reich K, Kabashima K, Igawa K, Suzuki T et al. An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. *Lancet* 2023;401(10372):204–14.
360. Weidinger S, Bieber T, Cork MJ, Reich A, Wilson R, Quarantino S et al. Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial. *Br J Dermatol* 2023;189(5):531–9.
361. Weidinger S, Blauvelt A, Papp K, Reich A, Lee C-H, Worm M et al. 227 efficacy and safety of amlitelimab (an anti-OX40 ligand antibody) in patients with moderate-to-severe atopic dermatitis (AD): 24-week results from a phase 2b trial (STREAM-AD). *J Invest Dermatol* 2023;143(11):S370.
362. Phan K, Smith SD. Mycophenolate mofetil and atopic dermatitis: systematic review and meta-analysis. *J Dermatolog Treat* 2020;31(8):810–4.
363. Chan S, Cornelius V, Cro S, Harper JJ, Lack G. Treatment Effect of Omalizumab on Severe Pediatric Atopic Dermatitis: The ADAPT Randomized Clinical Trial. *JAMA Pediatr* 2020;174(1):29–37.
364. Wollenberg A, Thomsen SF, Lacour JP, Jaumont X, Lazarewicz S. Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence. *World Allergy Organ J* 2021;14(3):100519.
365. Wegner J, Weinmann-Menke J, von Stebut E. Immunoabsorption for treatment of severe atopic dermatitis. *Atheroscler Suppl* 2017;30(264–70).
366. Jolles S. A review of high-dose intravenous immunoglobulin treatment for atopic dermatitis. *Clin Exp Dermatol* 2002;27(1):3–7.
367. Chin WK, Lee SWH. A systematic review on the off-label use of montelukast in atopic dermatitis treatment. *Int J Clin Pharm* 2018;40(5):963–76.
368. Simpson EL, Imafuku S, Poulin Y, Ungar B, Zhou L, Malik K et al. A Phase 2 Randomized Trial of Apremilast in Patients with Atopic Dermatitis. *J Invest Dermatol* 2019;139(5):1063–72.
369. Samrao A, Berry TM, Goreshi R, Simpson EL. A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. *Arch Dermatol* 2012;148(8):890–7.
370. Vyas HR, Shah SR, Shah BJ, Parmar KS, Jangid N, Choudhary A et al. A single-centre prospective study comparing efficacy and safety of apremilast with cyclosporine in moderate to severe atopic dermatitis. *Australas J Dermatol* 2023;64(4):e333–e9.
371. Agnihotri G, Lio PA. Revisiting Therapies for Atopic Dermatitis that Failed Clinical Trials. *Clin Drug Investig* 2020;40(5):421–31.
372. Werfel T, Heratizadeh A, Niebuhr M, Kapp A, Roesner LM, Karch A et al. Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber. *J Allergy Clin Immunol* 2015;136(1):96–103.e9.
373. Garritsen FM, ter Haar NM, Spuls PI. House dust mite reduction in the management of atopic dermatitis. A critically appraised topic. *Br J Dermatol* 2013;168(4):688–91.
374. Nankervis H, Pynn EV, Boyle RJ, Rushton L, Williams HC, Hewson DM et al. House dust mite reduction and avoidance measures for treating eczema. *Cochrane Database Syst Rev* 2015;1(Cd008426).
375. Fieten KB, Weststrate AC, van Zuuren EJ, Bruijnzeel-Koomen CA, Pasmans SG. Alpine climate treatment of atopic dermatitis: a systematic review. *Allergy* 2015;70(1):12–25.

376. Thorsteinsdottir S, Thyssen JP, Stokholm J, Vissing NH, Waage J, Bisgaard H. Domestic dog exposure at birth reduces the incidence of atopic dermatitis. *Allergy* 2016;71(12):1736–44.
377. Pelucchi C, Galeone C, Bach JF, La Vecchia C, Chatenoud L. Pet exposure and risk of atopic dermatitis at the pediatric age: a meta-analysis of birth cohort studies. *J Allergy Clin Immunol* 2013;132(3):616–22.e7.
378. Kim A, Silverberg JI. A systematic review of vigorous physical activity in eczema. *Br J Dermatol* 2016;174(3):660–2.
379. Murota H, Yamaga K, Ono E, Katayama I. Sweat in the pathogenesis of atopic dermatitis. *Allergol Int* 2018;67(4):455–9.
380. Murota H, Yamaga K, Ono E, Murayama N, Yokozeki H, Katayama I. Why does sweat lead to the development of itch in atopic dermatitis? *Exp Dermatol* 2019;28(12):1416–21.
381. Jaros J, Wilson C, Shi VY. Fabric Selection in Atopic Dermatitis: An Evidence-Based Review. *Am J Clin Dermatol* 2020;
382. Lopes C, Silva D, Delgado L, Correia O, Moreira A. Functional textiles for atopic dermatitis: a systematic review and meta-analysis. *Pediatr Allergy Immunol* 2013;24(6):603–13.
383. Bao Q, Chen L, Lu Z, Ma Y, Guo L, Zhang S et al. Association between eczema and risk of depression: A systematic review and meta-analysis of 188,495 participants. *J Affect Disord* 2018;238(458–64).
384. Ronnstad ATM, Halling-Overgaard AS, Hamann CR, Skov L, Egeberg A, Thyssen JP. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: A systematic review and meta-analysis. *J Am Acad Dermatol* 2018;79(3):448–56 e30.
385. Chan CWH, Law BMH, Liu YH, Ambrocio ARB, Au N, Jiang M et al. The Association between Maternal Stress and Childhood Eczema: A Systematic Review. *Int J Environ Res Public Health* 2018;15(3):
386. Flanigan C, Sheikh A, DunnGalvin A, Brew BK, Almqvist C, Nwaru BI. Prenatal maternal psychosocial stress and offspring's asthma and allergic disease: A systematic review and meta-analysis. *Clin Exp Allergy* 2018;48(4):403–14.
387. Mochizuki H, Lavery MJ, Nattkemper LA, Albornoz C, Valdes Rodriguez R, Stull C et al. Impact of acute stress on itch sensation and scratching behaviour in patients with atopic dermatitis and healthy controls. *Br J Dermatol* 2019;180(4):821–7.
388. Oh SH, Bae BG, Park CO, Noh JY, Park IH, Wu WH et al. Association of stress with symptoms of atopic dermatitis. *Acta Derm Venereol* 2010;90(6):582–8.
389. Ngoc LTN, Park D, Lee Y, Lee YC. Systematic Review and Meta-Analysis of Human Skin Diseases Due to Particulate Matter. *Int J Environ Res Public Health* 2017;14(12):
390. Kramer U, Behrendt H. [Air pollution and atopic eczema : Systematic review of findings from environmental epidemiological studies]. *Hautarzt* 2019;70(3):169–84. Luftverschmutzung und atopisches Ekzem : Systematisches Review der Erkenntnisse aus umweltepidemiologischen Studien.
391. Yazd NKK, Dunnick, C. Environmental Risk Factors for Development of Atopic Dermatitis: a Systematic Review. *Curr Derm Rep* 2017;6:169–177(
392. Kantor R, Kim A, Thyssen JP, Silverberg JI. Association of atopic dermatitis with smoking: A systematic review and meta-analysis. *J Am Acad Dermatol* 2016;75(6):1119–25 e1.
393. Pilz AC, Schielein MC, Schuster B, Heinrich L, Haufe E, Abraham S et al. Atopic dermatitis: disease characteristics and comorbidities in smoking and non-smoking patients from the TREATgermany registry. *J Eur Acad Dermatol Venereol* 2022;36(3):413–21.
394. Tsakok T, Marrs T, Mohsin M, Baron S, du Toit G, Till S et al. Does atopic dermatitis cause food allergy? A systematic review. *J Allergy Clin Immunol* 2016;137(4):1071–8.
395. Eigenmann PA, Sicherer SH, Borkowski TA, Cohen BA, Sampson HA. Prevalence of IgE-mediated food allergy among children with atopic dermatitis. *Pediatrics* 1998;101(3):E8.

396. Sicherer SH, Sampson HA. Food hypersensitivity and atopic dermatitis: pathophysiology, epidemiology, diagnosis, and management. *J Allergy Clin Immunol* 1999;104(3 Pt 2):S114–22.
397. Breuer K, Heratizadeh A, Wulf A, Baumann U, Constien A, Tetau D et al. Late eczematous reactions to food in children with atopic dermatitis. *Clin Exp Allergy* 2004;34(5):817–24.
398. Reekers R, Busche M, Wittmann M, Kapp A, Werfel T. Birch pollen-related foods trigger atopic dermatitis in patients with specific cutaneous T-cell responses to birch pollen antigens. *J Allergy Clin Immunol* 1999;104(2 Pt 1):466–72.
399. Wassmann-Otto A, Heratizadeh A, Wichmann K, Werfel T. Birch pollen-related foods can cause late eczematous reactions in patients with atopic dermatitis. *Allergy* 2018;73(10):2046–54.
400. Breuer K, Wulf A, Constien A, Tetau D, Kapp A, Werfel T. Birch pollen-related food as a provocation factor of allergic symptoms in children with atopic eczema/dermatitis syndrome. *Allergy* 2004;59(9):988–94.
401. Sampson HA. The evaluation and management of food allergy in atopic dermatitis. *Clin Dermatol* 2003;21(3):183–92.
402. Werfel T, Ballmer-Weber B, Eigenmann PA, Niggemann B, Rancé F, Turjanmaa K et al. Eczematous reactions to food in atopic eczema: position paper of the EAACI and GA2LEN. *Allergy* 2007;62(7):723–8.
403. Muraro A, Werfel T, Hoffmann-Sommergruber K, Roberts G, Beyer K, Bindslev-Jensen C et al. EAACI food allergy and anaphylaxis guidelines: diagnosis and management of food allergy. *Allergy* 2014;69(8):1008–25.
404. Niggemann B, Reibel S, Wahn U. The atopy patch test (APT)-- a useful tool for the diagnosis of food allergy in children with atopic dermatitis. *Allergy* 2000;55(3):281–5.
405. Turjanmaa K, Darsow U, Niggemann B, Rancé F, Vanto T, Werfel T. EAACI/GA2LEN position paper: present status of the atopy patch test. *Allergy* 2006;61(12):1377–84.
406. Niggemann B. The role of the atopy patch test (APT) in diagnosis of food allergy in infants and children with atopic dermatitis. *Pediatr Allergy Immunol* 2001;12 Suppl 14(37–40).
407. Roehr CC, Reibel S, Ziegert M, Sommerfeld C, Wahn U, Niggemann B. Atopy patch tests, together with determination of specific IgE levels, reduce the need for oral food challenges in children with atopic dermatitis. *J Allergy Clin Immunol* 2001;107(3):548–53.
408. Darsow U, Ring J. Airborne and dietary allergens in atopic eczema: a comprehensive review of diagnostic tests. *Clin Exp Dermatol* 2000;25(7):544–51.
409. Bindslev-Jensen C, Ballmer-Weber BK, Bengtsson U, Blanco C, Ebner C, Hourihane J et al. Standardization of food challenges in patients with immediate reactions to foods--position paper from the European Academy of Allergology and Clinical Immunology. *Allergy* 2004;59(7):690–7.
410. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. *Health Technol Assess* 2000;4(37):1–191.
411. Bath-Hextall F, Delamere FM, Williams HC. Dietary exclusions for improving established atopic eczema in adults and children: systematic review. *Allergy* 2009;64(2):258–64.
412. Hanifin JM, Cooper KD, Ho VC, Kang S, Krafchik BR, Margolis DJ et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association "Administrative Regulations for Evidence-Based Clinical Practice Guidelines". *J Am Acad Dermatol* 2004;50(3):391–404.
413. Isolauri E, Arvola T, Sütas Y, Moilanen E, Salminen S. Probiotics in the management of atopic eczema. *Clin Exp Allergy* 2000;30(11):1604–10.
414. Fölster-Holst R, Müller F, Schnopp N, Abeck D, Kreislermaier I, Lenz T et al. Prospective, randomized controlled trial on *Lactobacillus rhamnosus* in infants with moderate to severe atopic dermatitis. *Br J Dermatol* 2006;155(6):1256–61.

415. Rosenfeldt V, Benfeldt E, Nielsen SD, Michaelsen KF, Jeppesen DL, Valerius NH et al. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. *J Allergy Clin Immunol* 2003;111(2):389–95.
416. Grüber C. Probiotics and prebiotics in allergy prevention and treatment: future prospects. *Expert Rev Clin Immunol* 2012;8(1):17–9.
417. Makrgeorgou A, Leonardi-Bee J, Bath-Hextall FJ, Murrell DF, Tang ML, Roberts A et al. Probiotics for treating eczema. *Cochrane Database Syst Rev* 2018;11(11):Cd006135.
418. Tan-Lim CSC, Esteban-Ipac NAR, Mantaring JBV, 3rd, Chan Shih Yen E, Recto MST, Sison OT et al. Comparative effectiveness of probiotic strains for the treatment of pediatric atopic dermatitis: A systematic review and network meta-analysis. *Pediatr Allergy Immunol* 2020;
419. Bath-Hextall FJ, Jenkinson C, Humphreys R, Williams HC. Dietary supplements for established atopic eczema. *Cochrane Database Syst Rev* 2012;2):Cd005205.
420. Aldaghi M, Tehrani H, Karrabi M, Abadi FS, Sahebkar M. The effect of multistrain synbiotic and vitamin D3 supplements on the severity of atopic dermatitis among infants under 1 year of age: a double-blind, randomized clinical trial study. *J Dermatolog Treat* 2020;1–6.
421. Udompataikul M, Srisatwaja W. Comparative trial of moisturizer containing licochalcone A vs. hydrocortisone lotion in the treatment of childhood atopic dermatitis: a pilot study. *J Eur Acad Dermatol Venereol* 2011;25(6):660–5.
422. Fortes C, Mastroeni S, Mannooranparampil TJ, Di Lallo D. Pre-natal folic acid and iron supplementation and atopic dermatitis in the first 6 years of life. *Arch Dermatol Res* 2019;311(5):361–7.
423. Kucuksezer UC, Ozdemir C, Cevhertas L, Ogulur I, Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy and allergen tolerance. *Allergol Int* 2020;69(4):549–60.
424. Noon L. PROPHYLACTIC INOCULATION AGAINST HAY FEVER. *The Lancet* 1911;177(4580):1572–3.
425. Cox LS, Hankin C, Lockey R. Allergy immunotherapy adherence and delivery route: location does not matter. *J Allergy Clin Immunol Pract* 2014;2(2):156–60.
426. Novak N, Bieber T, Hoffmann M, Fölster-Holst R, Homey B, Werfel T et al. Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. *J Allergy Clin Immunol* 2012;130(4):925–31.e4.
427. Novak N. Allergen specific immunotherapy for atopic dermatitis. *Curr Opin Allergy Clin Immunol* 2007;7(6):542–46.
428. Bae JM, Choi YY, Park CO, Chung KY, Lee KH. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. *J Allergy Clin Immunol* 2013;132(1):110–7.
429. Gendelman SR, Lang DM. Specific immunotherapy in the treatment of atopic dermatitis: a systematic review using the GRADE system. *Ann Allergy Asthma Immunol* 2013;111(6):555–61.
430. Hajdu K, Kapitány A, Dajnoki Z, Soltész L, Baráth S, Hendrik Z et al. Improvement of clinical and immunological parameters after allergen-specific immunotherapy in atopic dermatitis. *J Eur Acad Dermatol Venereol* 2021;35(6):1357–61.
431. Tam H, Calderon MA, Manikam L, Nankervis H, García Núñez I, Williams HC et al. Specific allergen immunotherapy for the treatment of atopic eczema. *Cochrane Database Syst Rev* 2016;2(Cd008774).
432. Ridolo E, Martignago I, Riario-Sforza GG, Incorvaia C. Allergen immunotherapy in atopic dermatitis. *Expert Rev Clin Immunol* 2018;14(1):61–8.
433. Tan EK, Millington GW, Levell NJ. Acupuncture in dermatology: an historical perspective. *Int J Dermatol* 2009;48(6):648–52.
434. Langevin HM, Churchill DL, Cipolla MJ. Mechanical signaling through connective tissue: a mechanism for the therapeutic effect of acupuncture. *FASEB J* 2001;15(12):2275–82.

435. Pfab F, Athanasiadis GI, Huss-Marp J, Fuqin J, Heuser B, Cifuentes L et al. Effect of acupuncture on allergen-induced basophil activation in patients with atopic eczema: a pilot trial. *J Altern Complement Med* 2011;17(4):309–14.
436. Pfab F, Huss-Marp J, Gatti A, Fuqin J, Athanasiadis GI, Irnich D et al. Influence of acupuncture on type I hypersensitivity itch and the wheal and flare response in adults with atopic eczema - a blinded, randomized, placebo-controlled, crossover trial. *Allergy* 2010;65(7):903–10.
437. Jiao R, Yang Z, Wang Y, Zhou J, Zeng Y, Liu Z. The effectiveness and safety of acupuncture for patients with atopic eczema: a systematic review and meta-analysis. *Acupunct Med* 2020;38(1):3–14.
438. Beretta S, Fabiano V, Petrucci M, Budelli A, Zuccotti GV. Fermented rice flour in pediatric atopic dermatitis. *Dermatitis* 2015;26(2):104–6.
439. Sgouros D, Katoulis A, Rigopoulos D. Novel topical agent containing superoxide dismutase 100 000 IU and 4% of plant extracts as a mono-therapy for atopic dermatitis. *J Cosmet Dermatol* 2018;17(6):1069–72.
440. Abbasi S, Kamalinejad M, Babaie D, Shams S, Sadr Z, Gheysari M et al. A new topical treatment of atopic dermatitis in pediatric patients based on *Ficus carica* L. (Fig): A randomized, placebo-controlled clinical trial. *Complement Ther Med* 2017;35(85–91).
441. Hon KL, Tsang YC, Pong NH, Lee VW, Luk NM, Chow CM et al. Patient acceptability, efficacy, and skin biophysiology of a cream and cleanser containing lipid complex with shea butter extract versus a ceramide product for eczema. *Hong Kong Med J* 2015;21(5):417–25.
442. Ernst E. Adverse effects of herbal drugs in dermatology. *Br J Dermatol* 2000;143(5):923–9.
443. Cho SM, Kim ME, Kim JY, Park JC, Nahm DH. Clinical efficacy of autologous plasma therapy for atopic dermatitis. *Dermatology* 2014;228(1):71–7.
444. Cho SM, Kim ME, Kwon B, Nahm DH. Immunomodulatory effects induced by intramuscular administration of autologous total immunoglobulin G in patients with atopic dermatitis. *Int Immunopharmacol* 2017;52(1–6).
445. Nahm DH, Ahn A, Kim ME, Cho SM, Park MJ. Autologous Immunoglobulin Therapy in Patients With Severe Recalcitrant Atopic Dermatitis: Long-Term Changes of Clinical Severity and Laboratory Parameters. *Allergy Asthma Immunol Res* 2016;8(4):375–82.
446. Gu S, Yang AW, Li CG, Lu C, Xue CC. Topical application of Chinese herbal medicine for atopic eczema: a systematic review with a meta-analysis. *Dermatology* 2014;228(4):294–302.
447. Gu S, Yang AW, Xue CC, Li CG, Pang C, Zhang W et al. Chinese herbal medicine for atopic eczema. *Cochrane Database Syst Rev* 2013;9):Cd008642.
448. Eberlein B, Huss-Marp J, Pfab F, Fischer R, Franz R, Schlich M et al. Influence of alpine mountain climate of Bavaria on patients with atopic diseases: studies at the Environmental Research Station Schneefernerhaus (UFS - Zugspitze) - a pilot study. *Clin Transl Allergy* 2014;4(17).
449. Senra MS, Wollenberg A. Psychodermatological aspects of atopic dermatitis. *Br J Dermatol* 2014;170 Suppl 1(38–43).
450. Rønstad ATM, Halling-Overgaard AS, Hamann CR, Skov L, Egeberg A, Thyssen JP. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: A systematic review and meta-analysis. *J Am Acad Dermatol* 2018;79(3):448–56.e30.
451. Eicher L, Knop M, Aszodi N, Senner S, French LE, Wollenberg A. A systematic review of factors influencing treatment adherence in chronic inflammatory skin disease - strategies for optimizing treatment outcome. *J Eur Acad Dermatol Venereol* 2019;33(12):2253–63.
452. Stalder JF, Bernier C, Ball A, De Raeve L, Gieler U, Deleuran M et al. Therapeutic patient education in atopic dermatitis: worldwide experiences. *Pediatr Dermatol* 2013;30(3):329–34.
453. de Bes J, Legierse CM, Prinsen CA, de Korte J. Patient education in chronic skin diseases: a systematic review. *Acta Derm Venereol* 2011;91(1):12–7.

454. Ersser SJ, Cowdell F, Latter S, Gardiner E, Flohr C, Thompson AR et al. Psychological and educational interventions for atopic eczema in children. *Cochrane Database Syst Rev* 2014;2014(1):Cd004054.
455. Zhao M, Liang Y, Shen C, Wang Y, Ma L, Ma X. Patient Education Programs in Pediatric Atopic Dermatitis: A Systematic Review of Randomized Controlled Trials and Meta-Analysis. *Dermatol Ther (Heidelb)* 2020;10(3):449–64.
456. Ridd MJ, King AJL, Le Roux E, Waldecker A, Huntley AL. Systematic review of self-management interventions for people with eczema. *Br J Dermatol* 2017;177(3):719–34.
457. Heratizadeh A, Werfel T, Wollenberg A, Abraham S, Plank-Habibi S, Schnopp C et al. Effects of structured patient education in adults with atopic dermatitis: Multicenter randomized controlled trial. *J Allergy Clin Immunol* 2017;140(3):845–53.e3.
458. Gradwell C, Thomas KS, English JS, Williams HC. A randomized controlled trial of nurse follow-up clinics: do they help patients and do they free up consultants' time? *Br J Dermatol* 2002;147(3):513–7.
459. Chida Y, Steptoe A, Hirakawa N, Sudo N, Kubo C. The Effects of Psychological Intervention on Atopic Dermatitis. *Int Arch Allergy Immunol* 2007;144(1):1–9.
460. Hamann CR, Egeberg A, Wollenberg A, Gislason G, Skov L, Thyssen JP. Pregnancy complications, treatment characteristics and birth outcomes in women with atopic dermatitis in Denmark. *J Eur Acad Dermatol Venereol* 2019;33(3):577–87.
461. Chi CC, Wang SH, Wojnarowska F, Kirtschig G, Davies E, Bennett C. Safety of topical corticosteroids in pregnancy. *Cochrane Database Syst Rev* 2015;10):Cd007346.
462. Chi CC, Kirtschig G, Aberer W, Gabbud JP, Lipozenčić J, Kárpáti S et al. Evidence-based (S3) guideline on topical corticosteroids in pregnancy. *Br J Dermatol* 2011;165(5):943–52.
463. Murphy VE, Fittock RJ, Zarzycki PK, Delahunty MM, Smith R, Clifton VL. Metabolism of synthetic steroids by the human placenta. *Placenta* 2007;28(1):39–46.
464. Agency EM. Neoral Soft Gelatin Capsules - Summary of Product Characteristics (SmPC) - (emc). In).
465. Avallone G, Cavallo F, Tancredi A, Maronese CA, Bertello M, Fraghì A et al. Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate-to-severe atopic dermatitis: A nationwide retrospective cohort study. *J Eur Acad Dermatol Venereol* 2024;38(9):1799–808.
466. Bosma AL, Gerbens LAA, Middelkamp-Hup MA, Spuls PI. Paternal and maternal use of dupilumab in patients with atopic dermatitis: a case series. *Clin Exp Dermatol* 2021;46(6):1089–92.
467. Khamisy-Farah R, Damiani G, Kong JD, Wu JH, Bragazzi NL. Safety profile of Dupilumab during pregnancy: a data mining and disproportionality analysis of over 37,000 reports from the WHO individual case safety reporting database (VigiBase™). *Eur Rev Med Pharmacol Sci* 2021;25(17):5448–51.
468. Heilskov S, Deleuran MS, Vestergaard C. Immunosuppressive and Immunomodulating Therapy for Atopic Dermatitis in Pregnancy: An Appraisal of the Literature. *Dermatol Ther (Heidelb)* 2020;10(6):1215–28.
469. Drljevic-Nielsen A, Heilskov S, Deleuran MS, Vestergaard C. Immunosuppressive and immunomodulating therapy for atopic dermatitis in pregnancy: an appraisal of the literature. *Ital J Dermatol Venerol* 2024;159(1):23–33.
470. Deleuran M, Dézfoulian B, Elberling J, Knutar I, Lapeere H, Lossius AH et al. Systemic anti-inflammatory treatment of atopic dermatitis during conception, pregnancy and breastfeeding: Interdisciplinary expert consensus in Northern Europe. *J Eur Acad Dermatol Venereol* 2024;38(1):31–41.

471. Akuffo-Addo E, Nicholas MN, Lansang P. Reported Pregnancy Outcomes in Women With Severe Atopic Dermatitis Treated With Dupilumab: A Systematic Review. *J Cutan Med Surg* 2023;27(2):177–8.
472. Preuß SL, Bieber K, Vorobyev A, Recke A, Moderegger EL, Zirpel H et al. Dupilumab shows no elevated risk for maternal adverse pregnancy outcomes: A propensity-matched cohort study. *J Eur Acad Dermatol Venereol* 2025;39(9):1576–87.
473. Dulai AS, Murase EM, Avallone G, Ferrucci SM, Marzano AV, Ribero S et al. International Multi-Center Case Series of Gestational Dupilumab Exposure in the Treatment of Atopic Dermatitis: Maternal Complications and Fetal Outcomes. *J Am Acad Dermatol* 2025;
474. Jang W, Jo H, Park J, Kim S, Cho H, Jeong YD et al. Use of Biologics to Treat Asthma during Pregnancy and Adverse Events in Pregnant Women and Newborns: A Global Pharmacovigilance Analysis. *Int Arch Allergy Immunol* 2025;186(9):875–88.
475. Bowman CJ, Champion SN, Catlin NR, Nowland WS, Stethem CM, Radi ZA et al. Reversible effects on female rat fertility with abrocitinib, a Janus kinase 1 inhibitor. *Birth Defects Res* 2024;116(5):e2345.
476. Weber-Schoendorfer C, Schaefer C. The safety of cetirizine during pregnancy. A prospective observational cohort study. *Reprod Toxicol* 2008;26(1):19–23.
477. Moretti ME, Caprara D, Coutinho CJ, Bar-Oz B, Berkovitch M, Addis A et al. Fetal safety of loratadine use in the first trimester of pregnancy: a multicenter study. *J Allergy Clin Immunol* 2003;111(3):479–83.
478. Diav-Citrin O, Shechtman S, Aharonovich A, Moerman L, Arnon J, Wajnberg R et al. Pregnancy outcome after gestational exposure to loratadine or antihistamines: a prospective controlled cohort study. *J Allergy Clin Immunol* 2003;111(6):1239–43.
479. Bookstaver PB, Bland CM, Griffin B, Stover KR, Eiland LS, McLaughlin M. A Review of Antibiotic Use in Pregnancy. *Pharmacotherapy* 2015;35(11):1052–62.
480. Lin KJ, Mitchell AA, Yau WP, Louik C, Hernández-Díaz S. Safety of macrolides during pregnancy. *Am J Obstet Gynecol* 2013;208(3):221.e1–8.
481. Matro R, Martin CF, Wolf D, Shah SA, Mahadevan U. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development. *Gastroenterology* 2018;155(3):696–704.
482. Gutierrez JC, Hwang K. The toxicity of methotrexate in male fertility and paternal teratogenicity. *Expert Opin Drug Metab Toxicol* 2017;13(1):51–8.
483. Williams HC. Clinical practice. Atopic dermatitis. *N Engl J Med* 2005;352(22):2314–24.
484. Rudikoff D, Cohen SR, Scheinfeld N. *Clinical aspects and differential diagnosis of atopic dermatitis. In: Atopic dermatitis and eczematous disorders.* CRC Press; 2014.
485. Marrs T, Perkin MR, Logan K, Craven J, Radulovic S, McLean WHI et al. Bathing frequency is associated with skin barrier dysfunction and atopic dermatitis at three months of age. *J Allergy Clin Immunol Pract* 2020;8(8):2820–2.
486. Ruff SMD, Engebretsen KA, Zachariae C, Johansen JD, Silverberg JI, Egeberg A et al. The association between atopic dermatitis and hand eczema: a systematic review and meta-analysis. *Br J Dermatol* 2018;178(4):879–88.
487. Nørreslet LB, Ebbenhøj NE, Ellekilde Bonde JP, Thomsen SF, Agner T. The impact of atopic dermatitis on work life - a systematic review. *J Eur Acad Dermatol Venereol* 2018;32(1):23–38.
488. Bregnhøj A, Sosted H, Menne T, Johansen JD. Healthy worker effect in hairdressing apprentices. *Contact Dermatitis* 2011;64(2):80–4.
489. Wei J, Gerlich J, Vogelberg C, von Mutius E, Windstetter D, Genuneit J et al. Do young adults with atopic dermatitis avoid harmful workplace exposure at their first job? A prospective cohort study. *Int Arch Occup Environ Health* 2016;89(3):397–406.

490. Nyrén M, Lindberg M, Stenberg B, Svensson M, Svensson A, Meding B. Influence of childhood atopic dermatitis on future worklife. *Scand J Work Environ Health* 2005;31(6):474–8.
491. Holm EA, Esmann S, Jemec GB. The handicap caused by atopic dermatitis--sick leave and job avoidance. *J Eur Acad Dermatol Venereol* 2006;20(3):255–9.
492. Bandier J, Ross-Hansen K, Carlsen BC, Menne T, Linneberg A, Stender S et al. Carriers of filaggrin gene (FLG) mutations avoid professional exposure to irritants in adulthood. *Contact Dermatitis* 2013;69(6):355–62.
493. Lammintausta K, Kalimo K. Does a patient's occupation influence the course of atopic dermatitis? *Acta Derm Venereol* 1993;73(2):119–22.
494. Whiteley J, Emir B, Seitzman R, Makinson G. The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey. *Curr Med Res Opin* 2016;32(10):1645–51.
495. Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, Lobo F et al. The direct and indirect cost burden of atopic dermatitis: an employer-payer perspective. *Manag Care Interface* 2007;20(10):26–32.
496. Zuberbier T, Orlow SJ, Paller AS, Taieb A, Allen R, Hernanz-Hermosa JM et al. Patient perspectives on the management of atopic dermatitis. *J Allergy Clin Immunol* 2006;118(1):226–32.
497. Fivenson D, Arnold RJ, Kaniecki DJ, Cohen JL, Frech F, Finlay AY. The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organization. *J Manag Care Pharm* 2002;8(5):333–42.
498. van Os-Medendorp H, Appelman-Noordermeer S, Bruijnzeel-Koomen C, de Bruin-Weller M. Sick Leave and Factors Influencing Sick Leave in Adult Patients with Atopic Dermatitis: A Cross-Sectional Study. *J Clin Med* 2015;4(4):535–47.
499. Yano C, Saeki H, Ishiji T, Ishiuiji Y, Sato J, Tofuku Y et al. Impact of disease severity on work productivity and activity impairment in Japanese patients with atopic dermatitis. *J Dermatol* 2013;40(9):736–9.
500. Ibler KS, Jemec GB. Permanent disability pension due to skin diseases in Denmark 2003-2008. *Acta Dermatovenerol Croat* 2011;19(3):161–4.
501. Landeck L, Visser M, Skudlik C, Brans R, Kezic S, John SM. Clinical course of occupational irritant contact dermatitis of the hands in relation to filaggrin genotype status and atopy. *Br J Dermatol* 2012;167(6):1302–9.
502. Malkonen T, Alanko K, Jolanki R, Luukkonen R, Aalto-Korte K, Lauerma A et al. Long-term follow-up study of occupational hand eczema. *Br J Dermatol* 2010;163(5):999–1006.
503. Agner T, Andersen KE, Brandao FM, Bruynzeel DP, Bruze M, Frosch P et al. Contact sensitisation in hand eczema patients-relation to subdiagnosis, severity and quality of life: a multi-centre study. *Contact Dermatitis* 2009;61(5):291–6.
504. Lerbaek A, Kyvik KO, Ravn H, Menne T, Agner T. Clinical characteristics and consequences of hand eczema - an 8-year follow-up study of a population-based twin cohort. *Contact Dermatitis* 2008;58(4):210–6.
505. Meding B, Lantto R, Lindahl G, Wrangsjo K, Bengtsson B. Occupational skin disease in Sweden--a 12-year follow-up. *Contact Dermatitis* 2005;53(6):308–13.
506. Cvetkovski RS, Rothman KJ, Olsen J, Mathiesen B, Iversen L, Johansen JD et al. Relation between diagnoses on severity, sick leave and loss of job among patients with occupational hand eczema. *Br J Dermatol* 2005;152(1):93–8.
507. Dickel H, Bruckner TM, Schmidt A, Diepgen TL. Impact of atopic skin diathesis on occupational skin disease incidence in a working population. *J Invest Dermatol* 2003;121(1):37–40.
508. Holm JO, Veierod MB. An epidemiological study of hand eczema. III. Characterization of hairdressers with and without hand eczema, regarding demographic factors and medical histories. *Acta Derm Venereol Suppl (Stockh)* 1994;187(15–7).

509. Lysdal SH, Sosted H, Andersen KE, Johansen JD. Hand eczema in hairdressers: a Danish register-based study of the prevalence of hand eczema and its career consequences. *Contact Dermatitis* 2011;65(3):151–8.
510. Cvetkovski RS, Zachariae R, Jensen H, Olsen J, Johansen JD, Agner T. Prognosis of occupational hand eczema: a follow-up study. *Arch Dermatol* 2006;142(3):305–11.
511. Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM. Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: An analysis using the National Health and Wellness Survey. *J Am Acad Dermatol* 2017;77(2):274–9.e3.
512. Eckert L, Gupta S, Gadkari A, Mahajan P, Gelfand JM. Burden of illness in adults with atopic dermatitis: Analysis of National Health and Wellness Survey data from France, Germany, Italy, Spain, and the United Kingdom. *J Am Acad Dermatol* 2019;81(1):187–95.
513. Ariëns LFM, van Nimwegen KJM, Shams M, de Bruin DT, van der Schaft J, van Os-Medendorp H et al. Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment. *Acta Derm Venereol* 2019;99(9):762–8.
514. Kwak Y, Kim Y. Associations between prevalence of adult atopic dermatitis and occupational characteristics. *Int J Nurs Pract* 2017;23(4):
515. Theodosiou G, Montgomery S, Metsini A, Dalgard FJ, Svensson A, Kobyletzki LB. Burden of Atopic Dermatitis in Swedish Adults: A Population-based Study. *Acta Derm Venereol* 2019;99(11):964–70.
516. Arima K, Gupta S, Gadkari A, Hiragun T, Kono T, Katayama I et al. Burden of atopic dermatitis in Japanese adults: Analysis of data from the 2013 National Health and Wellness Survey. *J Dermatol* 2018;45(4):390–6.
517. Frimat P, Boughattas W, Even D. Atopic dermatitis: professional orientation. *Eur J Dermatol* 2015;25(1):3–6.
518. Apfelbacher CJ, Radulescu M, Diepgen TL, Funke U. Occurrence and prognosis of hand eczema in the car industry: results from the PACO follow-up study (PACO II). *Contact Dermatitis* 2008;58(6):322–9.
519. Radon K, Nowak D, Vogelberg C, Rueff F. Career Advice for Young Allergy Patients. *Dtsch Arztebl Int* 2016;113(31-32):519–24.